



Zambia

Country Operational Plan

FY 2015



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		17,012,866		17,012,866	484,026
HHS/CDC	2,412,531	115,295,479		117,708,010	1,309,890
HHS/HRSA		1,881,442		1,881,442	0
HHS/OS		350,000		350,000	0
PC		4,348,056		4,348,056	157,700
State		981,032		981,032	433,940
State/AF		388,755		388,755	0
State/PRM		155,000		155,000	0
USAID		170,472,196	0	170,472,196	10,011,718
Total	2,412,531	310,884,826	0	313,297,357	12,397,274

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC	6,808	1,515,657	5,466,649			0	5,475,032	0	12,494,146
HBHC		1,203,913	9,232,943		197,577		5,922,707	0	16,557,140
HKID	6,808	1,000,000	250,000			150,000	20,671,588	0	22,078,396
HLAB		954,089	4,967,059	1,000,000			3,907,435	0	10,828,583
HMBL			800,505					0	800,505
HMIN			0					0	0
HTXD			0				52,332,684	0	52,332,684
HTXS		5,122,383	35,834,241	200,000			29,587,948	0	70,744,572
HVAB	0	3,913	954,502		33,607	0	1,508,658	0	2,530,680
HVCT	0	811,743	7,991,191			0	10,393,924	0	19,246,858
HVMS	960,608	559,462	6,930,339		4,073,619		4,041,219	0	16,915,247



HVOP	0	415,657	1,640,274		43,253	88,755	4,989,841	0	7,222,780
HVSI	6,808	794,171	6,988,951				2,858,311	0	10,648,241
HVTB		715,657	9,572,096				5,566,777	0	15,854,530
IDUP			0					0	0
MTCT		1,015,657	11,124,524				9,543,670	0	21,683,851
OHSS	0	2,197,201	3,807,255	681,442		150,000	7,314,130	0	14,150,028
PDCS		80,521	5,354,501				849,015	0	6,284,037
PDTX		622,842	6,792,980				5,509,257	0	12,925,079
	981,032	17,012,866	117,708,010	1,881,442	4,348,056	388,755	170,472,196	0	313,297,357



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	16,407,078	0
HKID	21,868,899	0
HVTB	15,662,682	0
PDCS	6,127,215	0
Total Technical Area Planned Funding:	60,065,874	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	10,242,523	0
HVSI	7,930,394	0
OHSS	12,992,477	0
Total Technical Area Planned Funding:	31,165,394	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	12,320,585	0
HMBL	783,644	0
HMIN	0	0
HVAB	2,391,400	0
HVCT	18,946,302	0
HVOP	6,995,557	0
IDUP	0	0
MTCT	21,265,540	0



Total Technical Area Planned Funding:	62,703,028	0
--	-------------------	----------

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	52,289,499	0
HTXS	70,261,795	0
PDTX	12,768,603	0
Total Technical Area Planned Funding:	135,319,897	0

Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	88 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	374,001	423,279
	Number of new ANC and L&D clients	427,063	459,110
	By: Known positives at entry	24,075	18,441
	By: Number of new positives identified	27,575	9,761
	Sum of Positives Status disaggregates	51,650	28,202
	Required only for DREAMS Countries - By Number of new positives: <15		12
	Required only for DREAMS Countries - By Number of new positives: 15-19		58
	Required only for DREAMS Countries - By Number of new positives: 20-24		102
	Required only for DREAMS Countries - By Number of new positives: 25+		164

	Required only for DREAMS Countries - By Number of known positives: <15		10
	Required only for DREAMS Countries - By Number of known positives: 15-19		407
	Required only for DREAMS Countries - By Number of known positives: 20-24		2,482
	Required only for DREAMS Countries - By Number of known positives: 25+		4,418
	Required only for DREAMS Countries - Denominator: <15		220
	Required only for DREAMS Countries - Denominator: <15-19		1,590
	Required only for DREAMS Countries - Denominator: 20-24		5,823
	Required only for DREAMS Countries - Denominator: 25+		10,719
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	94 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	265,762	231,260

	Number of new ANC and L&D clients	283,241	238,003
	By: Known positives at entry	10,432	9,380
	By: Number of new positives identified	18,181	11,843
	Sum of Positives Status disaggregates	28,613	21,223
	Required only for DREAMS countries - By known positives: <15		212
	Required only for DREAMS countries - By known positives: 15-19		431
	Required only for DREAMS countries - By known positives: 20-24		1,009
	Required only for DREAMS countries - By known positives: 25+		1,627
	Required only for DREAMS countries - By new positives: <15		206
	Required only for DREAMS countries - By new positives: 15-19		417
	Required only for DREAMS countries - By new positives: 20-24		815
	Required only for DREAMS countries - By new positives: 25+		1,273
	Required only for DREAMS countries - Denominator: <15		5,011
	Required only for DREAMS countries - Denominator:		13,658

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		20,519
	Required only for DREAMS countries - Denominator: 25+		22,697
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	96 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	45,500	19,584
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	47,241	17,928
	Life-long ART (including Option B+)	45,500	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	19,367	1,754
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	26,133	3,418

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	2
	Single-dose nevirapine (with or without tail)	0	1
	Sum of Regimen Type disaggregates	45,500	3
	Sum of New and Current disaggregates	45,500	5,172
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	91 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	35,408	15,228
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	38,938	14,152

	Life-long ART (including Option B+)	35,408	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	12,668	4,267
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	22,740	2,479
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	79
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	4,327
	Single-dose nevirapine (with or without tail)	0	27
	Sum of Regimen Type disaggregates	35,408	4,433
	Sum of New and Current disaggregates	35,408	6,746
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		20,892
	Number of HIV-exposed infants registered in the birth		21,969

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		304
	HIV-infected: Not linked to ART		15
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		1,978
	HIV-uninfected: Still breastfeeding		3,295
	HIV-uninfected: Breastfeeding status unknown		488
	Other: In care but no test done		108
	Other: Lost to follow-up		116
	Other: Died		118
	Other: Transferred out		145
PMTCT_FO_TA	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		10,401
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		10,528
	HIV-infected: Linked to ART		1,898

	HIV-infected: Not linked to ART		210
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		479
	HIV-uninfected: Not breastfeeding		3,147
	HIV-uninfected: Still breastfeeding		3,106
	Other: Died		51
	Other: In care but no test done		208
	Other: Lost to follow-up		61
	Other: Transferred out		51
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months		0
	Sex: Male		0
	Sex: Female		0
	Sum of Sex disaggregates		0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	392	1,475
	By AE type: Number of	10	

	VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	4	
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	6	
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	343	
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	303	
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	40	
	By AE Type: Number of	40	

	VMMC clients with one or more moderate or severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	30	
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	10	
VMMC_AE_TA	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)		25
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)		
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: By Medical		

	device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical		

	intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	247,636	214,103
	By Age: <1	21,901	117
	By Age: 1-9	0	13,196
	By Age: 10-14	69,254	30,341
	By Age: 15-19	69,254	30,265
	By Age: 20-24	42,631	23,287
	By Age: 25-29		14,842
	By Age: 30-49		9,008
	By Age: 50+	1,717	1,797
	Sum of age disaggregates	247,636	99,003
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	29,716	5,780
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	216,825	96,650
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,095	17,949
	By circumcision technique: Surgical VMMC	247,636	117,519

	By circumcision technique: Device-based VMMC	0	2,604
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	210,491	104,687
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	37,145	15,543
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	15,364	1,244
	By Age: <1	12	9
	By Age: 1-9	0	15
	By Age: 10-14	4,011	62
	By Age: 15-19	4,142	151
	By Age: 20-24	3,253	360
	By Age: 25-29		394
	By Age: 30-49		201
	By Age: 50+	1,348	5
	Sum of Age disaggregations	15,364	602
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	92	47
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC)	15,272	995

	program		
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	201
	By circumcision technique: Surgical VMMC	14,659	1,192
	By circumcision technique: Device-based VMMC	705	51
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	12,460	1,024
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	2,199	220
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	13 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	796,977	1,039,471
	Total number of people in the	6,324,555	9,103,897

	target population		
	Age/sex: 10-14 Male	71,940	16,999
	Age/sex: 15-19 Male	78,515	24,248
	Age/sex: 20-24 Male	122,387	23,390
	Age/sex: 25-49 Male	85,418	30,083
	Age/sex: 50+ Male	17,447	11,116
	Age/sex: 10-14 Female	69,228	64,829
	Age/sex: 15-19 Female	81,982	70,468
	Age/sex: 20-24 Female	134,061	39,722
	Age/sex: 25-49 Female	114,699	48,376
	Age/sex: 50+ Female	21,300	11,318
	Sum of Age/Sex disaggregates	796,977	340,549
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	38 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	97,039	301,178
	Total number of people in the target population	258,476	1,272,548
	Age/sex: 10-14 Male	5,122	16,620
	Age/sex: 15-19 Male	16,241	17,384
	Age/sex: 20-24 Male	7,844	25,705
	Age/sex: 25-49 Male	18,814	46,189
	Age/sex: 50+ Male	857	12,284
	Age/sex: 10-14 Female	5,745	17,232

	Age/sex: 15-19 Female	16,929	19,059
	Age/sex: 20-24 Female	8,182	30,193
	Age/sex: 25-49 Female	16,827	49,723
	Age/sex: 50+ Female	478	13,200
	Sum of Age/Sex disaggregates	97,039	247,589
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,098	8,583
	Total estimated number of key population in the catchment area		3,272
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15,775	7,270
	By key population type: Males who inject drugs (13	160

	Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13	120
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	285	461
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based	13	

	on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		2,163
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		240
KP_PREV_TA	KP_PREV_TA Percentage of	n/a	

	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)		
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,530	150
	Total estimated number of key population in the catchment area		
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,415	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	

	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	0	
	<p>By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	14,115	
	<p>By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	0	
	<p>By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)</p>		

	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,194,825	877,661
	By Test Result: Negative	1,046,642	327,099
	By Test Result: Positive	148,183	28,046
	Sum of Test Result disaggregates	1,194,825	355,145



	Test Result by Age and Sex: Positive: <1 Male		676
	Test Result by Age and Sex: Positive: 1-4 Male		306
	Test Result by Age and Sex: Positive: 5-9 Male		623
	Test Result by Age and Sex: Positive: 10-14 Male		1,558
	Test Result by Age and Sex: Positive: 15-19 Male		2,373
	Test Result by Age and Sex: Positive: 20-24 Male		4,041
	Test Result by Age and Sex: Positive: 25-49 Male		4,070
	Test Result by Age and Sex: Positive: 50+ Male		668
	Test Result by Age and Sex: Positive: <1 Female		654
	Test Result by Age and Sex: Positive: 1-4 Female		289
	Test Result by Age and Sex: Positive: 5-9 Female		289
	Test Result by Age and Sex: Positive: 10-14 Female		2,851
	Test Result by Age and Sex: Positive: 15-19 Female		13,133
	Test Result by Age and Sex: Positive: 20-24 Female		15,677
	Test Result by Age and Sex: Positive: 25-49 Female		5,840
	Test Result by Age and Sex: Positive: 50+ Female		909
	Test Result by Age and Sex: Negative: <1 Male		7,641



	Test Result by Age and Sex: Negative: 1-4 Male		2,961
	Test Result by Age and Sex: Negative: 5-9 Male		11,512
	Test Result by Age and Sex: Negative: 10-14 Male		24,307
	Test Result by Age and Sex: Negative: 15-19 Male		26,087
	Test Result by Age and Sex: Negative: 20-24 Male		41,189
	Test Result by Age and Sex: Negative: 25-49 Male		41,779
	Test Result by Age and Sex: Negative: 50+ Male		6,303
	Test Result by Age and Sex: Negative: <1 Female		7,356
	Test Result by Age and Sex: Negative: 1-4 Female		2,819
	Test Result by Age and Sex: Negative: 5-9 Female		2,329
	Test Result by Age and Sex: Negative: 10-14 Female		5,765
	Test Result by Age and Sex: Negative: 15-19 Female		19,368
	Test Result by Age and Sex: Negative: 20-24 Female		74,348
	Test Result by Age and Sex: Negative: 25-49 Female		57,162
	Test Result by Age and Sex: Negative: 50+ Female		7,331
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	82,183	45,506
	Aggregated Age/sex - USE	416,403	128,437

	WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	81,091	17,746
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	615,148	126,725
	Sum of Aggregated Age/Sex <15	163,274	63,252
	Sum of Aggregated Age/Sex 15+	1,031,551	255,162
	Sum of Aggregated Age/Sex disaggregates	1,194,825	318,414
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		740
	Service Delivery Point by Result: Antenatal Clinic - Negative		5,246
	Service Delivery Point by Result: Labor & delivery - All results		4,733
	Service Delivery Point by Result: Labor & delivery - Positive		128
	Service Delivery Point by Result: Labor & delivery - Negative		4,572
	Service Delivery Point by Result: Under 5 Clinic – All results		901

	Service Delivery Point by Result: Under 5 Clinic - Positive		37
	Service Delivery Point by Result: Under 5 Clinic - Negative		841
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		132,792
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		4,242
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		76,431
	Service Delivery Point by Result: Tuberculosis – All results		2,973
	Service Delivery Point by Result: Tuberculosis - Positive		427
	Service Delivery Point by Result: Tuberculosis - Negative		2,091
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		2,578
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		322
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		1,931
	Service Delivery Point by Result: Outpatient		3,490

	Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		288
	Service Delivery Point by Result: Outpatient Department - Negative		1,678
	Service Delivery Point by Result: Inpatient – All Results		19,185
	Service Delivery Point by Result: Inpatient - Positive		1,514
	Service Delivery Point by Result: Inpatient - Negative		17,602
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		2,866
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		434
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		2,363
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		65,280
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		5,960
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		41,594
	Service Delivery Point by Result: Voluntary Counseling		

	& Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		3,600
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		34,488
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		2,309
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		17,032
	Service Delivery Point by Result: Mobile – All Results		66,084
	Service Delivery Point by Result: Mobile - Positive		6,558
	Service Delivery Point by Result: Mobile - Negative		59,288
	Service Delivery Point by Result: Home-based – All Results		641
	Service Delivery Point by Result: Home-based - Positive		320
	Service Delivery Point by		228

	Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		12,076
	Service Delivery Point by Result: Other - Positive		921
	Service Delivery Point by Result: Other - Negative		11,100
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	772,943	348,073
	By Test Result: Negative	663,526	308,485
	By Test Result: Positive	109,417	28,204
	Sum of Test Result disaggregates	772,943	336,689
	Test Result by Age and Sex: Positive: <1 Male		338
	Test Result by Age and Sex: Positive: 1-4 Male		275
	Test Result by Age and Sex: Positive: 5-9 Male		377
	Test Result by Age and Sex: Positive: 10-14 Male		570
	Test Result by Age and Sex: Positive: 15-19 Male		1,463
	Test Result by Age and Sex: Positive: 20-24 Male		3,320
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		757
	Test Result by Age and Sex:		338



	Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		302
	Test Result by Age and Sex: Positive: 5-9 Female		483
	Test Result by Age and Sex: Positive: 10-14 Female		706
	Test Result by Age and Sex: Positive: 15-19 Female		2,356
	Test Result by Age and Sex: Positive: 20-24 Female		5,974
	Test Result by Age and Sex: Positive: 25-49 Female		7,116
	Test Result by Age and Sex: Positive: 50+ Female		897
	Test Result by Age and Sex: Negative: <1 Male		3,796
	Test Result by Age and Sex: Negative: 1-4 Male		3,366
	Test Result by Age and Sex: Negative: 5-9 Male		4,294
	Test Result by Age and Sex: Negative: 10-14 Male		5,577
	Test Result by Age and Sex: Negative: 15-19 Male		16,477
	Test Result by Age and Sex: Negative: 20-24 Male		36,718
	Test Result by Age and Sex: Negative: 25-49 Male		49,526
	Test Result by Age and Sex: Negative: 50+ Male		7,401
	Test Result by Age and Sex: Negative: <1 Female		4,289
	Test Result by Age and Sex:		3,667

	Negative: 1-4 Female		
	Test Result by Age and Sex: Negative: 5-9 Female		5,263
	Test Result by Age and Sex: Negative: 10-14 Female		6,019
	Test Result by Age and Sex: Negative: 15-19 Female		24,417
	Test Result by Age and Sex: Negative: 20-24 Female		62,545
	Test Result by Age and Sex: Negative: 25-49 Female		70,997
	Test Result by Age and Sex: Negative: 50+ Female		9,683
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	33,797	22,868
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	301,928	114,830
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,633	19,450
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	421,585	140,485
	Sum of Aggregated Age/Sex <15	49,430	42,318
	Sum of Aggregated Age/Sex 15+	723,513	255,315
	Sum of Aggregated Age/Sex disaggregates	772,943	297,633
	Service Delivery Point by Result: Antenatal Clinic - All results		

	Service Delivery Point by Result: Antenatal Clinic - Positive		1,864
	Service Delivery Point by Result: Antenatal Clinic - Negative		23,301
	Service Delivery Point by Result: Labor & delivery - All results		802
	Service Delivery Point by Result: Labor & delivery - Positive		69
	Service Delivery Point by Result: Labor & delivery - Negative		709
	Service Delivery Point by Result: Under 5 Clinic – All results		317
	Service Delivery Point by Result: Under 5 Clinic - Positive		4
	Service Delivery Point by Result: Under 5 Clinic - Negative		266
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		74,704
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		4,639
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		44,537
	Service Delivery Point by Result: Tuberculosis – All		2,715

	results		
	Service Delivery Point by Result: Tuberculosis - Positive		849
	Service Delivery Point by Result: Tuberculosis - Negative		1,748
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		3,838
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		2,176
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		1,424
	Service Delivery Point by Result: Outpatient Department – All Results		7,013
	Service Delivery Point by Result: Outpatient Department - Positive		734
	Service Delivery Point by Result: Outpatient Department - Negative		6,208
	Service Delivery Point by Result: Inpatient – All Results		7,067
	Service Delivery Point by Result: Inpatient - Positive		749
	Service Delivery Point by Result: Inpatient - Negative		6,200
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		936

	Service Delivery Point by Result: HIV care and treatment clinic - Positive		106
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		142
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		14,500
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		1,034
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		13,167
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		8,504
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		114,127
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		955

	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		28,604
	Service Delivery Point by Result: Mobile – All Results		242
	Service Delivery Point by Result: Mobile - Positive		11
	Service Delivery Point by Result: Mobile - Negative		113
	Service Delivery Point by Result: Home-based – All Results		71
	Service Delivery Point by Result: Home-based - Positive		0
	Service Delivery Point by Result: Home-based - Negative		0
	Service Delivery Point by Result: Other – All Results		955
	Service Delivery Point by Result: Other - Positive		64
	Service Delivery Point by Result: Other - Negative		724
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		26,888
	Test Result by Aggregated Age and Sex: Negative <15 Female		8,073
	Test Result by Aggregated		36,142

	Age and Sex: Negative 15+ Female		
	Test Result by Aggregated Age and Sex: Positive <15 Male		572
	Test Result by Aggregated Age and Sex: Positive 15+ Male		3,382
	Test Result by Aggregated Age and Sex: Positive <15 Female		741
	Test Result by Aggregated Age and Sex: Positive 15+ Female		3,889
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		24,246
	Total number of registered new and relapsed TB cases, during the reporting period.		23,872
	Sex: Male		4,363
	Sex: Female		4,131
	Age: <1		49
	Age: 1-4		146
	Age: 5-9		125
	Age: 10-14		199
	Age: 15-19		
	Age: 20+		5,481

	Status: Positive		2,965
	Status: Negative		5,292
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		11,918
	Total number of registered new and relapsed TB cases, during the reporting period.		13,278
	Age 15-19		
	Age: <1		11
	Age: 1-4		143
	Age: 10-14		372
	Age: 20+		10,573
	Age: 5-9		279
	Sex: Female		6,812
	Sex: Male		5,046
	Status: Negative		5,704
	Status: Positive		5,954
	GEND_GBV_DSD	Number of people receiving post-GBV care	15,642
Age/Sex: <10 Male			538
Age/Sex: 10-14 Male			876
Age/Sex: 15-17 Male			975
Age/Sex: 18-24 Male			1,210
Age/Sex: 25+ Male			1,030
Age/Sex: <10 Female			1,082
Age/Sex: 10-14 Female			1,865

	Age/Sex: 15-17 Female		2,768
	Age/Sex: 18-24 Female		2,915
	Age/Sex: 25+ Female		3,382
	Sum of Age/Sex Disaggregates		16,641
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	13,391	10,785
	By type of service: Sexual Violence (Post-Rape Care)	2,354	7,971
	By PEP service provision (related to sexual violence services provided)	535	
GEND_GB_V_TA	Number of people receiving post-GBV care		0
	Age/Sex: <10 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-17 Male		0
	Age/Sex: 18-24 Male		0
	Age/Sex: 25+ Male		0
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 15-17 Female		0
	Age/Sex: 18-24 Female		0
	Age/Sex: 25+ Female		0
	Sum of Age/Sex Disaggregates		0
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)		0
	By type of service: Sexual Violence (Post-Rape Care)		0
	By PEP service provision		

	(related to sexual violence services provided)		
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	73,963	13,527
	Age/Sex: <10 Male		0
	Age/Sex: 10-14 Male		1,006
	Age/Sex: 15-19 Male		1,437
	Age/Sex: 20-24 Male		1,631
	Age/Sex: 25+ Male		1,176
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		1,242
	Age/Sex: 15-19 Female		2,586
	Age/Sex: 20-24 Female		2,632
	Age/Sex: 25+ Female		1,411
	By Age: 0-9	5,014	0
	By Age: 10-14	12,284	5,652
	By Age: 15-19	15,611	6,191
	By Age: 20-24	17,710	5,832
	By Age: 25+	23,344	1,108
	Sum of Age disaggregates	73,963	18,783
GEND_NORM_TA	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria		101,772
	Age/Sex: <10 Male		15,252
	Age/Sex: 10-14 Male		20,850
	Age/Sex: 15-19 Male		14,763
	Age/Sex: 20-24 Male		10
	Age/Sex: 25+ Male		15
	Age/Sex: <10 Female		15,253
Age/Sex: 10-14 Female		20,854	

	Age/Sex: 15-19 Female		14,754
	Age/Sex: 20-24 Female		3
	Age/Sex: 25+ Female		18
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25+		
	Sum of Age disaggregates		
	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	3,213	55,962
	Age/Sex: <1 Male		317
	Age/Sex: 1-4 Male		2,020
	Age/Sex: 5-9 Male		6,437
	Age/Sex: 10-14 Male		8,624
	Age/Sex: 15-17 Male		9,979
	Age/Sex: 18-24 Male		30
	Age/Sex: 25+ Male		8
	Age/Sex: <1 Female		339
	Age/Sex: 1-4 Female		2,593
	Age/Sex: 5-9 Female		7,509
	Age/Sex: 10-14 Female		10,985
	Age/Sex: 15-17 Female		11,827
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		40
	Age/Sex: 25+ Female		10
	Sum of Age/Sex disaggregates		60,718
OVC_ACC_DSD	Number of active beneficiaries receiving		144
OVC_ACC_TA	Number of active beneficiaries receiving		144

	support from PEPFAR OVC programs to access HIV services		
	Age/Sex: <1 Male		6
	Age/Sex: 1-4 Male		5
	Age/Sex: 5-9 Male		5
	Age/Sex: 10-14 Male		5
	Age/Sex: 15-17 Male		6
	Age/Sex: 18-24 Male		10
	Age/Sex: 25+ Male		8
	Age/Sex: <1 Female		13
	Age/Sex: 1-4 Female		8
	Age/Sex: 5-9 Female		10
	Age/Sex: 10-14 Female		8
	Age/Sex: 15-17 Female		10
	Age/Sex: 18-24 Female		25
	Age/Sex: 25+ Female		25
	Sum of Age/Sex disaggregates		144
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	770,074	509,546
	Age/Sex: <1 Male		2,284
	Age/Sex: 1-4 Male		20,031
	Age/Sex: 5-9 Male		42,805
	Age/Sex: 10-14 Male		57,771
	Age/Sex: 15-17 Male		37,701
	By: Age/sex: Male 18-24		11,595
	By: Age/sex: Male 25+		26,557
	Age/Sex: <1 Female		2,397
	Age/Sex: 1-4 Female		21,725

	Age/Sex: 5-9 Female		44,987
	Age/Sex: 10-14 Female		61,356
	Age/Sex: 15-17 Female		47,264
	By: Age/sex: 18-24 Female		14,062
	By: Age/sex: 25+ Female		28,626
	Sum of Age/Sex disaggregates		338,321
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		



	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		

	Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age		

	and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS		

	countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		465
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		8,064
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		14,577
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		19,778
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		11,167
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		5,260
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		15,738
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		470
	Required only for DREAMS countries - By service, age and sex: Economic		7,933



	Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic		14,329
	Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic		19,823
	Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic		11,450
	Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic		4,883
	Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic		14,507
	Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,045	1,680
	Age/Sex: <1 Male		71
	Age/Sex: 1-4 Male		107
	Age/Sex: 5-9 Male		109
	Age/Sex: 10-14 Male		116
	Age/Sex: 15-17 Male		126
	By age/sex: 18-24 Male		146
	By age/sex: 25+ Male		105
	Age/Sex: <1 Female		80

	Age/Sex: 1-4 Female		121
	Age/Sex: 5-9 Female		121
	Age/Sex: 10-14 Female		126
	Age/Sex: 15-17 Female		156
	By age/sex: 18-24 Female		166
	By age/sex: 25+ Female		130
	Sum of Age/Sex disaggregates		1,024
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		7
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		8
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education		

	Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		10



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		7
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		10
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social		

	Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social		
	Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social		
	Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social		
	Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic		
	Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area,		35



	age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		5
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		14
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		30
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		30
	Required only for DREAMS		

	countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		8
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		10
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		25
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	226,158	746,266
	Age/sex: <1 Male	1,037	3,376

	Age/sex: 1-4 Male	2,086	7,887
	Age/sex: 5-9 Male	3,974	11,368
	Age/sex: 10-14 Male	2,932	9,332
	Age/sex: 15-19 Male	2,925	15,458
	Age/sex: 20-24 Male	6,980	25,702
	Age/sex: 25-49 Male	51,215	95,771
	Age/sex: 50+ Male	14,533	24,299
	Age/sex: <1 Female	1,106	3,408
	Age/sex: 1-4 Female	2,726	6,710
	Age/sex: 5-9 Female	5,024	11,997
	Age/sex: 10-14 Female	4,464	9,805
	Age/sex: 15-19 Female	5,458	15,904
	Age/sex: 20-24 Female	12,956	38,485
	Age/sex: 25-49 Female	86,263	138,088
	Age/sex: 50+ Female	22,479	39,565
	Sun of Age/Sex disaggregates	226,158	457,155
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,029	13,500
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	75,654	25,233
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,319	12,619
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	127,156	29,497
	Sum of Aggregated Age/Sex disaggregates	226,158	80,849
CARE_CURR_TA	Number of HIV positive adults and children who	214,473	159,662

	received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Male	237	492
	Age/sex: 1-4 Male	792	1,734
	Age/sex: 5-9 Male	2,464	2,728
	Age/sex: 10-14 Male	2,140	3,489
	Age/sex: 15-19 Male	1,655	5,434
	Age/sex: 20-24 Male	1,423	11,155
	Age/sex: 25-49 Male	52,145	22,321
	Age/sex: 50+ Male	17,683	4,186
	Age/sex: <1 Female	206	576
	Age/sex: 1-4 Female	1,084	1,759
	Age/sex: 5-9 Female	2,962	3,645
	Age/sex: 10-14 Female	2,583	4,297
	Age/sex: 15-19 Female	2,650	7,489
	Age/sex: 20-24 Female	4,823	15,764
	Age/sex: 25-49 Female	97,465	67,942
	Age/sex: 50+ Female	24,161	5,011
	Sum of Age/Sex disaggregates	214,473	158,022
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,633	3,519
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	72,906	6,793
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,835	4,746
	Aggregated Age/sex - USE	129,099	10,424

	WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates	214,473	25,482
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	45,734	160,242
	Age/sex: <1 Male	341	828
	Age/sex: 1-4 Male	1,001	1,805
	Age/sex: 5-9 Male	588	1,969
	Age/sex: 10-14 Male	815	1,753
	Age/sex: 15-19 Male	1,082	3,221
	Age/sex: 20-24 Male	1,697	7,544
	Age/sex: 25-49 Male	12,099	17,443
	Age/sex: 50+ Male	1,487	3,027
	Age/sex: <1 Female	363	883
	Age/sex: 1-4 Female	810	1,602
	Age/sex: 5-9 Female	617	2,252
	Age/sex: 10-14 Female	937	2,012
	Age/sex: 15-19 Female	1,429	3,891
	Age/sex: 20-24 Female	4,277	11,264
	Age/sex: 25-49 Female	16,504	29,059
	Age/sex: 50+ Female	1,687	5,299
	Sum of Age/sex disaggregates	45,734	93,852
	Aggregated Age/sex: <15 Male	2,745	3,269

	Aggregated Age/sex: 15+ Male	16,365	7,267
	Aggregated Age/sex: <15 Female	2,727	3,326
	Aggregated Age/sex: 15+ Female	23,897	8,026
	Sum of Aggregated Age/sex disaggregates	45,734	21,888
CARE_NEW_TA	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		33,894
	Age/sex: <1 Female		258
	Age/sex: 1-4 Female		459
	Age/sex: 5-9 Female		803
	Age/sex: 10-14 Female		915
	Age/sex: 15-19 Female		2,276
	Age/sex: 20-24 Female		7,262
	Age/sex: 25-49 Female		6,012
	Age/sex: 50+ Female		946
	Age/sex: <1 Male		239
	Age/sex: 1-4 Male		413
	Age/sex: 5-9 Male		627
	Age/sex: 10-14 Male		814
	Age/sex: 15-19 Male		1,270
	Age/sex: 20-24 Male		5,505
	Age/sex: 25-49 Male		4,557
	Age/sex: 50+ Male		809

	Aggregated Age/sex: <15 Female		1,072
	Aggregated Age/sex: <15 Male		842
	Aggregated Age/sex: 15+ Female		3,298
	Aggregated Age/sex: 15+ Male		2,192
	Sum of Aggregated Age/sex disaggregates	45,734	21,888
	Sum of age/sex disaggregates		33,165
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	100 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	22,822	1,120
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	22,822	2,209
	Age: <1	667	106
	Age: 1-4	2,638	103
	Age: 5-14	5,514	313
	Age: 15-17	3,085	245
	Age: 18+	10,918	350
	Sum of Age disaggregates	22,822	1,117
	Aggregated Age: <18	11,904	
	Aggregated Age: 18+	10,918	

	Sum of Aggregated Age disaggregates	22,822	
	By Pregnancy/Postpartum Status: Pregnant		48
	By Pregnancy/Postpartum Status: Postpartum		79
FN_THER_TA	FN_THER_TA Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	n/a	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.		245
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.		245
	Age: <1		21
	Age: 1-4		87
	Age: 5-14		69
	Age: 15-17		35
	Age: 18+		33
	Sum of Age disaggregates		245
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <18		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 18+		
	By Pregnancy/Postpartum Status: Pregnant		

	By Pregnancy/Postpartum Status: Postpartum		
	Sum of Aggregated Age disaggregates		
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		7,329
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		125
	Age: 1-4		237
	Age: 5-9		279
	Age: 10-14		391
	Age: 15-19		526
	Age: 20+		1,664
	Sum of Age disaggregates		3,222
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		780
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		943

	Sex: Male		1,572
	Sex: Female		1,584
TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		3,784
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		9
	Age: 1-4		47
	Age: 5-9		92
	Age: 10-14		90
	Age: 15-19		250
	Age: 20+		3,195
	Sum of Age disaggregates		3,683
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		0
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		37
	Sex: Male		1,551

	Sex: Female		2,219
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		588,341
	Number of HIV positive adults and children who received care and treatment services		591,269
	Age: <1		3,302
	Age: 1-4		10,688
	Age: 5-14		21,868
	Age: 15-17		75,981
	Age: 18+ years		192,181
	Sum of Age disaggregates		304,020
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		8,302
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		24,992
	By Pregnancy/Postpartum Status: Pregnant		14,505
	By Pregnancy/Postpartum Status: Postpartum		10,305
	FN_ASSESS_TA	FN_ASSESS_TA Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a

	The number of PLHIV who were nutritionally assessed via anthropometric measurement		86,585
	Number of HIV positive adults and children who received care and treatment services		91,565
	Age: <1		1,934
	Age: 1-4		3,368
	Age: 5-14		4,206
	Age: 15-17		9,256
	Age: 18+ years		67,820
	Sum of Age disaggregates		86,584
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		6,150
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		12,592
	By Pregnancy/Postpartum Status: Pregnant		24,864
	By Pregnancy/Postpartum Status: Postpartum		5,527
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	36 %	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6,730	14,292
	The number of registered	18,742	13,934

	new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		
	Age: <1		34
	Age: 1-4		104
	Age: 5-9		96
	Age: 10-14		140
	Age: 15-19		1,278
	Age: 20+		3,857
	Sum of Age disaggregates		5,509
	Male	2,197	2,680
	Female	4,533	2,828
	Sum of Sex disaggregates	6,730	5,508
	Newly tested	1,060	
	Known HIV-positive	5,670	3,118
	Sum of Test Status disaggregates	6,730	3,118
	Aggregated Age: <15	2,135	87
	Aggregated Age: 15+	4,595	3,326
	Sum of Aggregated Age disaggregates	6,730	3,413
	Timeliness: Art initiation <8 weeks of start of TB treatment		2,984
	Timeliness: Art initiation >8 weeks of start of TB treatment		1,350
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered		7,639

	new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		8,424
	Age: <1		17
	Age: 1-4		115
	Age: 5-9		166
	Age: 10-14		169
	Age: 15-19		457
	Age: 20+		6,682
	Sum of Age disaggregates		7,606
	Aggregated Age: <15		0
	Aggregated Age: 15+		77
	Sum of Aggregated Age disaggregates		77
	Male		3,263
	Female		4,343
	Sum of Sex disaggregates		7,606
	Known HIV-positive		2,530
	Newly tested		
	Sum of Test Status disaggregates		2,530
	Timeliness: Art initiation <8 weeks of start of TB treatment		3,784
	Timeliness: Art initiation >8 weeks of start of TB		3,822

	treatment		
TB_OUTCOME_DSD	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		19,783
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		19,100
	Outcome by Age: Cured <1		13
	Outcome by Age: Cured 1-4		24
	Outcome by Age: Cured 5-9		29
	Outcome by Age: Cured 10-14		40
	Outcome by Age: Cured: 15-19		1,585
	Outcome by Age: Cured 20+		4,126
	Outcome by Age: Treatment Complete <1		0
	Outcome by Age: Treatment Complete 1-4		1
	Outcome by Age: Treatment Complete 5-9		8
	Outcome by Age: Treatment Complete 10-14		10
	Outcome by Age: Treatment Complete 15-19		26



	Outcome by Age: Treatment Complete 20+		850
	Outcome by Age: Treatment Failed <1		1
	Outcome by Age: Treatment Failed 1-4		1
	Outcome by Age: Treatment Failed 5-9		1
	Outcome by Age: Treatment Failed 10-14		1
	Outcome by Age: Treatment Failed 15-19		104
	Outcome by Age: Treatment Failed 20+		196
	Outcome by Age: Died <1		1
	Outcome by Age: Died 1-4		1
	Outcome by Age: Died 5-9		38
	Outcome by Age: Died 10-14		1
	Outcome by Age: Died 15-19		1
	Outcome by Age: Died 20+		72
	Outcome by Age: Lost to Follow-up <1		1
	Outcome by Age: Lost to Follow-up 1-4		1
	Outcome by Age: Lost to Follow-up 5-9		2
	Outcome by Age: Lost to Follow-up 10-14		2
	Outcome by Age: Lost to Follow-up 15-19		2
	Outcome by Age: Lost to Follow-up 20+		201
	Outcome by Age: Not Evaluated <1		1



	Outcome by Age: Not Evaluated 1-4		1
	Outcome by Age: Not Evaluated 5-9		1
	Outcome by Age: Not Evaluated 10-14		1
	Outcome by Age: Not Evaluated 15-19		1
	Outcome by Age: Not Evaluated 20+		55
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		458
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_OUTCOME_TA	TB_OUTCOME_TA TB	n/a	

	treatment outcomes among registered new and relapsed TB cases who are HIV-positive		
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		11,248
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		18,378
	Outcome by Age: Cured <1		4
	Outcome by Age: Cured 1-4		54
	Outcome by Age: Cured 5-9		142
	Outcome by Age: Cured 10-14		139
	Outcome by Age: Cured 15-19		148
	Outcome by Age: Cured 20+		4,604
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Age: Treatment Complete <1		2
	Outcome by Age: Treatment Complete 1-4		65
	Outcome by Age: Treatment Complete 5-9		125
	Outcome by Age: Treatment Complete 10-14		122



Outcome by Age: Treatment Complete 15-19		148
Outcome by Age: Treatment Complete 20+		4,560
Outcome by Sex: Treatment Complete Female		2,354
Outcome by Sex: Treatment Complete Male		2,660
Outcome by Age: Treatment Failed <1		0
Outcome by Age: Treatment Failed 1-4		2
Outcome by Age: Treatment Failed 5-9		5
Outcome by Age: Treatment Failed 10-14		2
Outcome by Age: Treatment Failed 15-19		20
Outcome by Age: Treatment Failed 20+		120
Outcome by Sex: Treatment Failed Female		
Outcome by Sex: Treatment Failed Male		
Outcome by Age: Died <1		1
Outcome by Age: Died 1-4		2
Outcome by Age: Died 5-9		2
Outcome by Age: Died 10-14		3
Outcome by Age: Died 15-19		5
Outcome by Age: Died 20+		362
Outcome by Sex: Died Female		
Outcome by Sex: Died Male		
Outcome by Age: Lost to		10

	Follow-up <1		
	Outcome by Age: Lost to Follow-up 1-4		5
	Outcome by Age: Lost to Follow-up 5-9		5
	Outcome by Age: Lost to Follow-up 10-14		5
	Outcome by Age: Lost to Follow-up 15-19		2
	Outcome by Age: Lost to Follow-up 20+		221
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Age: Not Evaluated <1		5
	Outcome by Age: Not Evaluated 1-4		10
	Outcome by Age: Not Evaluated 5-9		5
	Outcome by Age: Not Evaluated 10-14		8
	Outcome by Age: Not Evaluated 15-19		2
	Outcome by Age: Not Evaluated 20+		291
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB	98 %	

	symptoms at the last clinical visit to an HIV care facility during the reporting period.		
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	222,589	365,887
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	226,158	746,266
	Age: <1	252	1,718
	Age: 1-4	1,350	12,265
	Age: 5-9	3,003	18,202
	Age: 10-14	5,463	19,420
	Age: 15-19	19,131	31,085
	Age: 20+		61,670
	Sum of Age disaggregates	29,199	144,360
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	10,068	46,686
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	212,521	51,663
	Sum of Aggregated Age disaggregates	222,589	98,349
	Sex: Male	95,240	69,198
	Sex: Female	127,349	76,346
	Sum of Sex disaggregates	222,589	145,544
TB_SCREEN_TA	TB_SCREEN_TA	n/a	

	Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.		
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		206,182
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	214,473	159,662
	Age: <1		675
	Age: 1-4		3,710
	Age: 5-9		6,228
	Age: 10-14		5,746
	Age: 15-19		10,852
	Age: 20+		165,182
	Sum of Age disaggregates		192,393
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		116
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		1,999
	Sum of Aggregated Age disaggregates		2,115
	Sex: Female		121,438
	Sex: Male		84,653

	Sum of Sex disaggregates		206,091
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	90 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	65,326	28,111
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	72,465	
	By infants who received a virologic test within 2 months of birth	33,746	7,049
	By infants who received their first virologic HIV test between 2 and 12 months of age	31,580	6,834
	Sum of Infant Age disaggregates	65,326	13,883
	By infants with a positive virologic test result within 12 months of birth	7,836	
	Number of infants with a positive virological test result within 2 months of birth		187
	Number of infants with a positive virological test result within 12 months of birth		635
	PMTCT_EID_TA	PMTCT_EID_TA Percent of	n/a

	infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)		
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		6,227
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		3,339
	By infants who received their first virologic HIV test between 2 and 12 months of age		2,884
	Sum of Infant Age disaggregates		6,223
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		194
	Number of infants with a positive virological test result within 12 months of birth		66
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on	n/a	

	cotrimoxazole (CTX) prophylaxis within two months of birth		
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		15,243
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		18,375
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		232,923
	Age/Sex: <1 Male		833

	Age/Sex: 1-4 Male		3,523
	Age/Sex: 5-9 Male		5,819
	Age/Sex: 10-14 Male		8,135
	Age/Sex: 15-19 Male		11,526
	Age/Sex: 20-24 Male		19,845
	Age/Sex: 25-49 Male		27,951
	Age/Sex: 50+ Male		16,843
	Age/Sex: <1 Female		826
	Age/Sex: 1-4 Female		3,489
	Age/Sex: 5-9 Female		6,032
	Age/Sex: 10-14 Female		8,457
	Age/Sex: 15-19 Female		14,275
	Age/Sex: 20-24 Female		24,418
	Age/Sex: 25-49 Female		34,630
	Age/Sex: 50+ Female		12,243
	Number of HIV-infected adults and children receiving care and support services outside of the health facility		796
	Age/Sex: <1 Female		9
	Age/Sex: <1 Male		6
	Age/Sex: 1-4 Female		14
	Age/Sex: 1-4 Male		10
	Age/Sex: 10-14 Female		9
	Age/Sex: 10-14 Male		6
	Age/Sex: 15-19 Female		60
	Age/Sex: 15-19 Male		44
	Age/Sex: 20-24 Female		162
	Age/Sex: 20-24 Male		117
	Age/Sex: 25-49 Female		185
	Age/Sex: 25-49 Male		131
	Age/Sex: 5-9 Female		19
CARE_COMM_TA			

	Age/Sex: 5-9 Male		14
	Age/Sex: 50+ Female		5
	Age/Sex: 50+ Male		5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	654,591	644,213
	Age/Sex: <1 Male	2,449	1,217
	Age/Sex: 1-4 Male	4,977	4,538
	Age/Sex: 5-14 Male	16,208	11,458
	Age/Sex: 15-19 Male		28,301
	Age/Sex: 20+ Male		92,440
	Age/Sex: <1 Female	2,547	1,313
	Age/Sex: 1-4 Female	5,042	4,696
	Age/Sex: 5-14 Female	16,265	18,686
	Age/Sex: 15-19 Female		38,960
	Age/Sex: 20+ Female		145,211
	Aggregated Age/Sex: <1 Male	2,449	298
	Aggregated Age/Sex: <1 Female	2,547	412
	Aggregated Age/Sex: 15+ Male	225,162	20,081
	Aggregated Age/Sex: 1-14 Female		2,709
	Aggregated Age/Sex: 15+ Female	381,941	25,789
	Sum of Aggregated Age/Sex <15	47,488	
	Sum of Aggregated Age/Sex 15+	607,103	45,870
	Sum of Aggregated Age/Sex disaggregates	654,591	45,870
	Aggregated Age/Sex: 1-14		2,759

	Male		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	4,996	6,178
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	25,016	133,152
	Age/Sex: <1 Male	126	483
	Age/Sex: 1-4 Male	184	1,909
	Age/Sex: 5-14 Male	594	3,941
	Age/Sex: 15-19 Male		11,262
	Age/Sex: 20+ Male		36,223
	Age/Sex: <1 Female	130	493
	Age/Sex: 1-4 Female	187	2,131
	Age/Sex: 5-14 Female	596	5,179
	Age/Sex: 15-19 Female		12,934
	Age/Sex: 20+ Female		50,684
	Sum of Age/Sex disaggregations	1,817	125,239
	Aggregated Age/Sex: <1 Male	126	152
	Aggregated Age/Sex: <1 Female	130	71
	Aggregated Age/Sex: 1-14 Male		1,108
	Aggregated Age/Sex: 15+ Male	7,739	8,054
	Aggregated Age/Sex: 1-14 Female		1,321
	Aggregated Age/Sex: 15+ Female	11,860	10,489
	Sum of Aggregated Age/Sex <15	1,817	
	Sum of Aggregated Age/Sex	19,599	18,543

	15+		
	Sum of Aggregated Age/Sex disaggregates	21,416	18,543
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	256	2,652
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	120,980	126,469
	By Age/Sex: <1 Male	662	602
	By Age/Sex: 1-4 Male	1,897	1,163
	By Age/Sex: 5-9 Male	1,544	1,042
	By Age/Sex: 10-14 Male	1,932	1,340
	By Age/Sex: 15-19 Male	2,242	2,397
	By Age/Sex: 20-24 Male	3,920	5,807
	By Age/Sex: 25-49 Male	29,105	16,312
	By Age/Sex: 50+ Male	5,975	2,441
	By Age/Sex: <1 Female	912	715
	By Age/Sex: 1-4 Female	1,667	1,221
	By Age/Sex: 5-9 Female	1,776	1,398
	By Age/Sex: 10-14 Female	3,132	1,661
	By Age/Sex: 15-19 Female	3,772	3,338
	By Age/Sex: 20-24 Female	9,669	9,582
	By Age/Sex: 25-49 Female	44,960	20,440
	By Age/Sex: 50+ Female	7,815	4,651
	Sum of Age/Sex disaggregates	120,980	74,110
	Aggregated Grouping by Age: <1 Male	662	348
	Aggregated Grouping by Age/Sex: 1-14 Male		1,744
Aggregated Grouping by Age/Sex: 15+ Male	41,242	6,123	
Aggregated Grouping by	912	349	

	Age/Sex: <1 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	66,216	6,844
	Sum of Aggregated Age/Sex disaggregates	120,980	12,967
	Pregnancy status	12,132	12,290
	Breastfeeding status	556	308
	Aggregated Grouping by Age/Sex: 1-14 Female		2,054
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		28,458
	By Age/Sex: <1 Male		219
	By Age/Sex: 1-4 Male		222
	By Age/Sex: 5-9 Male		266
	By Age/Sex: 10-14 Male		650
	By Age/Sex: 15-19 Male		1,618
	By Age/Sex: 20-24 Male		3,774
	By Age/Sex: 25-49 Male		4,668
	By Age/Sex: 50+ Male		541
	By Age/Sex: <1 Female		241
	By Age/Sex: 1-4 Female		445
	By Age/Sex: 5-9 Female		512
	By Age/Sex: 10-14 Female		708
	By Age/Sex: 15-19 Female		1,954
	By Age/Sex: 20-24 Female		5,095
	By Age/Sex: 25-49 Female		6,998
	By Age/Sex: 50+ Female		629
	Sum of Age/Sex disaggregates		28,540
	Aggregated Grouping by Age: <1 Male		117
	Aggregated Grouping by		219

	Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		2,147
	Aggregated Grouping by Age: <1 Female		99
	Aggregated Grouping by Age/Sex: 1-14 Female		617
	Aggregated Grouping by Age/Sex: 15+ Female		3,013
	Sum of Aggregated Age/Sex disaggregates		5,160
	Pregnancy status		2,673
	Breastfeeding status		228
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	85 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	89,775	103,769
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	105,618	109,692
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		725

	ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,823
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		3,443
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		18,435
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		835
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		2,131
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		4,013

	ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		26,384
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		888
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,930
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		3,895

	to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		19,825
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,060
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		2,205
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		4,449

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		29,122
	Numerator by Status: Pregnant		2,657
	Numerator by Status: Breastfeeding		1,748
	Denominator by Status: Pregnant		2,894
	Denominator by Status: Breastfeeding		2,026
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		22,581
	Total number of adults and children who initiated ART in the 12 months prior to the		23,262

	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		257
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		644
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		2,310
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		6,517
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		261
	Age/Sex: 5-14 Female		817

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		2,589
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		8,803
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		278
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		975

	to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,887
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		6,638
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		339
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		1,319

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		2,142
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		9,403
	Numerator by Status: Pregnant		929
	Numerator by Status: Breastfeeding		264
	Denominator by Status: Pregnant		1,485
	Denominator by Status: Breastfeeding		385
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12	n/a	

	months after initiation of ART		
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		369,943
	Number of adults and children on ART at least 6 months whose medical records were reviewed		435,813
	Age/Sex: <1 Male		935
	Age/Sex: 1-4 Male		2,312
	Age/Sex: 5-14 Male		6,842
	Age/Sex: 15-19 Male		12,875
	Age/Sex: 20+ Male		60,232
	Age/Sex: <1 Female		861
	Age/Sex: 1-4 Female		2,430
	Age/Sex: 5-14 Female		7,633
	Age/Sex: 15-19 Female		16,178
	Age/Sex: 20+ Female		93,241
	Results Category: Undetectable		133,640
	Results Category: Detectable		34,240
TX_VIRAL_TA	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months.		76,884
	Number of adults and children on ART at least 6		87,873

	months whose medical records were reviewed.		
	Age/Sex: <1 Male		247
	Age/Sex: 1-4 Male		609
	Age/Sex: 5-14 Male		1,769
	Age/Sex: 15-19 Male		6,524
	Age/Sex: 20+Male		21,620
	Age/Sex: <1 Female		302
	Age/Ses: 1-4 Female		627
	Age/Sex: 5-14 Female		2,147
	Age/Sex: 15-19 Female		7,412
	Age/Sex: 20+ Female		33,669
	Result Category: Undetectable		40,380
	Result Category: Detectable		9,277
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	181	2
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	292	140
	By clinical laboratories	256	103
	By Point-of-care testing sites	36	10
LAB_CAP_TA	Number of PEPFAR-supported testing		97

	facilities with capacity to perform clinical laboratory tests		
	By clinical laboratories		89
	By Point-of-care testing sites		14
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	78	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	472	34
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	481	27
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	440	11
	CD4: Number of laboratories that perform this testing	177	21
	CD4: Number of laboratories that participate in this PT program	161	15
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	161	15

	Early infant diagnostics: Number of laboratories that perform this testing	4	
	Early infant diagnostics: Number of laboratories that participate in this PT program	3	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3	
	HIV viral load: Number of laboratories that perform this testing	3	
	HIV viral load: Number of laboratories that participate in this PT program	2	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2	
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		23
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		23
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful		12

	passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		12
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		12
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		12
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency		

	testing (PT) program		
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		11
	CD4: Number of laboratories that participate in this PT program		12
	CD4: Number of laboratories that perform this testing		24
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	Early infant diagnostics: Number of laboratories that participate in this PT program		
	Early infant diagnostics: Number of laboratories that perform this testing		
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		10
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		35
	HIV serologic/diagnostic testing: Number of laboratories that perform this		41

	testing		
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	HIV viral load: Number of laboratories that participate in this PT program		
	HIV viral load: Number of laboratories that perform this testing		
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		9
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		17
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		18
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		9
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate		9

	in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		9
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		1
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		327,815
	Number of viral load tests performed from adults and children on ART within the current reporting period		387,792
	Age/Sex: <1 Male		623
	Age/Sex: 1-4 Male		2,061

	Age/Sex: 5-14 Male		6,264
	Age/Sex: 15-19 Male		13,499
	Age/Sex: 20+ Male		54,865
	Age/Sex: <1 Female		446
	Age/Sex: 1-4 Female		2,102
	Age/Sex: 5-14 Female		6,789
	Age/Sex: 15-19 Female		16,922
	Age/Sex: 20+ Female		79,395
	Pregnant		5,429
	Breastfeeding		8,562
	Test indication: Routine monitoring		53,349
	Test indication: Targeted monitoring		
TX_UNDETECT_TA	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		69,601
	Number of viral load tests performed from adults and children on ART within the current reporting period		72,748
	Age/Sex: <1 Female		181
	Age/Sex: <1 Male		157
	Age/Sex: 1-4 Female		826
	Age/Sex: 1-4 Male		860
	Age/Sex: 15-19 Female		9,484
	Age/Sex: 15-19 Male		7,080

	Age/Sex: 20+ Female		25,534
	Age/Sex: 20+ Male		18,829
	Age/Sex: 5-14 Female		2,559
	Age/Sex: 5-14 Male		2,452
	Breastfeeding		3,403
	Pregnant		3,016
	Test indication: Routine monitoring		37,329
	Test indication: Targeted monitoring		15,089
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	3,735	1,000
	By Graduates: Doctors	134	
	By Graduates: Nurses	250	100
	By Graduates: Midwives	153	50
	By Graduates: Social service workers	266	
	By Graduates: Laboratory professionals	1	
	By Graduates: Other	2,931	350
	Sum of Graduates disaggreagtes	3,735	500
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing	90 %	



	integrated voluntary family planning services		
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	36	190
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	40	197
	Service delivery type: Care and Support		93
	Service delivery type: Treatment		54
	Service delivery type: PMTCT		52
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
FPINT_SITE_TA	FPINT_SITE_TA Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	n/a	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		203



	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment		256
	Service delivery type: Care and Support		48
	Service delivery type: Treatment		21
	Service delivery type: PMTCT		14
	Sum of Service Delivery Type (Care, Tx and PMTCT) disaggregates		83

Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7422	Central Contraceptive Procurement	Private Contractor	U.S. Agency for International Development	GHP-State	1,000,000
7423	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	61,143,463
7427	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
7428	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
10203	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
10207	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	1,881,442
10219	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	5,187,372

			Prevention		
10220	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,105,159
10224	National HIV/AIDS/STI/TB Council - Zambia	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	346,803
10225	Provincial Health Office - Eastern Province	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,749,786
10227	Provincial Health Office - Western Province	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,163,154
10235	University of Zambia School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	465,490



10236	University Teaching Hospital	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	8,505,801
10238	Zambia National Blood Transfusion Service	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,353,644
10241	Catholic Relief Services	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,187,292
10260	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	3,990,680
10274	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,047,612
10354	Save the Children US	NGO	U.S. Agency for International Development	GHP-State	1,600,000
10364	Creative Associates	NGO	U.S. Agency for International	GHP-State	368,750

	International Inc		Development		
10726	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	1,382,793
10816	Boston University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10875	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	155,000
10984	Project Concern International	NGO	U.S. Department of Defense	GHP-State	3,200,336
11027	National HIV/AIDS/STI/TB Council - Zambia	Parastatal	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
11626	JHPIEGO	University	U.S. Department of Defense	GHP-State	4,119,574
11627	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	3,608,382
11694	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	203,606

12267	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	1,500,000
12271	Population Council	NGO	U.S. Agency for International Development	GHP-State	0
12272	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
12276	Macha Research Trust, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12821	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	0
12942	Project Concern International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12988	Care International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13006	CENTER FOR INFECTIOUS DISEASE AND	NGO	U.S. Department of Health and Human	GHP-State	0

	RESEARCH IN ZAMBIA		Services/Centers for Disease Control and Prevention		
13016	Catholic Medical Mission Board	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13033	Population Council	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,291,523
13076	John Snow, Inc.	Private Contractor	U.S. Department of Defense	GHP-State	650,000
13562	Chreso Ministries	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,636,664
13580	Centre for Infectious Diseases Research in Zambia (CIDRZ)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	23,419,169
13684	University of Zambia School of	University	U.S. Department of Health and	GHP-State	842,885



	Medicine		Human Services/Centers for Disease Control and Prevention		
13731	Development Aid from People to People Humana Zambia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,208,388
13787	Churches Health Association of Zambia	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,157,141
13792	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	0
14338	World Vision International	FBO	U.S. Agency for International Development	GHP-State	0
14339	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	88,755
14420	Lusaka Provincial Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,343,344
14421	Southern	Host Country	U.S. Department	GHP-State	6,029,280

	Provincial Health Office	Government Agency	of Health and Human Services/Centers for Disease Control and Prevention		
14452	Population Services International	NGO	U.S. Department of Defense	GHP-State	750,000
14507	FHI 360	NGO	U.S. Department of Defense	GHP-State	3,784,574
16634	Expanded Church Response Trust	NGO	U.S. Agency for International Development	GHP-State	4,317,938
16656	TBD	TBD	Redacted	Redacted	Redacted
16690	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	381,033
16833	Emory University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	407,212
16903	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0

17100	Zambia Center for Communication Programs	NGO	U.S. Agency for International Development	GHP-State	1,009,500
17168	Expanded Church Response Trust	NGO	U.S. Agency for International Development	GHP-State	0
17354	FHI 360	NGO	U.S. Agency for International Development	GHP-State	600,000
17355	(ASSIST) - Applying Science to Strengthen and Improve Systems Project	Private Contractor	U.S. Agency for International Development	GHP-State	500,000
17356	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,267,467
17360	Education Development Center	NGO	U.S. Agency for International Development	GHP-State	0
17395	Luapula Foundation	NGO	U.S. Agency for International Development	GHP-State	1,000,000
17396	TBD	TBD	Redacted	Redacted	Redacted
17399	TBD	TBD	Redacted	Redacted	Redacted
17400	TBD	TBD	Redacted	Redacted	Redacted
17403	World Vision International	FBO	U.S. Agency for International Development	GHP-State	1,800,752
17410	TBD	TBD	Redacted	Redacted	Redacted
17413	TBD	TBD	Redacted	Redacted	Redacted
17421	TBD	TBD	Redacted	Redacted	Redacted
17422	TBD	TBD	Redacted	Redacted	Redacted
17425	TBD	TBD	Redacted	Redacted	Redacted

17439	TBD	TBD	Redacted	Redacted	Redacted
17448	Women and Law in Southern Africa	NGO	U.S. Agency for International Development	GHP-State	457,839
17449	Counterpart International	NGO	U.S. Agency for International Development	GHP-State	244,327
17477	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	650,000
17478	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
17479	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,258,896
17483	TBD	TBD	Redacted	Redacted	Redacted
17497	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,275,371

17499	Tropical Diseases Research Centre	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	520,000
17500	University of Zambia	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	74,989
17502	University of North Carolina	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17513	Ministry of Health, Zambia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,013,655
17514	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,566,894
17517	TBD	TBD	Redacted	Redacted	Redacted

17519	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17523	TBD	TBD	Redacted	Redacted	Redacted
17761	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	263,616
17781	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-State	482,965
17788	TBD	TBD	Redacted	Redacted	Redacted
17807	TBD	TBD	Redacted	Redacted	Redacted
17833	Population Council	NGO	U.S. Agency for International Development	GHP-State	1,500,000
17873	TBD	TBD	Redacted	Redacted	Redacted
17891	TBD	TBD	Redacted	Redacted	Redacted
17897	TBD	TBD	Redacted	Redacted	Redacted
17927	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7422	Mechanism Name: Central Contraceptive Procurement (CCP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Central Contraceptive Procurement	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Condom procurement	1,000,000
--------------------	-----------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 7422



Mechanism Name:	Central Contraceptive Procurement (CCP)		
Prime Partner Name:	Central Contraceptive Procurement		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7423	Mechanism Name: Supply Chain Management System Project (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 61,143,463	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	61,143,463

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 7423			
Mechanism Name: Supply Chain Management System Project (SCMS)			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,236,208	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,636,946	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	530,810	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	3,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	52,289,499	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7427	Mechanism Name: Partnership for Integrated Social Marketing (PRISM)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 7427			
Mechanism Name: Partnership for Integrated Social Marketing (PRISM)			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7428	Mechanism Name: Corridors of Hope III
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	7428		
Mechanism Name:	Corridors of Hope III		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,000	
PP_PREV_DSD	Total number of people in the target population	30,000	
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	360	
PP_PREV_DSD	Age/sex: 20-24 Male	1,350	
PP_PREV_DSD	Age/sex: 25-49 Male	1,200	
PP_PREV_DSD	Age/sex: 50+ Male	90	
PP_PREV_DSD	Age/sex: 10-14 Female	0	
PP_PREV_DSD	Age/sex: 15-19 Female	0	
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,000	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,597	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or	3,597	

	small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,450	
HTC_TST_DSD	By Test Result: Negative	4,397	
HTC_TST_DSD	By Test Result: Positive	1,053	
HTC_TST_DSD	Sum of Test Result disaggregates	5,450	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	0	
HTC_TST_DSD	Age/sex: 5-9 Male	0	
HTC_TST_DSD	Age/sex: 10-14 Male	0	
HTC_TST_DSD	Age/sex: 15-19 Male	218	
HTC_TST_DSD	Age/sex: 20-24 Male	817	
HTC_TST_DSD	Age/sex: 25-49 Male	727	
HTC_TST_DSD	Age/sex: 50+ Male	55	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	0	
HTC_TST_DSD	Age/sex: 5-9 Female	0	
HTC_TST_DSD	Age/sex: 10-14 Female	36	
HTC_TST_DSD	Age/sex: 15-19 Female	436	
HTC_TST_DSD	Age/sex: 20-24 Female	1,635	
HTC_TST_DSD	Age/sex: 25-49 Female	1,453	
HTC_TST_DSD	Age/sex: 50+ Female	73	
HTC_TST_DSD	Sum of Age/Sex disaggregates	5,450	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,817	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	36	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	3,597	



	PERMISSION ONLY: 15+ Female		
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	36	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,414	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,450	

Implementing Mechanism Details

Mechanism ID: 10203	Mechanism Name: The Zambia Prevention, Care and Treatment Partnership II (ZPCT II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 10203			
Mechanism Name: The Zambia Prevention, Care and Treatment Partnership II (ZPCT II)			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	8,046	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	11,045	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	8,046	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,107	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,212	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	8,046	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	6,319	
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	380	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	500	
PMTCT_ARV_TA	Life-long ART (including Option B+)	380	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	100	

PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	280	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	380	
PMTCT_ARV_TA	Sum of New and Current disaggregates	380	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	116,997	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	128,476	
PMTCT_STAT_DSD	By: Known positives at entry	3,636	
PMTCT_STAT_DSD	By: Number of new positives identified	7,409	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	11,045	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	800	
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,000	
PMTCT_STAT_TA	By: Known positives at entry	60	
PMTCT_STAT_TA	By: Number of new positives identified	80	
PMTCT_STAT_TA	Sum of Positives Status disaggregates	140	
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	90	
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	

VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	10	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	80	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	80	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	20,495	
VMMC_CIRC_DSD	By Age: <1	38	
VMMC_CIRC_DSD	By Age: 1-9	2,857	
VMMC_CIRC_DSD	By Age: 10-14	4,425	

VMMC_CIRC_DSD	By Age: 15-19	5,065	
VMMC_CIRC_DSD	By Age: 20-24	3,815	
VMMC_CIRC_DSD	By Age: 25-49	4,191	
VMMC_CIRC_DSD	By Age: 50+	104	
VMMC_CIRC_DSD	Sum of age disaggregates	20,495	
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	2,050	
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	12,000	
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	6,445	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,445	
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	14,550	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	1,886	
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22	
VMMC_CIRC_TA	By Age: <1	10	
VMMC_CIRC_TA	By Age: 1-9	0	
VMMC_CIRC_TA	By Age: 10-14	0	
VMMC_CIRC_TA	By Age: 15-19	0	
VMMC_CIRC_TA	By Age: 20-24	5	
VMMC_CIRC_TA	By Age: 25-49	5	
VMMC_CIRC_TA	By Age: 50+	2	

VMMC_CIRC_TA	Sum of Age disaggregations	22	
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	2	
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	20	
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0	
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	22	
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	393,524	
HTC_TST_DSD	By Test Result: Negative	346,301	
HTC_TST_DSD	By Test Result: Positive	47,223	
HTC_TST_DSD	Sum of Test Result disaggregates	393,524	
HTC_TST_DSD	Age/sex: <1 Male	2,300	
HTC_TST_DSD	Age/sex: 1-4 Male	9,225	
HTC_TST_DSD	Age/sex: 5-9 Male	5,351	
HTC_TST_DSD	Age/sex: 10-14 Male	6,221	
HTC_TST_DSD	Age/sex: 15-19 Male	13,433	
HTC_TST_DSD	Age/sex: 20-24 Male	26,317	
HTC_TST_DSD	Age/sex: 25-49 Male	63,179	
HTC_TST_DSD	Age/sex: 50+ Male	6,349	
HTC_TST_DSD	Age/sex: <1 Female	1,887	

HTC_TST_DSD	Age/sex: 1-4 Female	9,066	
HTC_TST_DSD	Age/sex: 5-9 Female	4,807	
HTC_TST_DSD	Age/sex: 10-14 Female	5,648	
HTC_TST_DSD	Age/sex: 15-19 Female	40,446	
HTC_TST_DSD	Age/sex: 20-24 Female	68,158	
HTC_TST_DSD	Age/sex: 25-49 Female	124,715	
HTC_TST_DSD	Age/sex: 50+ Female	6,422	
HTC_TST_DSD	Sum of Age/Sex disaggregates	393,524	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	23,097	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	109,278	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21,408	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	239,741	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	44,505	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	349,019	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	393,524	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,698	
HTC_TST_TA	By Test Result: Negative	4,134	
HTC_TST_TA	By Test Result: Positive	564	
HTC_TST_TA	Sum of Test Result disaggregates	4,698	
HTC_TST_TA	Age/sex: <1 Male	35	
HTC_TST_TA	Age/sex: 1-4 Male	155	
HTC_TST_TA	Age/sex: 5-9 Male	42	
HTC_TST_TA	Age/sex: 10-14 Male	40	
HTC_TST_TA	Age/sex: 15-19 Male	169	
HTC_TST_TA	Age/sex: 20-24 Male	260	
HTC_TST_TA	Age/sex: 25-49 Male	1,205	
HTC_TST_TA	Age/sex: 50+ Male	78	

HTC_TST_TA	Age/sex: <1 Female	19	
HTC_TST_TA	Age/sex: 1-4 Female	125	
HTC_TST_TA	Age/sex: 5-9 Female	43	
HTC_TST_TA	Age/sex: 10-14 Female	46	
HTC_TST_TA	Age/sex: 15-19 Female	290	
HTC_TST_TA	Age/sex: 20-24 Female	580	
HTC_TST_TA	Age/sex: 25-49 Female	1,550	
HTC_TST_TA	Age/sex: 50+ Female	61	
HTC_TST_TA	Sum of Age/Sex disaggregates	4,698	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	272	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,712	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	233	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,481	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	505	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	4,193	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	4,698	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	295,188	
CARE_CURR_DSD	Age/sex: <1 Male	1,100	
CARE_CURR_DSD	Age/sex: 1-4 Male	1,711	
CARE_CURR_DSD	Age/sex: 5-9 Male	3,800	
CARE_CURR_DSD	Age/sex: 10-14 Male	3,400	
CARE_CURR_DSD	Age/sex: 15-19 Male	6,500	
CARE_CURR_DSD	Age/sex: 20-24 Male	9,800	
CARE_CURR_DSD	Age/sex: 25-49 Male	78,813	
CARE_CURR_DSD	Age/sex: 50+ Male	8,400	

CARE_CURR_DSD	Age/sex: <1 Female	1,100	
CARE_CURR_DSD	Age/sex: 1-4 Female	1,780	
CARE_CURR_DSD	Age/sex: 5-9 Female	3,000	
CARE_CURR_DSD	Age/sex: 10-14 Female	4,080	
CARE_CURR_DSD	Age/sex: 15-19 Female	15,000	
CARE_CURR_DSD	Age/sex: 20-24 Female	36,500	
CARE_CURR_DSD	Age/sex: 25-49 Female	102,704	
CARE_CURR_DSD	Age/sex: 50+ Female	17,500	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	295,188	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,011	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	103,513	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,960	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	171,704	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	295,188	
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	5,658	
CARE_CURR_TA	Age/sex: <1 Male	34	
CARE_CURR_TA	Age/sex: 1-4 Male	38	
CARE_CURR_TA	Age/sex: 5-9 Male	61	
CARE_CURR_TA	Age/sex: 10-14 Male	48	
CARE_CURR_TA	Age/sex: 15-19 Male	400	
CARE_CURR_TA	Age/sex: 20-24 Male	800	
CARE_CURR_TA	Age/sex: 25-49 Male	900	
CARE_CURR_TA	Age/sex: 50+ Male	400	
CARE_CURR_TA	Age/sex: <1 Female	30	
CARE_CURR_TA	Age/sex: 1-4 Female	38	

CARE_CURR_TA	Age/sex: 5-9 Female	49	
CARE_CURR_TA	Age/sex: 10-14 Female	60	
CARE_CURR_TA	Age/sex: 15-19 Female	500	
CARE_CURR_TA	Age/sex: 20-24 Female	900	
CARE_CURR_TA	Age/sex: 25-49 Female	1,100	
CARE_CURR_TA	Age/sex: 50+ Female	300	
CARE_CURR_TA	Sum of Age/Sex disaggregates	5,658	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	177	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	181	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,800	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,500	
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	5,658	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	25,169	
CARE_NEW_DSD	Age/sex: <1 Male	37	
CARE_NEW_DSD	Age/sex: 1-4 Male	215	
CARE_NEW_DSD	Age/sex: 5-9 Male	137	
CARE_NEW_DSD	Age/sex: 10-14 Male	117	
CARE_NEW_DSD	Age/sex: 15-19 Male	693	
CARE_NEW_DSD	Age/sex: 20-24 Male	1,169	
CARE_NEW_DSD	Age/sex: 25-49 Male	6,101	
CARE_NEW_DSD	Age/sex: 50+ Male	526	
CARE_NEW_DSD	Age/sex: <1 Female	49	
CARE_NEW_DSD	Age/sex: 1-4 Female	160	
CARE_NEW_DSD	Age/sex: 5-9 Female	144	

CARE_NEW_DSD	Age/sex: 10-14 Female	154	
CARE_NEW_DSD	Age/sex: 15-19 Female	419	
CARE_NEW_DSD	Age/sex: 20-24 Female	2,564	
CARE_NEW_DSD	Age/sex: 25-49 Female	12,156	
CARE_NEW_DSD	Age/sex: 50+ Female	528	
CARE_NEW_DSD	Sum of Age/sex disaggregates	25,169	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	506	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	8,489	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	507	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	15,667	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	25,169	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	25,169	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,856	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,000	
TB_ART_DSD	Age: 0-4	97	
TB_ART_DSD	Age: 5-14	806	
TB_ART_DSD	Age: 15+	2,097	
TB_ART_DSD	Male	1,031	
TB_ART_DSD	Female	1,969	
TB_ART_DSD	Sum of Sex disaggregates	3,000	
TB_ART_DSD	Aggregated Age: <15	903	
TB_ART_DSD	Aggregated Age: 15+	2,097	
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,000	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,559	
PMTCT_EID_DSD	Number of HIV- positive pregnant women	11,045	

	identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,752	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,807	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,559	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	114	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	192,952	
TX_CURR_DSD	Age/Sex: <1 Male	423	
TX_CURR_DSD	Age/Sex: 1-4 Male	1,136	
TX_CURR_DSD	Age/Sex: 5-14 Male	5,104	
TX_CURR_DSD	Age/Sex: 15+ Male	69,213	
TX_CURR_DSD	Age/Sex: <1 Female	472	
TX_CURR_DSD	Age/Sex: 1-4 Female	1,158	
TX_CURR_DSD	Age/Sex: 5-14 Female	5,097	
TX_CURR_DSD	Age/Sex: 15+ Female	110,349	
TX_CURR_DSD	Sum of age/sex disaggregates	13,390	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	423	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	472	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,240	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	69,213	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,255	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	110,249	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	12,495	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	179,462	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	191,957	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	895	
TX_NEW_DSD	Number of adults and children newly enrolled	15,169	

	on antiretroviral therapy (ART)		
TX_NEW_DSD	By Age/Sex: <1 Male	37	
TX_NEW_DSD	By Age/Sex: 1-4 Male	215	
TX_NEW_DSD	By Age/Sex: 5-9 Male	137	
TX_NEW_DSD	By Age/Sex: 10-14 Male	117	
TX_NEW_DSD	By Age/Sex: 15-19 Male	193	
TX_NEW_DSD	By Age/Sex: 20-24 Male	669	
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,101	
TX_NEW_DSD	By Age/Sex: 50+ Male	526	
TX_NEW_DSD	By Age/Sex: <1 Female	49	
TX_NEW_DSD	By Age/Sex: 1-4 Female	160	
TX_NEW_DSD	By Age/Sex: 5-9 Female	144	
TX_NEW_DSD	By Age/Sex: 10-14 Female	154	
TX_NEW_DSD	By Age/Sex: 15-19 Female	419	
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,564	
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,156	
TX_NEW_DSD	By Age/Sex: 50+ Female	528	
TX_NEW_DSD	Sum of Age/Sex disaggregates	15,169	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	37	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	506	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,489	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	49	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	507	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	8,667	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	15,169	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,903	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	15,169	

	those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	359	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	492	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,052	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	461	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	552	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,156	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	851	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,052	

TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,013	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,156	
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	84	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	75	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	9	
LAB_ACC_DSD	Sum of Support Type disaggregates	84	
LAB_ACC_TA	Sum of Support Type disaggregates	84	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	84	
LAB_CAP_DSD	By clinical laboratories	84	
LAB_CAP_DSD	By Point-of-care testing sites	0	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	75	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	9	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	84	
LAB_CAP_TA	Sum of Site Support Type disaggregates	84	

LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	393	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	431	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	393	
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	140	
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	140	
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	140	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0	
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	350	
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	350	

LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	350	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	100,000	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	295,188	
TB_SCREEN_DSD	Age: <1	15	
TB_SCREEN_DSD	Age: 1-4	20	
TB_SCREEN_DSD	Age: 5-9	151	
TB_SCREEN_DSD	Age: 10-14	608	
TB_SCREEN_DSD	Age: 15-19	906	
TB_SCREEN_DSD	Age: 20-24	24,000	
TB_SCREEN_DSD	Age: 25-49	64,300	
TB_SCREEN_DSD	Age: 50+	10,000	
TB_SCREEN_DSD	Sum of Age disaggregates	1,700	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	794	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	99,206	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	100,000	
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	5,658	

Implementing Mechanism Details

Mechanism ID: 10207	Mechanism Name: Twinning Centre
----------------------------	--



Funding Agency: HHS/HRSA	Procurement Type: Grant
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,881,442	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,881,442

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10207			
Mechanism Name: Twinning Centre			
Prime Partner Name: American International Health Alliance Twinning Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	681,442	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10219	Mechanism Name: EGPAF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,187,372	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	5,187,372

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10219			
Mechanism Name: EGPAF			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	165,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	392,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	20,372	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	400,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	220,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	40	7	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	40	7	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	40		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	20	3	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	20	4	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted

PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	40		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	40	7	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40	14	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	40	14	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	0		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	0		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,500	736	Redacted
HTC_TST_DSD	By Test Result: Negative	3,879	676	Redacted
HTC_TST_DSD	By Test Result: Positive	621	58	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	4,500	734	Redacted
HTC_TST_DSD	Age/sex: <1 Male	156		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	206		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	299		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	272		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	270		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	196		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	622		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	173		Redacted
HTC_TST_DSD	Age/sex: <1 Female	158		Redacted

HTC_TST_DSD	Age/sex: 1-4 Female	202		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	301		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	277		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	286		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	243		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	644		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	195		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	4,500		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	932	26	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,262	305	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	938	24	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,368	379	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,870	50	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,630	684	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,500	734	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	5,980	4,936	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	3	7	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	28	38	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	60	47	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	102	121	Redacted
CARE_CURR_DS	Age/sex: 15-19 Male	120	196	Redacted

D				
CARE_CURR_DS D	Age/sex: 20-24 Male	43	163	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,420	1,393	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	424	20	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	5	7	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	60	52	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	80	63	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	120	143	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	120	256	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	165	223	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	2,740	2,182	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	490	25	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	5,980	4,936	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	193	213	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,007	1,772	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	265	266	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,515	2,685	Redacted
CARE_CURR_DS	Sum of Aggregated Age/Sex	5,980	4,936	Redacted

D	disaggregates			
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	620	839	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	6	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	12	1	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	12	2	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	11	3	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	56	15	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	41	36	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	128	311	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	35	3	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	5	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	9	1	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	12	2	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	12	3	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	59	24	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	50	60	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	133	374	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	39	3	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	620	838	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	21	6	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	315	366	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	21	6	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	263	461	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	620	839	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	620	839	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic	30	4	Redacted

	HIV test within 12 months of birth during the reporting period			
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	30		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	15		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	15		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	30		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	0		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,109	3,271	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	5	8	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	10	49	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	125	136	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,066		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	5	6	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	28	59	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	120	162	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	3,750		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	293	3,271	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	5		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	5	8	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	5	6	Redacted

TX_CURR_DSD	Aggregated Age/Sex: <15 Male	140		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,066	1,123	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	153		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,750	1,728	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	293		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,816	2,851	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,109	2,851	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	10	420	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	475	695	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	6	2	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	10	2	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	11	6	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	10	12	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	41	25	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	30	29	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	94	190	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	26	23	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	5	4	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	8	6	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	12	8	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	17	12	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	43	12	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	37	52	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	96	270	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	29	42	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	475	695	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	6	2	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	37		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	191	267	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	5	4	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	42		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	205	376	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	475	643	Redacted
TX_NEW_DSD	Pregnancy status	40		Redacted
TX_NEW_DSD	Breastfeeding status	0		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	487	541	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	620	758	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART)	0		Redacted

	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children	0		Redacted

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	5,980	4,936	Redacted

Implementing Mechanism Details

Mechanism ID: 10220	Mechanism Name: Intrahealth International
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,105,159	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	2,105,159

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	10
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	10
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10220			
Mechanism Name: Intrahealth International			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Care	HBHC	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	110,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,248,561	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	96,598	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0		Redacted

PMTCT_ARV_DS D	Life-long ART (including Option B+)	0		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	0		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	0		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	0		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0		Redacted

PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	0		Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative	0		Redacted

	AE(s)			
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0		Redacted
VMMC_CIRC_DS D	By Age: <1	0		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	0		Redacted
VMMC_CIRC_DS D	By Age: 15-19	0		Redacted
VMMC_CIRC_DS D	By Age: 20-24	0		Redacted
VMMC_CIRC_DS D	By Age: 25-49	0		Redacted

VMMC_CIRC_DS D	By Age: 50+	0		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	0		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	0		Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0		Redacted
VMMC_CIRC_TA	By Age: <1	0		Redacted
VMMC_CIRC_TA	By Age: 1-9	0		Redacted
VMMC_CIRC_TA	By Age: 10-14	0		Redacted
VMMC_CIRC_TA	By Age: 15-19	0		Redacted

VMMC_CIRC_TA	By Age: 20-24	0		Redacted
VMMC_CIRC_TA	By Age: 25-49	0		Redacted
VMMC_CIRC_TA	By Age: 50+	0		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	36,300	14,339	Redacted
PP_PREV_DSD	Total number of people in the target population	532,564	2,782,755	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	281	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	3,358	1,149	Redacted

PP_PREV_DSD	Age/sex: 20-24 Male	4,645	1,412	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	8,470	1,175	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	44	72	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	4,287	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	3,902	1,644	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	6,962	2,274	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	8,868	1,886	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	51	159	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	36,300	14,339	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0		Redacted
PP_PREV_TA	Total number of people in the target population	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0		Redacted
PP_PREV_TA	Age/sex: 50+ Male	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0		Redacted
PP_PREV_TA	Age/sex: 50+ Female	0		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	0		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	330	148	Redacted
KP_PREV_DSD	By key population type: Female sex	330	148	Redacted

	workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0	Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	330		Redacted

	standards required)			
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0		Redacted
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted

KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	96,800	59,121	Redacted
HTC_TST_DSD	By Test Result: Negative	91,744	52,100	Redacted
HTC_TST_DSD	By Test Result: Positive	5,056	4,675	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	96,800	56,775	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	1,326		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	11,934		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	13,261		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	15,912		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	663		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,327		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	14,586		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	18,564		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	18,564		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	663		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	96,800		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,326	415	Redacted

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	41,770	22,591	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,327	757	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	52,377	33,012	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,653	1,172	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	94,147	55,603	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	96,800	56,775	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0		Redacted
HTC_TST_TA	By Test Result: Negative	0		Redacted
HTC_TST_TA	By Test Result: Positive	0		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	0		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	0		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	0		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	0		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	0		Redacted
HTC_TST_TA	Age/sex: 50+ Male	0		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	0		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	0		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	0		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	0		Redacted
HTC_TST_TA	Age/sex: 50+ Female	0		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	0		Redacted

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	0		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	0		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	0		Redacted
GEND_GBV_DSD	Number of people receiving post-GBV care	0		Redacted
GEND_GBV_DSD	Age: 0-9	0		Redacted
GEND_GBV_DSD	Age: 10-14	0		Redacted
GEND_GBV_DSD	Age: 15-17	0		Redacted
GEND_GBV_DSD	Age: 18-24	0		Redacted
GEND_GBV_DSD	Age: 25+	0		Redacted
GEND_GBV_DSD	Sum of Age disaggregates	0		Redacted
GEND_GBV_DSD	Sex: Male	0		Redacted
GEND_GBV_DSD	Sex: Female	0		Redacted
GEND_GBV_DSD	Sum of Sex disaggregates	0		Redacted
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0		Redacted
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0		Redacted
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0		Redacted
GEND_GBV_TA	Sum of Age disaggregates	0		Redacted
GEND_GBV_TA	Sum of Sex disaggregates	0		Redacted
GEND_NORM_DS	Number of people completing an	0	4,989	Redacted

D	intervention pertaining to gender norms, that meets minimum criteria			
GEND_NORM_DS D	By Age: 0-9	0	0	Redacted
GEND_NORM_DS D	By Age: 10-14	0	90	Redacted
GEND_NORM_DS D	By Age: 15-19	0	629	Redacted
GEND_NORM_DS D	By Age: 20-24	0	1,230	Redacted
GEND_NORM_DS D	By Age: 25+	0	1,108	Redacted
GEND_NORM_DS D	Sum of Age disaggregates	0	3,057	Redacted
GEND_NORM_DS D	By Sex: Male	0		Redacted
GEND_NORM_DS D	By Sex: Female	0		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	0		Redacted
GEND_NORM_DS D	By type of activity: Individual	0		Redacted
GEND_NORM_DS D	By type of activity: Small Group	0		Redacted
GEND_NORM_DS D	By type of activity: Community-level	0		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	0		Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0		Redacted
OVC_SERV_DSD	Sex: Male	0		Redacted
OVC_SERV_DSD	Sex: Female	0		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	0		Redacted
OVC_SERV_DSD	Age: <1	0		Redacted



OVC_SERV_DSD	Age: 1-4	0		Redacted
OVC_SERV_DSD	Age: 5-9	0		Redacted
OVC_SERV_DSD	Age: 10-14	0		Redacted
OVC_SERV_DSD	Age: 15-17	0		Redacted
OVC_SERV_DSD	Age: 18+	0		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	0		Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	0		Redacted
OVC_SERV_TA	Sex: Male	0		Redacted
OVC_SERV_TA	Sex: Female	0		Redacted
OVC_SERV_TA	Sum of Sex disaggregates	0		Redacted
OVC_SERV_TA	Age: <1	0		Redacted
OVC_SERV_TA	Age: 1-4	0		Redacted
OVC_SERV_TA	Age: 5-9	0		Redacted
OVC_SERV_TA	Age: 10-14	0		Redacted
OVC_SERV_TA	Age: 15-17	0		Redacted
OVC_SERV_TA	Age: 18+	0		Redacted
OVC_SERV_TA	Sum of Age disaggregates	0		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	0	0	Redacted
CARE_CURR_DS	Age/sex: 15-19 Male	0	0	Redacted

D				
CARE_CURR_DS D	Age/sex: 20-24 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	0	0	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	0	0	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	0	0	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	0	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	0	Redacted
CARE_CURR_DS	Sum of Aggregated Age/Sex	0	0	Redacted

D	disaggregates			
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0		Redacted
CARE_CURR_TA	Age/sex: <1 Male	0		Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	0		Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	0		Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	0		Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	0		Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	0		Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	0		Redacted
CARE_CURR_TA	Age/sex: 50+ Male	0		Redacted
CARE_CURR_TA	Age/sex: <1 Female	0		Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	0		Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	0		Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	0		Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	0		Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	0		Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	0		Redacted
CARE_CURR_TA	Age/sex: 50+ Female	0		Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	0		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0		Redacted

CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	0	0	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	0	0	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	0	0	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	0	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	0	0	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	0	0	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	0	0	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or	0		Redacted

	supplementary food during the reporting period.			
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	0		Redacted
FN_THER_DSD	Age: <1	0		Redacted
FN_THER_DSD	Age: 1-4	0		Redacted
FN_THER_DSD	Age: 5-14	0		Redacted
FN_THER_DSD	Age: 15-17	0		Redacted
FN_THER_DSD	Age: 18+	0		Redacted
FN_THER_DSD	Sum of Age disaggregates	0		Redacted
FN_THER_DSD	Aggregated Age: <18	0		Redacted
FN_THER_DSD	Aggregated Age: 18+	0		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	0		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	0		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	0		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	0		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	0		Redacted

TX_CURR_DSD	Age/Sex: 15+ Male	0		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	0		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	0		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	0		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	0		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	0		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0		Redacted
TX_CURR_TA	Age/Sex: <1 Male	0		Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	0		Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	0		Redacted
TX_CURR_TA	Age/Sex: 15+ Male	0		Redacted
TX_CURR_TA	Age/Sex: <1 Female	0		Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	0		Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	0		Redacted
TX_CURR_TA	Age/Sex: 15+ Female	0		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	0		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0		Redacted

TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	0		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	0		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	0		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	0		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	0		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	0		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	0		Redacted

	Male			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	0		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	0		Redacted
TX_NEW_DSD	Pregnancy status	0		Redacted
TX_NEW_DSD	Breastfeeding status	0		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	0		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning	0		Redacted

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months	0		Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	0		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	0		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	0		Redacted
LAB_CAP_DSD	By clinical laboratories	0		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	0		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	0		Redacted

LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0		Redacted

LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0		Redacted
HRH_PRE	By Graduates: Doctors	0		Redacted
HRH_PRE	By Graduates: Nurses	0		Redacted
HRH_PRE	By Graduates: Midwives	0		Redacted
HRH_PRE	By Graduates: Social service workers	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	By Graduates: Other	0		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	0		Redacted

HRH_PRE	By new graduates who are licensed and registered: Social service workers	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	0		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	0	Redacted
TB_SCREEN_DSD	Age: <1	0		Redacted
TB_SCREEN_DSD	Age: 1-4	0		Redacted
TB_SCREEN_DSD	Age: 5-9	0		Redacted
TB_SCREEN_DSD	Age: 10-14	0		Redacted
TB_SCREEN_DSD	Age: 15-19	0		Redacted
TB_SCREEN_DSD	Age: 20-24	0		Redacted
TB_SCREEN_DSD	Age: 25-49	0		Redacted
TB_SCREEN_DSD	Age: 50+	0		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	0		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	0		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	0		Redacted
TB_SCREEN_DSD	Sex: Male	0		Redacted
TB_SCREEN_DSD	Sex: Female	0		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	0		Redacted
TB_SCREEN_TA	Number of HIV positive adults and	0		Redacted



	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
--	---	--	--	--

Implementing Mechanism Details

Mechanism ID: 10224	Mechanism Name: National HIV/AIDS/STI/TB Council
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 346,803	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	346,803

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID:	10224		
Mechanism Name:	National HIV/AIDS/STI/TB Council		
Prime Partner Name:	National HIV/AIDS/STI/TB Council - Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	245,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	101,803	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10225	Mechanism Name: EPHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Health Office - Eastern Province	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 4,749,786	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	4,749,786

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	10
Food and Nutrition: Policy, Tools, and Service Delivery	10

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10225			
Mechanism Name: EPHO			
Prime Partner Name: Provincial Health Office - Eastern Province			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Governance and Systems	OHSS	203,606	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	431,872	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	509,308	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	375,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,360,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	339		Redacted

PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	376		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	376		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	169		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	207		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	376		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	376		Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,653	487	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,837	487	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,837		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	827	340	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,010	147	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy)	0		Redacted

	and delivery)			
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,837		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,837	487	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,390		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	5,989		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	216		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	162		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	378		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	26,230	28,331	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	29,144	31,078	Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,049	1,050	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	787	1,406	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,836	2,456	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	75	79	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	10		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category:	9		Redacted

	Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	1		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	40		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	38		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	2		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	1		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0		Redacted
VMMC_CIRC_DS	Number of males circumcised as part of	15,000	7,900	Redacted

D	the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period			
VMMC_CIRC_DS D	By Age: <1	150	2	Redacted
VMMC_CIRC_DS D	By Age: 1-9	450	8	Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,500	1,280	Redacted
VMMC_CIRC_DS D	By Age: 15-19	3,750	1,565	Redacted
VMMC_CIRC_DS D	By Age: 20-24	4,500	1,852	Redacted
VMMC_CIRC_DS D	By Age: 25-49	4,500		Redacted
VMMC_CIRC_DS D	By Age: 50+	150	272	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	15,000	4,979	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	900	341	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	13,500	7,559	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	600		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	15,000	7,900	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	15,000		Redacted
VMMC_CIRC_DS	By follow-up status: Number of	14,250	7,900	Redacted

D	surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery			
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	750		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	60,000		Redacted
PP_PREV_TA	Total number of people in the target population	164,900		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	9,500		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	11,000		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	9,500		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0		Redacted
PP_PREV_TA	Age/sex: 50+ Male	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	9,500		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	11,000		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	9,500		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0		Redacted
PP_PREV_TA	Age/sex: 50+ Female	0		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	60,000		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,405		Redacted
HTC_TST_DSD	By Test Result: Negative	29,161		Redacted
HTC_TST_DSD	By Test Result: Positive	3,244		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	32,405		Redacted
HTC_TST_DSD	Age/sex: <1 Male	100		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	100		Redacted

HTC_TST_DSD	Age/sex: 5-9 Male	25		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	748		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,246		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	3,739		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	2,991		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,592		Redacted
HTC_TST_DSD	Age/sex: <1 Female	75		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	75		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	25		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	748		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,944		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	7,777		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	9,721		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	499		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	32,405		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	973		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,568		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	923		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,941		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,896		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	30,509		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	32,405		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	262,177	105,568	Redacted
HTC_TST_TA	By Test Result: Negative	235,959	97,163	Redacted
HTC_TST_TA	By Test Result: Positive	26,218	8,405	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	262,177	105,568	Redacted

HTC_TST_TA	Age/sex: <1 Male	807		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	807		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	202		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	6,050		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	10,084		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	30,251		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	24,201		Redacted
HTC_TST_TA	Age/sex: 50+ Male	20,974		Redacted
HTC_TST_TA	Age/sex: <1 Female	605		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	605		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	202		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	6,050		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	15,731		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	62,922		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	78,653		Redacted
HTC_TST_TA	Age/sex: 50+ Female	4,033		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	262,177		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,866	4,412	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	85,510	22,089	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,462	4,350	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	161,339	33,674	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	15,328	8,762	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	246,849	55,763	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	262,177	64,525	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO	25,536	19,979	Redacted

	staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Age/sex: <1 Male	98	33	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	196	193	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	295	209	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	688	314	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,866	646	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	2,357	1,008	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	5,795	4,019	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	196	1,603	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	98	34	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	196	195	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	295	238	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	884	373	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	2,063	1,138	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	3,339	1,709	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	6,875	6,241	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	295	2,026	Redacted
CARE_CURR_DS	Sun of Age/Sex disaggregates	25,536	19,979	Redacted

D				
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,277		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,214		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,277		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,768		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	25,536		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	65,664	75,738	Redacted
CARE_CURR_TA	Age/sex: <1 Male	253	139	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	505	260	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	758	390	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	1,768	600	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	4,799	943	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	6,061	2,201	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	14,901	9,422	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	505	1,405	Redacted
CARE_CURR_TA	Age/sex: <1 Female	253	139	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	505	262	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	758	392	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	2,273	602	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	5,304	1,567	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	8,587	3,934	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	17,679	52,099	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	758	1,384	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	65,667	75,739	Redacted

CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,283	23	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	26,266	264	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,283	28	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	32,832	448	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	65,664	763	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	23,519	6,231	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	90	14	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	181	26	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	271	31	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	633	66	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	1,719	146	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	2,171	279	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	5,337	999	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	181	264	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	90	14	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	181	24	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	271	34	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	814	71	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1,900	228	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	3,076	465	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	6,333	3,127	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	271	443	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	23,519	6,231	Redacted

CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,176		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	9,408		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,176		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	11,760		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	23,520		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	23,520		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	900	166	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,387	166	Redacted
FN_THER_DSD	Age: <1	36	11	Redacted
FN_THER_DSD	Age: 1-4	684	23	Redacted
FN_THER_DSD	Sum of Age disaggregates	720	166	Redacted
FN_THER_DSD	Aggregated Age: <18	720		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	720		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,932		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,932		Redacted
TB_ART_DSD	Age: 0-4	32		Redacted
TB_ART_DSD	Age: 5-14	900		Redacted
TB_ART_DSD	Age: 15+	1,000		Redacted
TB_ART_DSD	Male	773		Redacted
TB_ART_DSD	Female	1,159		Redacted

TB_ART_DSD	Sum of Sex disaggregates	1,932		Redacted
TB_ART_DSD	Newly tested	580		Redacted
TB_ART_DSD	Known HIV-positive	1,352		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,932		Redacted
TB_ART_DSD	Aggregated Age: <15	193		Redacted
TB_ART_DSD	Aggregated Age: 15+	1,739		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,932		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,771	449	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,213		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,771	449	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	80		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,851	449	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	89		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,707	24,301	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	62	145	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	400	327	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	473	1,280	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	7,483		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	62	143	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	400	325	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	473	1,403	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	9,354		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,870	24,301	Redacted

TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	18,707		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	62	7	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	935		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,483	268	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	935		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,354	401	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,870		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,837	669	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	18,707	669	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	18,769	37	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	48,104	23,620	Redacted
TX_CURR_TA	Age/Sex: <1 Male	159	51	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	1,030	126	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	1,217	502	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	19,241		Redacted
TX_CURR_TA	Age/Sex: <1 Female	158	51	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	1,030	126	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	1,217	502	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	24,052		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	4,811	23,618	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	159	7	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	159		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	2,406		Redacted

TX_CURR_TA	Aggregated Age/Sex: 15+ Male	19,241		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,405		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	24,052		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	4,811		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	43,293		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	48,104		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	318	37	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,200	5,163	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	64	14	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	128	25	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	176	40	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	192	91	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	400	223	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	560	396	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,720	886	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	800	396	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	64	15	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	128	26	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	176	42	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	192	104	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	560	307	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	880	703	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,360	1,496	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	800	399	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,200	5,163	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	128		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	560		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	4,480		Redacted

	Male			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	128		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	560		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,600		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,200		Redacted
TX_NEW_DSD	Pregnancy status	2,928	327	Redacted
TX_NEW_DSD	Breastfeeding status	2,928		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,190	4,018	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,100	6,197	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	100		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,260		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning	50		Redacted

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	100		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,350		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,710		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months	1,800		Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,819		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,830		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	1	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	2		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	2		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	2		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	32	30	Redacted
LAB_CAP_DSD	By clinical laboratories	32	12	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	32		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	27		Redacted

LAB_CAP_DSD	Sum of Site Support Type disaggregates	59		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	59		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	1		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	212	11	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	212	11	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	212	11	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	10	12	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	32	12	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	32	12	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1		Redacted

LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	57		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	57		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	57		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	212	15	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	212	15	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	89		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by	212		Redacted

	PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	301		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	89		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	212		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	301		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	212		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	212		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	301		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	301		Redacted
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	212		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	12,886		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,536	19,979	Redacted
TB_SCREEN_DSD	Age: <1	100		Redacted
TB_SCREEN_DSD	Age: 1-4	198		Redacted



TB_SCREEN_DSD	Age: 5-9	297		Redacted
TB_SCREEN_DSD	Age: 10-14	793		Redacted
TB_SCREEN_DSD	Age: 15-19	1,982		Redacted
TB_SCREEN_DSD	Age: 20-24	2,875		Redacted
TB_SCREEN_DSD	Age: 25-49	6,393		Redacted
TB_SCREEN_DSD	Age: 50+	248		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	3,370		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	1,388		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	11,498		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	12,886		Redacted
TB_SCREEN_DSD	Sex: Male	7,088		Redacted
TB_SCREEN_DSD	Sex: Female	5,798		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	12,886		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	65,664	75,738	Redacted

Implementing Mechanism Details

Mechanism ID: 10227	Mechanism Name: WPHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Provincial Health Office - Western Province	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 5,163,154	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount



GHP-State	5,163,154
-----------	-----------

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10227			
Mechanism Name: WPHO			
Prime Partner Name: Provincial Health Office - Western Province			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	900,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	160,000	0

Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	203,606	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	215,936	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	509,308	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	380,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,360,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	334,304	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	279	305	Redacted

PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	465	305	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	279		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	104	305	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	175		Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	93		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	372		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	279	305	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,194	582	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,194	582	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	2,194		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	823	582	Redacted

PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,371		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	548		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	2,742		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	2,194	582	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,876	3,687	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	4,080	3,687	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	116	41	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	349	264	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	465	305	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22,853	15,836	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	24,055	15,836	Redacted
PMTCT_STAT_TA	By: Known positives at entry	686		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	2,057	582	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,743	582	Redacted
VMMC_AE_DSD	Number of males circumcised surgically	120	47	Redacted

	or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)			
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more	0		Redacted

	moderate medical device-related AE(s), but no severe medical device-related AE(s)			
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	4,000	4,664	Redacted
VMMC_CIRC_DS D	By Age: <1	200	39	Redacted
VMMC_CIRC_DS D	By Age: 1-9	400		Redacted
VMMC_CIRC_DS D	By Age: 10-14	400	596	Redacted
VMMC_CIRC_DS D	By Age: 15-19	800	1,033	Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,000	1,252	Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,000		Redacted
VMMC_CIRC_DS D	By Age: 50+	200	50	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	4,000	2,970	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,000	3,795	Redacted
VMMC_CIRC_DS	By HIV status: Number of clients with	0	869	Redacted

D	undocumented/indeterminate HIV status or not tested for HIV at site			
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	4,000	4,664	Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	3,920	4,594	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	80	70	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0		Redacted
VMMC_CIRC_TA	By Age: <1	0		Redacted
VMMC_CIRC_TA	By Age: 1-9	0		Redacted
VMMC_CIRC_TA	By Age: 10-14	0		Redacted
VMMC_CIRC_TA	By Age: 15-19	0		Redacted
VMMC_CIRC_TA	By Age: 20-24	0		Redacted
VMMC_CIRC_TA	By Age: 25-49	0		Redacted
VMMC_CIRC_TA	By Age: 50+	0		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with	0		Redacted

	undocumented/indeterminate HIV status or not tested for HIV at site			
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	97,000	23,808	Redacted
PP_PREV_TA	Total number of people in the target population	975,282	198,860	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	2,328	609	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	6,984	1,626	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	13,968	3,274	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	18,624	4,590	Redacted
PP_PREV_TA	Age/sex: 50+ Male	4,656	1,221	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	2,522	662	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	7,566	1,773	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	15,132	3,628	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	20,176	5,011	Redacted
PP_PREV_TA	Age/sex: 50+ Female	5,044	1,414	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	97,000	23,808	Redacted
KP_PREV_TA	Number of key populations reached with individual and/or small group level	0		Redacted

	HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key	0		Redacted

	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,800	3,730	Redacted
HTC_TST_DSD	By Test Result: Negative	9,720	3,435	Redacted
HTC_TST_DSD	By Test Result: Positive	1,080	295	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	10,800	3,730	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	302		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	648		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	648		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	605		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	907		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,058		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	151		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	454		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	972		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	972		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	907		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,361		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,588		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	227		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	10,800		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,598	559	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,722	1,017	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	2,398	766	Redacted

	PERMISSION ONLY: <15 Female			
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,082	1,388	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,996	1,325	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,804	2,405	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,800	3,730	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	124,200	37,848	Redacted
HTC_TST_TA	By Test Result: Negative	111,780	34,857	Redacted
HTC_TST_TA	By Test Result: Positive	12,420	2,991	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	124,200	37,848	Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	3,478		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	7,452		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	7,452		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	6,955		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	10,433		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	12,172		Redacted
HTC_TST_TA	Age/sex: 50+ Male	1,739		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	5,216		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	11,178		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	11,178		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	10,433		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	15,649		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	18,257		Redacted
HTC_TST_TA	Age/sex: 50+ Female	2,608		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	124,200		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18,382	5,617	Redacted

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	31,298	10,289	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	27,572	7,683	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	46,948	14,259	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	45,954	13,300	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	78,246	24,548	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	124,200	37,848	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0		Redacted
GEND_NORM_DS D	By Age: 0-9	0		Redacted
GEND_NORM_DS D	By Age: 10-14	0		Redacted
GEND_NORM_DS D	By Age: 15-19	0		Redacted
GEND_NORM_DS D	By Age: 20-24	0		Redacted
GEND_NORM_DS D	By Age: 25+	0		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	0		Redacted
GEND_NORM_DS D	By Sex: Male	0		Redacted
GEND_NORM_DS D	By Sex: Female	0		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	0		Redacted
GEND_NORM_DS D	By type of activity: Individual	0		Redacted
GEND_NORM_DS	By type of activity: Small Group	0		Redacted

D				
GEND_NORM_DS D	By type of activity: Community-level	0		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	0		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,360	3,706	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	29	1	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	29	139	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	29	207	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	58	216	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	195	222	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	224	318	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	144	374	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	29	66	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	31	2	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	31	143	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	31	310	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	62	316	Redacted
CARE_CURR_DS	Age/sex: 15-19 Female	125	312	Redacted

D				
CARE_CURR_DS D	Age/sex: 20-24 Female	156	442	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	156	558	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	31	80	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	1,360	3,706	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	224	563	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	432	980	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	236	771	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	468	1,392	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	1,360	3,706	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	15,640	22,457	Redacted
CARE_CURR_TA	Age/sex: <1 Male	331	0	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	331	845	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	331	1,262	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	662	1,321	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	2,245	1,363	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	2,576	1,955	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	1,656	2,303	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	331	401	Redacted
CARE_CURR_TA	Age/sex: <1 Female	359	2	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	359	871	Redacted

CARE_CURR_TA	Age/sex: 5-9 Female	359	1,869	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	718	1,909	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	1,435	1,894	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	1,794	2,679	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	1,794	3,306	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	359	477	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	15,640	22,457	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,576	3,404	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,968	5,958	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,714	4,647	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,382	8,448	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	15,640	22,457	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	15,500	4,951	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	0	1	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	378	188	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	810	280	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	810	291	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	756	300	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	2,134	429	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	2,323	504	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	189	88	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	0	2	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	567	193	Redacted

CARE_NEW_DSD	Age/sex: 5-9 Female	1,215	418	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	1,215	426	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1,134	421	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	1,701	598	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,984	704	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	284	108	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	15,500	4,951	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,998	757	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	4,402	1,317	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	3,997	1,035	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,103	1,842	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	15,500	4,951	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	15,500	4,951	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,200		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	12,027		Redacted
FN_THER_DSD	Age: <1	250		Redacted
FN_THER_DSD	Age: 1-4	200		Redacted
FN_THER_DSD	Age: 5-14	250		Redacted
FN_THER_DSD	Age: 15-17	500		Redacted
FN_THER_DSD	Age: 18+	0		Redacted
FN_THER_DSD	Sum of Age disaggregates	1,200		Redacted
FN_THER_DSD	Aggregated Age: <18	1,200		Redacted
FN_THER_DSD	Aggregated Age: 18+	0		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,200		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented	0	31	Redacted

	HIV-positive status who are on ART during TB treatment during the reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	31	Redacted
TB_ART_DSD	Age: 0-4	0		Redacted
TB_ART_DSD	Age: 5-14	0		Redacted
TB_ART_DSD	Age: 15+	0		Redacted
TB_ART_DSD	Male	0	10	Redacted
TB_ART_DSD	Female	0	21	Redacted
TB_ART_DSD	Sum of Sex disaggregates	0	31	Redacted
TB_ART_DSD	Newly tested	0		Redacted
TB_ART_DSD	Known HIV-positive	0		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	0		Redacted
TB_ART_DSD	Aggregated Age: <15	0		Redacted
TB_ART_DSD	Aggregated Age: 15+	0	31	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	0	31	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,438	198	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,207		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,194	100	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	244	98	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,438	198	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	122		Redacted

TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,204	19,441	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	1	34	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	5	482	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	57	783	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	500		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	2	47	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	6	528	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	58	697	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	575		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	129	19,441	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	1	34	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	2	47	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	63		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	500	7,198	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	66		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	575	9,749	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	129		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,075	16,947	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,204	16,947	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	3	2,494	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	10,824	18,895	Redacted
TX_CURR_TA	Age/Sex: <1 Male	12	36	Redacted

TX_CURR_TA	Age/Sex: 1-4 Male	42	198	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	510	856	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	4,497		Redacted
TX_CURR_TA	Age/Sex: <1 Female	16	43	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	55	272	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	518	1,019	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	5,174		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	1,153	18,895	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	12	36	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	16	43	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	564		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,497	7,250	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	589		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,174	9,221	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,153		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	9,671	16,471	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	10,824	16,471	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	28	2,424	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,553	4,131	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	7	2	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	34	44	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	34	68	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	95	115	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	256	270	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	449	504	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	513	586	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	64	84	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	7	2	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	370	233	Redacted

TX_NEW_DSD	By Age/Sex: 5-9 Female	370	259	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	104	134	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	385	411	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1	426	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	769	887	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	95	106	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,553	4,131	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	7	2	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	170		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,282	1,442	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	7	2	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	851		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,250	1,833	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,553	3,275	Redacted
TX_NEW_DSD	Pregnancy status	192	48	Redacted
TX_NEW_DSD	Breastfeeding status	0	11	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,307	3,214	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,556	3,299	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	0		Redacted

	ART)			
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are	0		Redacted

	still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1	Redacted
LAB_ACC_DSD	By site support type: Direct Service	1		Redacted

	Delivery (DSD)			
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	10	1	Redacted
LAB_CAP_DSD	By clinical laboratories	10	1	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	10		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	10		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	20		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that	0		Redacted

	perform this testing			
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
HRH_PRE	Number of new HCW who graduated	0		Redacted

	from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre			
HRH_PRE	By Graduates: Doctors	0		Redacted
HRH_PRE	By Graduates: Nurses	0		Redacted
HRH_PRE	By Graduates: Midwives	0		Redacted
HRH_PRE	By Graduates: Social service workers	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	By Graduates: Other	0		Redacted
HRH_PRE	Sum of Graduates disaggregated	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Midwives	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	12	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	0	12	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service	0		Redacted

	delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	0		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	0		Redacted
FPINT_SITE_DSD	Service delivery type: Community	0		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	0		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	0		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	0		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	0		Redacted
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	0		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility	1,000	866	Redacted



	during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,360	3,706	Redacted
TB_SCREEN_DSD	Age: <1	0		Redacted
TB_SCREEN_DSD	Age: 1-4	0		Redacted
TB_SCREEN_DSD	Age: 5-9	0		Redacted
TB_SCREEN_DSD	Age: 10-14	0	10	Redacted
TB_SCREEN_DSD	Age: 15-19	0	14	Redacted
TB_SCREEN_DSD	Age: 20-24	0		Redacted
TB_SCREEN_DSD	Age: 25-49	0		Redacted
TB_SCREEN_DSD	Age: 50+	0		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	0	866	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	0	10	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	0	856	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	0	866	Redacted
TB_SCREEN_DSD	Sex: Male	0	442	Redacted
TB_SCREEN_DSD	Sex: Female	0	423	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	0	865	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	15,640	22,457	Redacted

Implementing Mechanism Details

Mechanism ID: 10235	Mechanism Name: UNZA SOM Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 465,490	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	465,490

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10235		
Mechanism Name:	UNZA SOM Follow-on		
Prime Partner Name:	University of Zambia School of Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	245,490	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	220,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10236	Mechanism Name: University Teaching Hospital (Combined HAP & LAB)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Teaching Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 8,505,801	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	8,505,801

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10236
----------------------	--------------



Mechanism Name:	University Teaching Hospital (Combined HAP & LAB)		
Prime Partner Name:	University Teaching Hospital		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	808,743	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	509,308	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	412,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Treatment	PDTX	750,000	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,693	2,700	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,925	2,700	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	4,693		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	175	250	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	4,518	2,450	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	4,693	0	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	4,693	2,700	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,500	15,986	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	9,500	15,986	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	4,750	7,177	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	175	250	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	4,925	7,427	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,268	2,389	Redacted
OVC_SERV_DSD	Sex: Male	414		Redacted
OVC_SERV_DSD	Sex: Female	854		Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	1,268		Redacted
OVC_SERV_DSD	Age: <1	50		Redacted
OVC_SERV_DSD	Age: 1-4	113		Redacted
OVC_SERV_DSD	Age: 5-9	97		Redacted
OVC_SERV_DSD	Age: 10-14	258		Redacted
OVC_SERV_DSD	Age: 15-17	133		Redacted
OVC_SERV_DSD	Age: 18+	617		Redacted
OVC_SERV_DSD	Sum of Age disaggregates	1,268		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,347	1,833	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	4,693		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,112	1,421	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	235	412	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,347	1,833	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	286		Redacted



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,500	18,849	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	60	39	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	448	455	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,034	715	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	208		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	60	40	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	448	454	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,034	715	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	208		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	3,084	18,849	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	60	39	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	60	40	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,542		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	208	8,216	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,542		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	208	8,215	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,084		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	416	16,431	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,500	16,431	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	120	2,418	Redacted

Implementing Mechanism Details

Mechanism ID: 10238	Mechanism Name: ZNBTS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Zambia National Blood Transfusion Service	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC



Total All Funding Sources: 1,353,644	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,353,644

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10238			
Mechanism Name: ZNBTS			
Prime Partner Name: Zambia National Blood Transfusion Service			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	783,644	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	70,000	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10241	Mechanism Name: CRS FBO follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,187,292	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	4,187,292

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 10241			
Mechanism Name: CRS FBO follow on			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	220,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	232,292	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	335,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,334	10,589	Redacted
HTC_TST_DSD	By Test Result: Negative	23,561	9,752	Redacted
HTC_TST_DSD	By Test Result: Positive	1,773	837	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	25,334	10,589	Redacted
HTC_TST_DSD	Age/sex: <1 Male	355		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	887		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	355		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	177		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	872		Redacted

HTC_TST_DSD	Age/sex: 20-24 Male	2,614		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	5,219		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	871		Redacted
HTC_TST_DSD	Age/sex: <1 Female	355		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	887		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	355		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	177		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	1,307		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	3,922		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	5,656		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	1,325		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	25,334		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,773	617	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,715	4,957	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,773	546	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,073	4,469	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,546	1,163	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	21,788	9,426	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	25,334	10,589	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,969		Redacted
HTC_TST_TA	By Test Result: Negative	297		Redacted
HTC_TST_TA	By Test Result: Positive	2,672		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	2,969		Redacted
HTC_TST_TA	Age/sex: <1 Male	42		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	104		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	42		Redacted

HTC_TST_TA	Age/sex: 10-14 Male	21		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	102		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	306		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	510		Redacted
HTC_TST_TA	Age/sex: 50+ Male	102		Redacted
HTC_TST_TA	Age/sex: <1 Female	42		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	104		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	42		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	21		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	153		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	459		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	766		Redacted
HTC_TST_TA	Age/sex: 50+ Female	153		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	2,969		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	208		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,022		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	208		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,531		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	416		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,553		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,969		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,640	25,737	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	96	319	Redacted

CARE_CURR_DS D	Age/sex: 1-4 Male	241	689	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	96	613	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	48	845	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	347	899	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	1,041	742	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	1,736	4,665	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	347	1,745	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	96	319	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	241	458	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	96	629	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	48	859	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	521	639	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,562	1,366	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	2,603	9,197	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	521	1,753	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	9,640	25,737	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	481		Redacted

CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,471		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	481		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,207		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	9,640		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,856		Redacted
CARE_CURR_TA	Age/sex: <1 Male	49		Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	121		Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	49		Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	24		Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	175		Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	524		Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	874		Redacted
CARE_CURR_TA	Age/sex: 50+ Male	175		Redacted
CARE_CURR_TA	Age/sex: <1 Female	49		Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	121		Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	49		Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	24		Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	262		Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	787		Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	1,311		Redacted
CARE_CURR_TA	Age/sex: 50+ Female	262		Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	4,856		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	191		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ	1,538		Redacted

	PERMISSION ONLY: 15+ Male			
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	217		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,910		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,856		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	39,578	4,452	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	200		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	998		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	200		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,454		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,852		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	2,852		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	72	380	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	105	453	Redacted
TB_ART_DSD	Age: 15+	72		Redacted
TB_ART_DSD	Male	24	209	Redacted
TB_ART_DSD	Female	48	171	Redacted
TB_ART_DSD	Sum of Sex disaggregates	72	380	Redacted

TB_ART_DSD	Newly tested	24		Redacted
TB_ART_DSD	Known HIV-positive	48	64	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	72	64	Redacted
TB_ART_DSD	Aggregated Age: <15	24		Redacted
TB_ART_DSD	Aggregated Age: 15+	48		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	72		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,241	17,365	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	242	225	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	605	95	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	363	438	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	4,728		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	242	226	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	605	97	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	363	446	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	7,093		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,420	17,365	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	242		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	242		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,210		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,728		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,210		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,093		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,420		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	11,821		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex	14,241		Redacted

	disaggregates			
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	484		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,807		Redacted
TX_CURR_TA	Age/Sex: <1 Male	116		Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	289		Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	174		Redacted
TX_CURR_TA	Age/Sex: 15+ Male	2,260		Redacted
TX_CURR_TA	Age/Sex: <1 Female	116		Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	289		Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	174		Redacted
TX_CURR_TA	Age/Sex: 15+ Female	3,389		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	1,158		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	116		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	116		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	579		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,260		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	579		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,389		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,158		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	5,649		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,807		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	232		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,091	3,690	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	158	46	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	475	127	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	178	105	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	316	115	Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	613	116	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	699	138	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	726	757	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	123	135	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	166	55	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	298	85	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	172	93	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	325	124	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	414	125	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	998	302	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,263	1,232	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	167	135	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,091	3,690	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	158		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,127		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,161		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	166		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	961		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,842		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	7,091		Redacted
TX_NEW_DSD	Pregnancy status	581	27	Redacted
TX_NEW_DSD	Breastfeeding status	176	9	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,476	2,871	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months	5,475	2,871	Redacted

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	808		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	918		Redacted

	follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing	5		Redacted

	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	2		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	5		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	5		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	4	13	Redacted
LAB_CAP_DSD	By clinical laboratories	3		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	3		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	2		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	2		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	4		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	4		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	7,501	10,454	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,640	25,737	Redacted



TB_SCREEN_DSD	Age: 25-49	7,501		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	725		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	6,776		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	7,501		Redacted
TB_SCREEN_DSD	Sex: Male	3,017	4,778	Redacted
TB_SCREEN_DSD	Sex: Female	4,484	5,676	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	7,501	10,454	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,856		Redacted

Implementing Mechanism Details

Mechanism ID: 10260	Mechanism Name: USAID DELIVER PROJECT
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,990,680	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	3,990,680

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10260			
Mechanism Name: USAID DELIVER PROJECT			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	3,990,680	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10274	Mechanism Name: MARCH Zambia
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,047,612	
---	--



Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,047,612

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	10
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	10
Key Populations: FSW	10
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10274
Mechanism Name:	MARCH Zambia
Prime Partner Name:	New Partner



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	797,612	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	37,400	5,109	Redacted
PP_PREV_DSD	Total number of people in the target population	60,500	13,128	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0	269	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	0	584	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	0	905	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	14,960	493	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0	420	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0	758	Redacted



PP_PREV_DSD	Age/sex: 20-24 Female	22,440	1,045	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	0	635	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	37,400	5,109	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,000		Redacted
PP_PREV_TA	Total number of people in the target population	60,500		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	5,200		Redacted
PP_PREV_TA	Age/sex: 50+ Male	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	7,800		Redacted
PP_PREV_TA	Age/sex: 50+ Female	0		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	13,000		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	300	46	Redacted

Implementing Mechanism Details

Mechanism ID: 10354	Mechanism Name: Zambia OVC System Strengthening Program (ZOVSS) / Zambia Rising
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save the Children US	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,600,000	
Applied Pipeline Amount: 2,191,890	
Funding Source	Funding Amount
GHP-State	1,600,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
Gender: Gender Equality	100,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10354



Mechanism Name:	Zambia OVC System Strengthening Program (ZOVSS) / Zambia Rising		
Prime Partner Name:	Save the Children US		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,600,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	320	
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	0	
HRH_PRE	By Graduates: Midwives	0	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	320	
HRH_PRE	Sum of Graduates disaggreagtes	320	

Implementing Mechanism Details

Mechanism ID: 10364	Mechanism Name: Read to Succeed (previously ISEP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Creative Associates International Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 368,750	
---	--



Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	368,750

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Education	300,000
Gender: Gender Equality	250,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation



Sub Area:	Capacity building
-----------	-------------------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10364			
Mechanism Name: Read to Succeed (previously ISEP)			
Prime Partner Name: Creative Associates International Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	368,750	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	52,000	
PP_PREV_DSD	Age/sex: 10-14 Male	21,000	
PP_PREV_DSD	Age/sex: 15-19 Male	2,191	
PP_PREV_DSD	Age/sex: 20-24 Male	2,809	
PP_PREV_DSD	Age/sex: 25-49 Male	0	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	21,000	
PP_PREV_DSD	Age/sex: 15-19 Female	2,191	
PP_PREV_DSD	Age/sex: 20-24 Female	2,809	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	



PP_PREV_DSD	Sum of Age/Sex disaggregates	52,000	
-------------	------------------------------	--------	--

Implementing Mechanism Details

Mechanism ID: 10726	Mechanism Name: The Thrive Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,382,793	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,382,793

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	200,000
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Human Resources for Health	60,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10726			
Mechanism Name: The Thrive Project			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,293	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	82,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	8,600	0
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	9,500	0
FN_THER_DSD	Age: <1	258	0
FN_THER_DSD	Age: 1-4	430	0
FN_THER_DSD	Age: 5-14	1,462	0
FN_THER_DSD	Age: 15-17	2,150	0
FN_THER_DSD	Age: 18+	4,300	0



FN_THER_DSD	Sum of Age disaggregates	8,600	0
FN_THER_DSD	Aggregated Age: <18	4,300	
FN_THER_DSD	Aggregated Age: 18+	4,300	
FN_THER_DSD	Sum of Aggregated Age disaggregates	8,600	

Implementing Mechanism Details

Mechanism ID: 10816		Mechanism Name: Boston University	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Boston University			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 10816			
Mechanism Name: Boston University			
Prime Partner Name: Boston University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10875	Mechanism Name: United Nations High Commissioner for Refugees/PRM
----------------------------	--



Funding Agency: State/PRM	Procurement Type: Umbrella Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 155,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	155,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10875			
Mechanism Name: United Nations High Commissioner for Refugees/PRM			
Prime Partner Name: United Nations High Commissioner for Refugees			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	730	300
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	15
VMMC_CIRC_DSD	By Age: 10-14	250	150
VMMC_CIRC_DSD	By Age: 15-19	300	50
VMMC_CIRC_DSD	By Age: 20-24	150	25
VMMC_CIRC_DSD	By Age: 25-49	20	
VMMC_CIRC_DSD	By Age: 50+	10	0
VMMC_CIRC_DSD	Sum of age disaggregates	730	240
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	30
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	730	250
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	20

VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	730	300
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	730	250
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	50
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,500	18,500
PP_PREV_DSD	Total number of people in the target population	35,874	18,500
PP_PREV_DSD	Age/sex: 10-14 Male	100	2,250
PP_PREV_DSD	Age/sex: 15-19 Male	200	1,650
PP_PREV_DSD	Age/sex: 20-24 Male	420	1,280
PP_PREV_DSD	Age/sex: 25-49 Male	2,000	1,750
PP_PREV_DSD	Age/sex: 50+ Male	80	980
PP_PREV_DSD	Age/sex: 10-14 Female	150	3,300
PP_PREV_DSD	Age/sex: 15-19 Female	250	2,200
PP_PREV_DSD	Age/sex: 20-24 Female	1,200	1,430
PP_PREV_DSD	Age/sex: 25-49 Female	3,000	2,150
PP_PREV_DSD	Age/sex: 50+ Female	100	1,510
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,500	18,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,500	1,800
HTC_TST_DSD	By Test Result: Negative	3,255	1,413
HTC_TST_DSD	By Test Result: Positive	245	387
HTC_TST_DSD	Sum of Test Result disaggregates	3,500	1,800

HTC_TST_DSD	Age/sex: <1 Male	50	
HTC_TST_DSD	Age/sex: 1-4 Male	100	
HTC_TST_DSD	Age/sex: 5-9 Male	100	
HTC_TST_DSD	Age/sex: 10-14 Male	100	
HTC_TST_DSD	Age/sex: 15-19 Male	130	
HTC_TST_DSD	Age/sex: 20-24 Male	300	
HTC_TST_DSD	Age/sex: 25-49 Male	700	
HTC_TST_DSD	Age/sex: 50+ Male	20	
HTC_TST_DSD	Age/sex: <1 Female	50	
HTC_TST_DSD	Age/sex: 1-4 Female	100	
HTC_TST_DSD	Age/sex: 5-9 Female	100	
HTC_TST_DSD	Age/sex: 10-14 Female	100	
HTC_TST_DSD	Age/sex: 15-19 Female	150	
HTC_TST_DSD	Age/sex: 20-24 Female	480	
HTC_TST_DSD	Age/sex: 25-49 Female	1,000	
HTC_TST_DSD	Age/sex: 50+ Female	20	
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,500	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	350	285
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,150	449
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	350	525
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,650	541
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	700	810
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,800	990
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,500	1,800
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	650	200
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically	800	200



	undernourished.		
FN_THER_DSD	Age: <1	0	20
FN_THER_DSD	Age: 1-4	0	20
FN_THER_DSD	Age: 5-14	0	35
FN_THER_DSD	Age: 15-17	0	45
FN_THER_DSD	Age: 18+	650	80
FN_THER_DSD	Sum of Age disaggregates	650	200
FN_THER_DSD	Aggregated Age: <18	350	
FN_THER_DSD	Aggregated Age: 18+	300	
FN_THER_DSD	Sum of Aggregated Age disaggregates	650	

Implementing Mechanism Details

Mechanism ID: 10984	Mechanism Name: DOD Project Concern International PCI
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,200,336	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	3,200,336

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	1
------------------------	---



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 10984			
Mechanism Name: DOD Project Concern International PCI			
Prime Partner Name: Project Concern International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	30,536	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	219,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	MTCT	400,000	0
------------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	239	239
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	299	239
PMTCT_ARV_TA	Life-long ART (including Option B+)	239	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	191	172
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	48	0
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	67
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	239	67
PMTCT_ARV_TA	Sum of New and Current disaggregates	239	172
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,819	2,310
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,915	2,310
PMTCT_STAT_TA	By: Known positives at entry	60	265
PMTCT_STAT_TA	By: Number of new positives identified	239	100

PMTCT_STAT_TA	Sum of Positives Status disaggregates	299	365
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	20,536	8,250
PP_PREV_TA	Total number of people in the target population	25,670	25,670
PP_PREV_TA	Age/sex: 10-14 Male	805	1,400
PP_PREV_TA	Age/sex: 15-19 Male	1,811	963
PP_PREV_TA	Age/sex: 20-24 Male	1,409	1,036
PP_PREV_TA	Age/sex: 25-49 Male	6,284	655
PP_PREV_TA	Age/sex: 50+ Male	0	101
PP_PREV_TA	Age/sex: 10-14 Female	838	1,076
PP_PREV_TA	Age/sex: 15-19 Female	1,885	1,008
PP_PREV_TA	Age/sex: 20-24 Female	1,466	992
PP_PREV_TA	Age/sex: 25-49 Female	6,038	737
PP_PREV_TA	Age/sex: 50+ Female	0	282
PP_PREV_TA	Sum of Age/Sex disaggregates	20,536	8,250
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,575	13,000
HTC_TST_DSD	By Test Result: Negative	12,860	0
HTC_TST_DSD	By Test Result: Positive	1,715	0
HTC_TST_DSD	Sum of Test Result disaggregates	14,575	0
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	858	
HTC_TST_DSD	Age/sex: 5-9 Male	572	
HTC_TST_DSD	Age/sex: 10-14 Male	143	
HTC_TST_DSD	Age/sex: 15-19 Male	644	
HTC_TST_DSD	Age/sex: 20-24 Male	643	
HTC_TST_DSD	Age/sex: 25-49 Male	4,286	
HTC_TST_DSD	Age/sex: 50+ Male	0	
HTC_TST_DSD	Age/sex: <1 Female	0	

HTC_TST_DSD	Age/sex: 1-4 Female	891	
HTC_TST_DSD	Age/sex: 5-9 Female	594	
HTC_TST_DSD	Age/sex: 10-14 Female	148	
HTC_TST_DSD	Age/sex: 15-19 Female	669	
HTC_TST_DSD	Age/sex: 20-24 Female	668	
HTC_TST_DSD	Age/sex: 25-49 Female	4,459	
HTC_TST_DSD	Age/sex: 50+ Female	0	
HTC_TST_DSD	Sum of Age/Sex disaggregates	14,575	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,573	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,573	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,633	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,796	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,206	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	11,369	0
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	14,575	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,030	
HTC_TST_TA	By Test Result: Negative	3,588	
HTC_TST_TA	By Test Result: Positive	442	
HTC_TST_TA	Sum of Test Result disaggregates	4,030	
HTC_TST_TA	Age/sex: <1 Male	103	
HTC_TST_TA	Age/sex: 1-4 Male	493	
HTC_TST_TA	Age/sex: 5-9 Male	0	
HTC_TST_TA	Age/sex: 10-14 Male	0	
HTC_TST_TA	Age/sex: 15-19 Male	441	
HTC_TST_TA	Age/sex: 20-24 Male	0	
HTC_TST_TA	Age/sex: 25-49 Male	0	
HTC_TST_TA	Age/sex: 50+ Male	0	

HTC_TST_TA	Age/sex: <1 Female	107	
HTC_TST_TA	Age/sex: 1-4 Female	512	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	0	
HTC_TST_TA	Age/sex: 15-19 Female	459	
HTC_TST_TA	Age/sex: 20-24 Female	766	
HTC_TST_TA	Age/sex: 25-49 Female	1,149	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	4,030	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	596	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	441	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	619	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,374	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,215	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,815	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	4,030	
GEND_GBV_DSD	Number of people receiving post-GBV care	161	
GEND_GBV_DSD	Age: 0-9	52	
GEND_GBV_DSD	Age: 10-14	23	
GEND_GBV_DSD	Age: 15-17	19	
GEND_GBV_DSD	Age: 18-24	14	
GEND_GBV_DSD	Age: 25+	56	
GEND_GBV_DSD	Sum of Age disaggregates	164	
GEND_GBV_DSD	Sex: Male	16	
GEND_GBV_DSD	Sex: Female	145	
GEND_GBV_DSD	Sum of Sex disaggregates	161	
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	129	



GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	64	
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	64	
GEND_GBV_TA	Sum of Age disaggregates	164	
GEND_GBV_TA	Sum of Sex disaggregates	161	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	30,256	
GEND_NORM_DSD	By Age: 0-9	3,788	
GEND_NORM_DSD	By Age: 10-14	4,343	
GEND_NORM_DSD	By Age: 15-19	4,768	
GEND_NORM_DSD	By Age: 20-24	5,035	
GEND_NORM_DSD	By Age: 25+	12,322	
GEND_NORM_DSD	Sum of Age disaggregates	30,256	
GEND_NORM_DSD	By Sex: Male	15,072	
GEND_NORM_DSD	By Sex: Female	15,184	
GEND_NORM_DSD	Sum of Sex disaggregates	30,256	
GEND_NORM_DSD	By type of activity: Individual	6,571	
GEND_NORM_DSD	By type of activity: Small Group	16,226	
GEND_NORM_DSD	By type of activity: Community-level	30,256	
GEND_NORM_TA	Sum of Sex disaggregates	30,256	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	2,153	482
OVC_ACC_DSD	Sex: Male	1,055	
OVC_ACC_DSD	Sex: Female	1,098	
OVC_ACC_DSD	Sum of Sex disaggregates	2,153	
OVC_ACC_DSD	Age: <1	28	
OVC_ACC_DSD	Age: 1-4	858	
OVC_ACC_DSD	Age: 5-9	572	
OVC_ACC_DSD	Age: 10-14	143	
OVC_ACC_DSD	Age: 15-17	243	

OVC_ACC_DSD	Age: 18+	309	
OVC_ACC_DSD	Sum of Age disaggregates	2,153	
OVC_ACC_TA	Sum of Sex disaggregates	2,153	
OVC_ACC_TA	Sum of Age disaggregates	2,153	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,960	
OVC_SERV_TA	Sex: Male	6,156	
OVC_SERV_TA	Sex: Female	6,804	
OVC_SERV_TA	Sum of Sex disaggregates	12,960	
OVC_SERV_TA	Age: <1	540	
OVC_SERV_TA	Age: 1-4	2,700	
OVC_SERV_TA	Age: 5-9	3,788	
OVC_SERV_TA	Age: 10-14	2,700	
OVC_SERV_TA	Age: 15-17	1,072	
OVC_SERV_TA	Age: 18+	2,160	
OVC_SERV_TA	Sum of Age disaggregates	12,960	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,238	
CARE_CURR_DSD	Age/sex: <1 Male	25	
CARE_CURR_DSD	Age/sex: 1-4 Male	168	
CARE_CURR_DSD	Age/sex: 5-9 Male	89	
CARE_CURR_DSD	Age/sex: 10-14 Male	68	
CARE_CURR_DSD	Age/sex: 15-19 Male	219	
CARE_CURR_DSD	Age/sex: 20-24 Male	123	
CARE_CURR_DSD	Age/sex: 25-49 Male	332	
CARE_CURR_DSD	Age/sex: 50+ Male	0	
CARE_CURR_DSD	Age/sex: <1 Female	29	
CARE_CURR_DSD	Age/sex: 1-4 Female	170	
CARE_CURR_DSD	Age/sex: 5-9 Female	70	

CARE_CURR_DSD	Age/sex: 10-14 Female	56	
CARE_CURR_DSD	Age/sex: 15-19 Female	184	
CARE_CURR_DSD	Age/sex: 20-24 Female	198	
CARE_CURR_DSD	Age/sex: 25-49 Female	507	
CARE_CURR_DSD	Age/sex: 50+ Female	0	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	2,238	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	350	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	674	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	325	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	889	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,238	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,344	
CARE_NEW_DSD	Age/sex: <1 Male	2	
CARE_NEW_DSD	Age/sex: 1-4 Male	68	
CARE_NEW_DSD	Age/sex: 5-9 Male	29	
CARE_NEW_DSD	Age/sex: 10-14 Male	16	
CARE_NEW_DSD	Age/sex: 15-19 Male	119	
CARE_NEW_DSD	Age/sex: 20-24 Male	71	
CARE_NEW_DSD	Age/sex: 25-49 Male	232	
CARE_NEW_DSD	Age/sex: 50+ Male	0	
CARE_NEW_DSD	Age/sex: <1 Female	2	
CARE_NEW_DSD	Age/sex: 1-4 Female	70	
CARE_NEW_DSD	Age/sex: 5-9 Female	30	
CARE_NEW_DSD	Age/sex: 10-14 Female	16	

CARE_NEW_DSD	Age/sex: 15-19 Female	124	
CARE_NEW_DSD	Age/sex: 20-24 Female	158	
CARE_NEW_DSD	Age/sex: 25-49 Female	407	
CARE_NEW_DSD	Age/sex: 50+ Female	0	
CARE_NEW_DSD	Sum of Age/sex disaggregates	1,344	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	115	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	422	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	118	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	689	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,344	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	1,344	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	821	284
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	864	284
FN_THER_DSD	Age: <1	24	29
FN_THER_DSD	Age: 1-4	149	20
FN_THER_DSD	Age: 5-14	125	134
FN_THER_DSD	Age: 15-17	177	93
FN_THER_DSD	Age: 18+	346	8
FN_THER_DSD	Sum of Age disaggregates	821	284
FN_THER_DSD	Aggregated Age: <18	475	
FN_THER_DSD	Aggregated Age: 18+	346	
FN_THER_DSD	Sum of Aggregated Age disaggregates	821	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	210	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	239	



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	210	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	210	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	4	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	20	0
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	20	0
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	20	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	20	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	20	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	20	
FPINT_SITE_DSD	Service delivery type: Community	15	
FPINT_SITE_DSD	Service delivery type: Clinical	5	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	20	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	20	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	20	

FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	20	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,126	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,238	
TB_SCREEN_DSD	Age: <1	18	
TB_SCREEN_DSD	Age: 1-4	62	
TB_SCREEN_DSD	Age: 5-9	66	
TB_SCREEN_DSD	Age: 10-14	62	
TB_SCREEN_DSD	Age: 15-19	49	
TB_SCREEN_DSD	Age: 20-24	40	
TB_SCREEN_DSD	Age: 25-49	115	
TB_SCREEN_DSD	Age: 50+	31	
TB_SCREEN_DSD	Sum of Age disaggregates	257	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	208	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	235	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	443	
TB_SCREEN_DSD	Sex: Male	217	
TB_SCREEN_DSD	Sex: Female	226	
TB_SCREEN_DSD	Sum of Sex disaggregates	443	

Implementing Mechanism Details

Mechanism ID: 11027	Mechanism Name: National AIDS Council Joint Financing Arrangement
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: State/AF
Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	150,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	11027		
Mechanism Name:	National AIDS Council Joint Financing Arrangement		
Prime Partner Name:	National HIV/AIDS/STI/TB Council - Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 11626	Mechanism Name: Jhpiego
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,119,574	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	4,119,574

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	11626		
Mechanism Name:	Jhpiego		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	15,536	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,702,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	151,796	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	314	80
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	376	80
PMTCT_ARV_TA	Life-long ART (including Option B+)	314	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	187	70
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	127	10
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	314	0
PMTCT_ARV_TA	Sum of New and Current disaggregates	314	80
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,130	924
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,130	924
PMTCT_STAT_TA	By: Known positives at entry	109	109
PMTCT_STAT_TA	By: Number of new positives identified	267	80
PMTCT_STAT_TA	Sum of Positives Status disaggregates	376	189
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	68	21
VMMC_AE_DSD	By AE type: Number of VMMC clients with	0	

	one or more moderate or severe surgical intra-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	34	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	30	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	4	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	

VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,001	7,500
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	0	
VMMC_CIRC_DSD	By Age: 10-14	2,171	3,000
VMMC_CIRC_DSD	By Age: 15-19	1,572	2,150
VMMC_CIRC_DSD	By Age: 20-24	1,607	1,200
VMMC_CIRC_DSD	By Age: 25-49	1,633	
VMMC_CIRC_DSD	By Age: 50+	18	25
VMMC_CIRC_DSD	Sum of age disaggregates	7,001	6,375
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	49	72
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	5,589	7,127
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,363	301
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	7,001	7,500
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,600	7,300
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	1,400	200
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,001	1,386
HTC_TST_TA	By Test Result: Negative	10,591	0

HTC_TST_TA	By Test Result: Positive	410	0
HTC_TST_TA	Sum of Test Result disaggregates	11,001	0
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	1,176	
HTC_TST_TA	Age/sex: 5-9 Male	2,208	
HTC_TST_TA	Age/sex: 10-14 Male	1,382	
HTC_TST_TA	Age/sex: 15-19 Male	1,344	
HTC_TST_TA	Age/sex: 20-24 Male	981	
HTC_TST_TA	Age/sex: 25-49 Male	9	
HTC_TST_TA	Age/sex: 50+ Male	0	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	444	
HTC_TST_TA	Age/sex: 10-14 Female	1,063	
HTC_TST_TA	Age/sex: 15-19 Female	1,954	
HTC_TST_TA	Age/sex: 20-24 Female	440	
HTC_TST_TA	Age/sex: 25-49 Female	0	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	11,001	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,384	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,716	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	444	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,457	0
HTC_TST_TA	Sum of Aggregated Age/Sex <15	3,828	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	7,173	0
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	11,001	0
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical	3,810	5,000

	assessment (WHO staging) OR CD4 count OR viral load		
CARE_CURR_TA	Age/sex: <1 Male	6	70
CARE_CURR_TA	Age/sex: 1-4 Male	0	98
CARE_CURR_TA	Age/sex: 5-9 Male	4	210
CARE_CURR_TA	Age/sex: 10-14 Male	112	150
CARE_CURR_TA	Age/sex: 15-19 Male	291	200
CARE_CURR_TA	Age/sex: 20-24 Male	726	1,207
CARE_CURR_TA	Age/sex: 25-49 Male	357	545
CARE_CURR_TA	Age/sex: 50+ Male	73	5
CARE_CURR_TA	Age/sex: <1 Female	2	52
CARE_CURR_TA	Age/sex: 1-4 Female	10	100
CARE_CURR_TA	Age/sex: 5-9 Female	14	300
CARE_CURR_TA	Age/sex: 10-14 Female	155	260
CARE_CURR_TA	Age/sex: 15-19 Female	472	315
CARE_CURR_TA	Age/sex: 20-24 Female	1,060	823
CARE_CURR_TA	Age/sex: 25-49 Female	426	655
CARE_CURR_TA	Age/sex: 50+ Female	102	10
CARE_CURR_TA	Sum of Age/Sex disaggregates	3,810	5,000
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	122	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,447	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	178	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,063	
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	3,810	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count	571	0

	OR viral load		
CARE_NEW_DSD	Age/sex: <1 Male	4	0
CARE_NEW_DSD	Age/sex: 1-4 Male	4	0
CARE_NEW_DSD	Age/sex: 5-9 Male	2	0
CARE_NEW_DSD	Age/sex: 10-14 Male	2	0
CARE_NEW_DSD	Age/sex: 15-19 Male	46	0
CARE_NEW_DSD	Age/sex: 20-24 Male	98	0
CARE_NEW_DSD	Age/sex: 25-49 Male	44	0
CARE_NEW_DSD	Age/sex: 50+ Male	2	0
CARE_NEW_DSD	Age/sex: <1 Female	6	0
CARE_NEW_DSD	Age/sex: 1-4 Female	8	0
CARE_NEW_DSD	Age/sex: 5-9 Female	6	0
CARE_NEW_DSD	Age/sex: 10-14 Female	70	0
CARE_NEW_DSD	Age/sex: 15-19 Female	120	0
CARE_NEW_DSD	Age/sex: 20-24 Female	121	0
CARE_NEW_DSD	Age/sex: 25-49 Female	38	0
CARE_NEW_DSD	Age/sex: 50+ Female	0	0
CARE_NEW_DSD	Sum of Age/sex disaggregates	571	0
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	14	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	190	0
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	98	0
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	269	0
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	571	0
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	571	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	267	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	326	
TB_ART_DSD	Age: 0-4	0	



TB_ART_DSD	Age: 5-14	38	
TB_ART_DSD	Age: 15+	229	
TB_ART_DSD	Male	95	
TB_ART_DSD	Female	172	
TB_ART_DSD	Sum of Sex disaggregates	267	
TB_ART_DSD	Newly tested	229	
TB_ART_DSD	Known HIV-positive	38	
TB_ART_DSD	Sum of Test Status disaggregates	267	
TB_ART_DSD	Aggregated Age: <15	38	
TB_ART_DSD	Aggregated Age: 15+	229	
TB_ART_DSD	Sum of Aggregated Age disaggregates	267	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,803	3,059
TX_CURR_TA	Age/Sex: <1 Male	6	3
TX_CURR_TA	Age/Sex: 1-4 Male	0	75
TX_CURR_TA	Age/Sex: 5-14 Male	116	50
TX_CURR_TA	Age/Sex: 15+ Male	2,000	
TX_CURR_TA	Age/Sex: <1 Female	2	1
TX_CURR_TA	Age/Sex: 1-4 Female	10	100
TX_CURR_TA	Age/Sex: 5-14 Female	169	14
TX_CURR_TA	Age/Sex: 15+ Female	2,500	
TX_CURR_TA	Sum of Age/Sex disaggregations	303	3,059
TX_CURR_TA	Aggregated Age/Sex: <1 Male	6	0
TX_CURR_TA	Aggregated Age/Sex: <1 Female	2	0
TX_CURR_TA	Aggregated Age/Sex: <15 Male	122	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,000	0
TX_CURR_TA	Aggregated Age/Sex: <15 Female	181	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,500	0
TX_CURR_TA	Sum of Aggregated Age/Sex <15	303	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	4,500	0
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,803	0
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14)	8	0

	<15		
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	14	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	14	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	14	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	14	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	14	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	14	
FPINT_SITE_DSD	Service delivery type: Community	0	
FPINT_SITE_DSD	Service delivery type: Clinical	14	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	14	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	14	
FPINT_SITE_TA	Sum of Numerator Site Support Type	14	



	disaggregates		
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	14	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	952	
TB_SCREEN_DSD	Age: <1	0	
TB_SCREEN_DSD	Age: 1-4	0	
TB_SCREEN_DSD	Age: 5-9	0	
TB_SCREEN_DSD	Age: 10-14	144	
TB_SCREEN_DSD	Age: 15-19	438	
TB_SCREEN_DSD	Age: 20-24	352	
TB_SCREEN_DSD	Age: 25-49	170	
TB_SCREEN_DSD	Age: 50+	16	
TB_SCREEN_DSD	Sum of Age disaggregates	582	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	144	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	976	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	1,120	
TB_SCREEN_DSD	Sex: Male	450	
TB_SCREEN_DSD	Sex: Female	670	
TB_SCREEN_DSD	Sum of Sex disaggregates	1,120	
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,810	5,000

Implementing Mechanism Details

Mechanism ID: 11627	Mechanism Name: DAO Lusaka
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 3,608,382	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	3,608,382

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Construction	2,976,235
Human Resources for Health	200,000
Motor Vehicles: Purchased	100,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 11627			
Mechanism Name: DAO Lusaka			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	614,946	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	987,601	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,702,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	303,593	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11694	Mechanism Name: CDC Technical Assistance - SMDP & FETP
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 203,606	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	203,606



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	11694		
Mechanism Name:	CDC Technical Assistance - SMDP & FETP		
Prime Partner Name:	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	203,606	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12267	Mechanism Name: Mawa (formerly ZERS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 1,500,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12267			
Mechanism Name: Mawa (formerly ZERS)			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	30,882	157,913



OVC_SERV_DSD	Sex: Male	15,155	
OVC_SERV_DSD	Sex: Female	15,727	
OVC_SERV_DSD	Sum of Sex disaggregates	30,882	
OVC_SERV_DSD	Age: <1	504	
OVC_SERV_DSD	Age: 1-4	4,730	
OVC_SERV_DSD	Age: 5-9	5,599	
OVC_SERV_DSD	Age: 10-14	4,494	
OVC_SERV_DSD	Age: 15-17	1,963	
OVC_SERV_DSD	Age: 18+	13,592	
OVC_SERV_DSD	Sum of Age disaggregates	30,882	

Implementing Mechanism Details

Mechanism ID: 12271	Mechanism Name: Community Compacts
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12271			
Mechanism Name: Community Compacts			
Prime Partner Name: Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,349	
PP_PREV_DSD	Total number of people in the target population	14,400	
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	370	
PP_PREV_DSD	Age/sex: 20-24 Male	1,000	
PP_PREV_DSD	Age/sex: 25-49 Male	830	



PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	367	
PP_PREV_DSD	Age/sex: 15-19 Female	395	
PP_PREV_DSD	Age/sex: 20-24 Female	715	
PP_PREV_DSD	Age/sex: 25-49 Female	672	
PP_PREV_DSD	Sum of Age/Sex disaggregates	4,349	

Implementing Mechanism Details

Mechanism ID: 12272		Mechanism Name: PEPFAR OVC Small Grants	
Funding Agency: State/AF		Procurement Type: USG Core	
Prime Partner Name: U.S. Department of State			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	150,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 12272			
Mechanism Name: PEPFAR OVC Small Grants			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	500	
OVC_SERV_DSD	Sex: Male	250	
OVC_SERV_DSD	Sex: Female	250	
OVC_SERV_DSD	Sum of Sex disaggregates	500	
OVC_SERV_DSD	Age: <1	10	
OVC_SERV_DSD	Age: 1-4	30	
OVC_SERV_DSD	Age: 5-9	150	
OVC_SERV_DSD	Age: 10-14	210	
OVC_SERV_DSD	Age: 15-17	50	
OVC_SERV_DSD	Age: 18+	50	
OVC_SERV_DSD	Sum of Age disaggregates	500	

Implementing Mechanism Details

Mechanism ID: 12276	Mechanism Name: Macha Research Trust, Inc
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Macha Research Trust, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12276			
Mechanism Name: Macha Research Trust, Inc			
Prime Partner Name: Macha Research Trust, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	125		Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	150		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	125		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	50		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	75		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	125		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	125		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	660		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	770		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	100		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	45		Redacted
PMTCT_STAT_DS	Sum of Positives Status disaggregates	145		Redacted



D				
---	--	--	--	--

Implementing Mechanism Details

Mechanism ID: 12821	Mechanism Name: STEP UP
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	12821		
Mechanism Name:	STEP UP		
Prime Partner Name:	Chemonics International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12942	Mechanism Name: PROJECT CONCERN INTERNATIONAL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12942			
Mechanism Name: PROJECT CONCERN INTERNATIONAL			
Prime Partner Name: Project Concern International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
------------------	-------	------	------	-------------------------

PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,197		Redacted
PP_PREV_DSD	Total number of people in the target population	5,729		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	331		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	662		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	357		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	1,019		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	178		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	345		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	689		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	370		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,060		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	186		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,197		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0		Redacted
PP_PREV_TA	Total number of people in the target population	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0		Redacted
PP_PREV_TA	Age/sex: 50+ Male	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0		Redacted

PP_PREV_TA	Age/sex: 25-49 Female	0		Redacted
PP_PREV_TA	Age/sex: 50+ Female	0		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	480		Redacted
HTC_TST_DSD	By Test Result: Negative	413		Redacted
HTC_TST_DSD	By Test Result: Positive	67		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	480		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	31		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	61		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	33		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	94		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	16		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	32		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	64		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	34		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	98		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	17		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	480		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	31		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	204		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	32		Redacted

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	213		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	63		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	417		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	480		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	237		Redacted
HTC_TST_TA	By Test Result: Negative	204		Redacted
HTC_TST_TA	By Test Result: Positive	33		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	237		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	15		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	31		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	16		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	46		Redacted
HTC_TST_TA	Age/sex: 50+ Male	8		Redacted
HTC_TST_TA	Age/sex: <1 Female	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	16		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	31		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	17		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	48		Redacted
HTC_TST_TA	Age/sex: 50+ Female	9		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	237		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	101		Redacted



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	105		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	31		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	206		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	237		Redacted

Implementing Mechanism Details

Mechanism ID: 12988	Mechanism Name: CARE
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 12988			
Mechanism Name: CARE			
Prime Partner Name: Care International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	975,765		Redacted
PP_PREV_DSD	Total number of people in the target population	975,765		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	19,515		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	48,788		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	146,365		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	214,668		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	29,273		Redacted



PP_PREV_DSD	Age/sex: 10-14 Female	29,273		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	48,788		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	195,153		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	214,668		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	29,274		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	975,765		Redacted

Implementing Mechanism Details

Mechanism ID: 13006	Mechanism Name: CIDRZ - Community Compact
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13006		
Mechanism Name:	CIDRZ - Community Compact		
Prime Partner Name:	CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	54,000	3,939	Redacted
HTC_TST_DSD	By Test Result: Negative	46,278	3,634	Redacted
HTC_TST_DSD	By Test Result: Positive	7,722	303	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	54,000	3,937	Redacted



HTC_TST_DSD	Age/sex: 25-49 Male	29,700		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	24,300		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	54,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,700	2,539	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,300	127	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	54,000	2,666	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	54,000	3,937	Redacted

Implementing Mechanism Details

Mechanism ID: 13016	Mechanism Name: CMMB
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Mission Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13016			
Mechanism Name: CMMB			
Prime Partner Name: Catholic Medical Mission Board			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0		Redacted
PP_PREV_DSD	Total number of people in the target population	0		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	0		Redacted

PP_PREV_DSD	Age/sex: 20-24 Male	0		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	0		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0		Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	0		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	0		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	0		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	0		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0		Redacted
HTC_TST_DSD	By Test Result: Negative	0		Redacted
HTC_TST_DSD	By Test Result: Positive	0		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	0		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	0		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	0		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	0		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	0		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	0		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	0		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	0		Redacted

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	0		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	0		Redacted

Implementing Mechanism Details

Mechanism ID: 13033	Mechanism Name: POPULATION COUNCIL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,291,523	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,291,523

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	10
-----------------------------	----



Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	10
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13033		
Mechanism Name:	POPULATION COUNCIL		
Prime Partner Name:	Population Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	41,523	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,600	1,906	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,200	976	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,080	160	Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	120	120	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	840	410	Redacted

	interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	360		Redacted

Implementing Mechanism Details

Mechanism ID: 13076	Mechanism Name: JSI Logistics Services
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 650,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	650,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13076			
Mechanism Name: JSI Logistics Services			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	26	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	26	
LAB_ACC_DSD	Sum of Support Type disaggregates	26	
LAB_ACC_TA	Sum of Support Type disaggregates	26	
LAB_CAP_DSD	Number of PEPFAR-supported testing	26	30



	facilities with capacity to perform clinical laboratory tests		
LAB_CAP_DSD	By clinical laboratories	26	30
LAB_CAP_DSD	By Point-of-care testing sites	0	0
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	26	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	26	
LAB_CAP_TA	Sum of Site Support Type disaggregates	26	

Implementing Mechanism Details

Mechanism ID: 13562	Mechanism Name: CHRESO Ministries
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Chreso Ministries	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,636,664	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	3,636,664

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13562			
Mechanism Name: CHRESO Ministries			
Prime Partner Name: Chreso Ministries			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	895,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	93,077	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	101,862	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	261,725	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	335,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	640	115	Redacted

PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	664		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	307		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	62	61	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	245	54	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	307	0	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	307	115	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,184	907	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,232	3,215	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	469	196	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	194	711	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	663	907	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	884		Redacted
VMMC_CIRC_DS D	By Age: 10-14	200		Redacted
VMMC_CIRC_DS	By Age: 15-19	222		Redacted

D				
VMMC_CIRC_DS D	By Age: 20-24	237		Redacted
VMMC_CIRC_DS D	By Age: 25-49	225		Redacted
VMMC_CIRC_DS D	By Age: 50+	0		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	884		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	128		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	791		Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	865		Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	865		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	330		Redacted

VMMC_CIRC_TA	By Age: <1	0		Redacted
VMMC_CIRC_TA	By Age: 1-9	0		Redacted
VMMC_CIRC_TA	By Age: 10-14	50		Redacted
VMMC_CIRC_TA	By Age: 15-19	80		Redacted
VMMC_CIRC_TA	By Age: 20-24	100		Redacted
VMMC_CIRC_TA	By Age: 25-49	100		Redacted
VMMC_CIRC_TA	By Age: 50+	0		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	330		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	46		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	284		Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	330		Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	330		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	44,748	10,924	Redacted

PP_PREV_DSD	Total number of people in the target population	101,136	1,000	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	840	1,016	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	3,600	842	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	8,040	727	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	5,448	1,918	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	240	488	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	840	1,113	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	7,800	903	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	6,600	859	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	11,100	2,428	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	240	630	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	44,748	10,924	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,000		Redacted
PP_PREV_TA	Total number of people in the target population	16,000		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	250		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	1,000		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	1,150		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	500		Redacted
PP_PREV_TA	Age/sex: 50+ Male	300		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	1,000		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	1,200		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	530		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	160		Redacted
PP_PREV_TA	Age/sex: 50+ Female	110		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	6,200		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level	780	29	Redacted

	HIV preventive interventions that are based on evidence and/or meet the minimum standards required			
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	780	29	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key	0		Redacted

	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	100		Redacted
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100		Redacted
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small	0		Redacted

	group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,455	4,251	Redacted
HTC_TST_DSD	By Test Result: Negative	5,820	3,634	Redacted
HTC_TST_DSD	By Test Result: Positive	2,635	632	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	8,455	4,266	Redacted
HTC_TST_DSD	Age/sex: <1 Male	306		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	52		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	143		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	185		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	564		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	1,038		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	1,386		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	312		Redacted
HTC_TST_DSD	Age/sex: <1 Female	318		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	56		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	174		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	192		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	572		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	1,296		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	1,416		Redacted

HTC_TST_DSD	Age/sex: 50+ Female	445		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	8,455		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	686	307	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,300	1,837	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	740	194	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,729	1,939	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,426	501	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,029	3,776	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	8,455	4,277	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,476		Redacted
HTC_TST_TA	By Test Result: Negative	1,020		Redacted
HTC_TST_TA	By Test Result: Positive	430		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	1,450		Redacted
HTC_TST_TA	Age/sex: <1 Male	10		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	10		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	25		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	26		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	100		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	225		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	227		Redacted
HTC_TST_TA	Age/sex: 50+ Male	52		Redacted
HTC_TST_TA	Age/sex: <1 Female	15		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	15		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	27		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	27		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	130		Redacted

HTC_TST_TA	Age/sex: 20-24 Female	202		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	300		Redacted
HTC_TST_TA	Age/sex: 50+ Female	85		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	1,476		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,875	21,510	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	421	166	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	635	124	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	846	165	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	1,057	214	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,481	907	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	3,384	1,950	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	4,230	4,200	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	846	1,337	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	635	95	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	1,057	158	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	1,692	251	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	2,537	401	Redacted
CARE_CURR_DS	Age/sex: 15-19 Female	3,595	1,105	Redacted

D				
CARE_CURR_DS D	Age/sex: 20-24 Female	5,286	2,441	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	2,748	6,118	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	425	1,878	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	30,875	21,510	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,959	224	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,941	1,840	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,921	162	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,054	2,636	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	30,875	4,862	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,500		Redacted
CARE_CURR_TA	Age/sex: <1 Male	9		Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	28		Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	30		Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	52		Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	185		Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	250		Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	400		Redacted
CARE_CURR_TA	Age/sex: 50+ Male	66		Redacted
CARE_CURR_TA	Age/sex: <1 Female	10		Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	25		Redacted

CARE_CURR_TA	Age/sex: 5-9 Female	110		Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	225		Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	400		Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	150		Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	500		Redacted
CARE_CURR_TA	Age/sex: 50+ Female	60		Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	2,500		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	119		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	901		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	370		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,110		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,500		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,182	2,961	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	4	12	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	10	40	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	29	14	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	94	36	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	142	70	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	569	190	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	510	958	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	120	101	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	4	4	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	12	26	Redacted

CARE_NEW_DSD	Age/sex: 5-9 Female	38	22	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	122	53	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	164	133	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	602	219	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	604	981	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	158	102	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	3,182	2,961	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	137	102	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,340	1,319	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	176	105	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,529	1,435	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,182	2,961	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	3,182	2,961	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	323		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	322		Redacted
FN_THER_DSD	Age: <1	0		Redacted
FN_THER_DSD	Age: 1-4	10		Redacted
FN_THER_DSD	Age: 5-14	158		Redacted
FN_THER_DSD	Age: 15-17	145		Redacted
FN_THER_DSD	Age: 18+	10		Redacted
FN_THER_DSD	Sum of Age disaggregates	323		Redacted
FN_THER_DSD	Aggregated Age: <18	313		Redacted
FN_THER_DSD	Aggregated Age: 18+	10		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	323		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented	152	528	Redacted

	HIV-positive status who are on ART during TB treatment during the reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	152	59	Redacted
TB_ART_DSD	Age: 0-4	0		Redacted
TB_ART_DSD	Age: 5-14	13		Redacted
TB_ART_DSD	Age: 15+	139		Redacted
TB_ART_DSD	Male	13	225	Redacted
TB_ART_DSD	Female	139	303	Redacted
TB_ART_DSD	Sum of Sex disaggregates	152	528	Redacted
TB_ART_DSD	Newly tested	67		Redacted
TB_ART_DSD	Known HIV-positive	85	50	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	152	50	Redacted
TB_ART_DSD	Aggregated Age: <15	127	8	Redacted
TB_ART_DSD	Aggregated Age: 15+	25	75	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	152	83	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	642	123	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	680		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	198	59	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	444	64	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	642	123	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	28		Redacted



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,633	11,549	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	141	22	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	105	163	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	284	256	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	6,050		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	162	31	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	109	151	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	282	322	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	9,500		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,083	11,549	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	141		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	162		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	530		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,050		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	553		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,500		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,083		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	15,550		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	16,633		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	303		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,608	2,454	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	8	6	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	18	28	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	31	24	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	83	37	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	106	68	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	216	113	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	413	664	Redacted

TX_NEW_DSD	By Age/Sex: 50+ Male	67	72	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	10	32	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	20	22	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	46	44	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	198	59	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	169	68	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	414	202	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	721	862	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	88	143	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,608	2,444	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	8	2	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	140		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	802	426	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	10	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	274		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,392	569	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,608	995	Redacted
TX_NEW_DSD	Pregnancy status	293		Redacted
TX_NEW_DSD	Breastfeeding status	38		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	283	1,910	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	307		Redacted

TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	477		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	660		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,709		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	485		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	529		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16,398		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12	1,017		Redacted

	months after initiating ART)			
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,168		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,115		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,674		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable	5		Redacted

	level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	5		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	5		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	5		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	5	9	Redacted
LAB_CAP_DSD	By clinical laboratories	5	9	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	6		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	5		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	5		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	5		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	5	5	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	5	5	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	5		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	5		Redacted

FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	5		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	5		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	5		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	5		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	5		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	5		Redacted
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	5		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	30,559	14,518	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,875	21,510	Redacted
TB_SCREEN_DSD	Age: <1	26	225	Redacted
TB_SCREEN_DSD	Age: 1-4	178	285	Redacted
TB_SCREEN_DSD	Age: 5-9	462	408	Redacted
TB_SCREEN_DSD	Age: 10-14	911	527	Redacted
TB_SCREEN_DSD	Age: 15-19	3,004	835	Redacted
TB_SCREEN_DSD	Age: 20-24	12,281		Redacted
TB_SCREEN_DSD	Age: 25-49	10,198		Redacted
TB_SCREEN_DSD	Age: 50+	3,499		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	4,581	14,518	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ	1,577	457	Redacted



	PERMISSION ONLY: <15			
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	28,982	482	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	30,559	939	Redacted
TB_SCREEN_DSD	Sex: Male	12,224	6,207	Redacted
TB_SCREEN_DSD	Sex: Female	18,335	8,311	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	30,559	14,518	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,500		Redacted

Implementing Mechanism Details

Mechanism ID: 13580	Mechanism Name: CIDRZ (HiLo)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Centre for Infectious Diseases Research in Zambia (CIDRZ)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 23,419,169	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	23,419,169

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13580			
Mechanism Name: CIDRZ (HiLo)			
Prime Partner Name: Centre for Infectious Diseases Research in Zambia (CIDRZ)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,944,756	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,325,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	881,796	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	81,442	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,025,697	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	770,478	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	3,600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	10,700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	2,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	21,671	0	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	24,089	0	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	10,860		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	0	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	0	Redacted

PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	10		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	10,711	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	13	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	21,594	0	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	0	0	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	19,759	8,984	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	19,759	9,514	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	21,370		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	13,897	774	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	7,473	896	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	21,370	4,222	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	21,370	1,670	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	177,021	97,475	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	186,072	103,312	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	8,107	6,451	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	15,982	6,789	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	24,089	13,240	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	159,712	65,931	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	166,073	69,715	Redacted
PMTCT_STAT_TA	By: Known positives at entry	7,293	4,187	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	12,466	4,407	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	19,759	8,594	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	50	188	Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	50		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative	50		Redacted

	AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)			
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	39		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	40		Redacted
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	10		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	25,000	18,761	Redacted
VMMC_CIRC_DS D	By Age: 1-9	2,000	1,942	Redacted
VMMC_CIRC_DS D	By Age: 10-14	8,000	5,328	Redacted
VMMC_CIRC_DS D	By Age: 15-19	7,000	4,813	Redacted
VMMC_CIRC_DS D	By Age: 20-24	4,000	2,753	Redacted

VMMC_CIRC_DS D	By Age: 25-49	3,400		Redacted
VMMC_CIRC_DS D	By Age: 50+	600	820	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	25,000	15,709	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	400	792	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	15,000	9,734	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	9,600	8,234	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	25,000	16,621	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	19,000	11,801	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	6,000	6,960	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,080		Redacted
VMMC_CIRC_TA	By Age: 10-14	1,856		Redacted
VMMC_CIRC_TA	By Age: 15-19	1,811		Redacted
VMMC_CIRC_TA	By Age: 20-24	1,481		Redacted
VMMC_CIRC_TA	By Age: 25-49	1,241		Redacted

VMMC_CIRC_TA	By Age: 50+	691		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	7,080		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0		Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0		Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	355		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	6,868		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	2,878		Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	475		Redacted
PP_PREV_TA	Total number of people in the target population	0		Redacted
PP_PREV_TA	Age/sex: 10-14 Male	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Male	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Male	0		Redacted



PP_PREV_TA	Age/sex: 50+ Male	475		Redacted
PP_PREV_TA	Age/sex: 10-14 Female	0		Redacted
PP_PREV_TA	Age/sex: 15-19 Female	0		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	0		Redacted
PP_PREV_TA	Age/sex: 25-49 Female	0		Redacted
PP_PREV_TA	Age/sex: 50+ Female	0		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	475		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	307,886	48,929	Redacted
HTC_TST_TA	By Test Result: Negative	278,724	45,060	Redacted
HTC_TST_TA	By Test Result: Positive	29,162	3,869	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	307,886	48,929	Redacted
HTC_TST_TA	Age/sex: <1 Male	7,826		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	0		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	0		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	23,109		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	123,154		Redacted
HTC_TST_TA	Age/sex: 50+ Male	88,022		Redacted
HTC_TST_TA	Age/sex: <1 Female	7,826		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	1,775		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	27,517		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	57,706		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	184,732		Redacted
HTC_TST_TA	Age/sex: 50+ Female	0		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	521,667		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,826	2,859	Redacted

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	111,130	13,990	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,601	2,090	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	179,329	29,990	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	17,427	4,949	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	290,459	43,980	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	307,886	48,929	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	158,571	249,372	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	202	110	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	566	1,596	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	1,739	2,771	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	1,467	2,641	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	1,087	2,084	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	902	6,966	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	38,558	66,016	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	12,897	16,668	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	183	138	Redacted
CARE_CURR_DS	Age/sex: 1-4 Female	779	1,730	Redacted

D				
CARE_CURR_DS D	Age/sex: 5-9 Female	2,030	2,891	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	1,699	2,624	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,701	3,608	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	3,637	16,075	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	73,214	92,972	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	17,910	30,482	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	158,571	249,372	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,974		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	53,444		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,691		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	96,462		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	158,571		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	215,882	15,479	Redacted
CARE_CURR_TA	Age/sex: <1 Male	232	8	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	777	114	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	2,479	197	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	2,125	188	Redacted



CARE_CURR_TA	Age/sex: 15-19 Male	1,488	161	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	1,182	486	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	52,710	3,848	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	17,949	1,227	Redacted
CARE_CURR_TA	Age/sex: <1 Female	199	6	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	1,078	121	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	2,901	207	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	2,391	186	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	2,273	238	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	4,754	884	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	98,787	5,757	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	24,557	1,851	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	215,882	15,479	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,613		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	73,329		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,569		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	130,371		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	215,882		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	44,000	44,152	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	41	53	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	472	492	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	250	295	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	195	200	Redacted

CARE_NEW_DSD	Age/sex: 15-19 Male	204	324	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	717	1,947	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	13,709	10,116	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	1,670	1,964	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	52	67	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	491	507	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	279	350	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	306	362	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1,019	1,100	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	3,807	4,558	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	18,923	17,912	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	1,865	3,905	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	44,000	44,152	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	958		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	16,300		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,128		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	25,614		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	44,000		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	44,000		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	8,878	688	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	10,445	688	Redacted
TB_ART_DSD	Age: 15+	8,878		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth	15,807	9,461	Redacted

	during the reporting period			
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	19,759		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	14,226	3,827	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,581	5,594	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	15,807	9,421	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	6,323		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	198,069	172,204	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	46	355	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	1,262	2,161	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	6,038	5,046	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	66,639		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	1,809	363	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,161	2,191	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	6,259	11,890	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	114,855		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	16,575	172,204	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	46		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	1,809		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	7,346		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	66,639		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	9,229		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	114,855		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	16,575		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	181,494		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex	198,069		Redacted

	disaggregates			
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	1,855		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	198,069	10,689	Redacted
TX_CURR_TA	Age/Sex: <1 Male	46	20	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	1,262	161	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	6,038	466	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	66,639		Redacted
TX_CURR_TA	Age/Sex: <1 Female	1,809	25	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	1,161	163	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	6,259	476	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	114,855		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	16,575	10,683	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	198,069		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	46		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,809		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,346		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	66,639		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	9,229		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	68,448		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	16,575		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	85,023		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	198,115		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	44,000	36,588	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	64	63	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	334	347	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	437	260	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	409	248	Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	278	216	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	397	1,218	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	12,350	10,702	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	3,247	1,436	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	171	81	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	377	344	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	423	374	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	521	437	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	569	1,151	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,820	4,004	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	18,123	12,223	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	4,480	3,481	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	44,000	36,585	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	64		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,244		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	16,272		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	171		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,492		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	24,992		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	44,000		Redacted
TX_NEW_DSD	Pregnancy status	8,207	10,555	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	26,505	28,474	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	37,864	31,561	Redacted

	period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	645		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted

TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform	78	21	Redacted

	clinical laboratory tests			
LAB_CAP_DSD	By clinical laboratories	57	15	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	21	10	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	78		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	78		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	78		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	78	25	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	49	18	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	46	1	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	36	11	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	20	3	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	20	3	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	22		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT	2		Redacted

	program			
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	2		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	64		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	50		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	50		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	14		Redacted
HRH_PRE	By Graduates: Nurses	14		Redacted
HRH_PRE	Sum of Graduates disaggregated	14		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	200,000	18,923	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting	158,571	249,372	Redacted



	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
TB_SCREEN_DSD	Age: 25-49	200,000		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	215,882	15,479	Redacted

Implementing Mechanism Details

Mechanism ID: 13684	Mechanism Name: UNZA ZEPACT
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 842,885	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	842,885

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	10
----------------------------	----

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13684			
Mechanism Name: UNZA ZEPACT			
Prime Partner Name: University of Zambia School of Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	162,885	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	680,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	335		Redacted
HRH_PRE	By Graduates: Doctors	8		Redacted
HRH_PRE	By Graduates: Nurses	10		Redacted



HRH_PRE	By Graduates: Midwives	10		Redacted
HRH_PRE	By Graduates: Social service workers	20		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	By Graduates: Other	287		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	335		Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0		Redacted

Implementing Mechanism Details

Mechanism ID: 13731	Mechanism Name: DAPP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People Humana Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,208,388	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,208,388

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Condom programming	10
Food and Nutrition: Commodities	10
Gender: GBV	10



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	10
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	10
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Water	10

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13731		
Mechanism Name:	DAPP		
Prime Partner Name:	Development Aid from People to People Humana Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Care	HVTB	20,630	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	110,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	39,970	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,426,063	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	261,725	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	206,129	34,636	Redacted
PP_PREV_DSD	Total number of people in the target population	454,160	180,000	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	17,242	3,005	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	21,451	7,445	Redacted

PP_PREV_DSD	Age/sex: 20-24 Male	14,791	2,823	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	35,546	2,348	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	10,095	1,736	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	16,574	3,046	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	21,159	7,365	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	16,760	2,804	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	40,473	2,322	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	12,038	1,742	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	206,129	34,636	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	350	24	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	350	24	Redacted
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	0		Redacted

	standards required)			
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	247		Redacted
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,300	22,375	Redacted
HTC_TST_DSD	By Test Result: Negative	54,270	20,606	Redacted
HTC_TST_DSD	By Test Result: Positive	6,030	1,769	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	60,300	22,375	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	15		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	378		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	5,408		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,699		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,457		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	10,146		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,734		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	18		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	372		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	5,365		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,204		Redacted

HTC_TST_DSD	Age/sex: 20-24 Female	5,337		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	11,118		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	3,049		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	60,300		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,801	1,948	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,036	8,745	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,755	1,937	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,708	9,745	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,556	3,885	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	48,744	18,490	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	60,300	22,375	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	252		Redacted
HRH_PRE	By Graduates: Doctors	0		Redacted
HRH_PRE	By Graduates: Nurses	0		Redacted
HRH_PRE	By Graduates: Midwives	0		Redacted
HRH_PRE	By Graduates: Social service workers	252		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted
HRH_PRE	By Graduates: Other	0		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	252		Redacted
HRH_PRE	By new graduates who are licensed and registered: Doctors	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	0		Redacted

HRH_PRE	By new graduates who are licensed and registered: Midwives	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Social service workers	252		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0		Redacted
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	0		Redacted

Implementing Mechanism Details

Mechanism ID: 13787	Mechanism Name: CHAZ
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Churches Health Association of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,157,141	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	5,157,141

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



(No data provided.)

Budget Code Information

Mechanism ID: 13787			
Mechanism Name: CHAZ			
Prime Partner Name: Churches Health Association of Zambia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	656,198	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	122,164	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	107,968	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	465,811	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	MTCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	505,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	930	239	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,033	213	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	930		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	400	74	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	530	165	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	930	0	Redacted

PMTCT_ARV_DS D	Sum of New and Current disaggregates	930	239	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,033	6,765	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	12,000	6,765	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	620	191	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	413	95	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	1,033	286	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	68	62	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	68		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	68		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,000	6,154	Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,336	368	Redacted
VMMC_CIRC_DS	By Age: 15-19	2,000	2,249	Redacted

D				
VMMC_CIRC_DS D	By Age: 20-24	1,482	1,986	Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,169		Redacted
VMMC_CIRC_DS D	By Age: 50+	13	22	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	6,000	4,625	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	523	720	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	5,288	5,170	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	189	264	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	6,000	6,154	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	6,000	5,974	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	30,000	1,380	Redacted
PP_PREV_DSD	Total number of people in the target population	674,383	798,006	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	750	104	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	7,500	248	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	4,500	152	Redacted

PP_PREV_DSD	Age/sex: 25-49 Male	1,800	130	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	250	34	Redacted
PP_PREV_DSD	Age/sex: 10-14 Female	750	104	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	7,950	273	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	4,500	158	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,800	151	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	200	26	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	30,000	1,380	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,000		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,000		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,000	22,870	Redacted
HTC_TST_DSD	By Test Result: Negative	35,600	22,206	Redacted
HTC_TST_DSD	By Test Result: Positive	4,400	2,464	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	40,000	24,670	Redacted
HTC_TST_DSD	Age/sex: <1 Male	800		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	1,860		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	954		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,858		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,721		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,765		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	2,317		Redacted

HTC_TST_DSD	Age/sex: 50+ Male	134		Redacted
HTC_TST_DSD	Age/sex: <1 Female	934		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	1,000		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	543		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,906		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	2,906		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	7,626		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	4,765		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	911		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	40,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,472	1,519	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,937	8,233	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,383	1,330	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,208	8,788	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,855	2,849	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	29,145	17,021	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	40,000	19,870	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	200		Redacted
GEND_NORM_DS D	By Age: 0-9	52		Redacted
GEND_NORM_DS D	By Age: 10-14	35		Redacted
GEND_NORM_DS D	By Age: 15-19	26		Redacted
GEND_NORM_DS D	By Age: 20-24	19		Redacted

GEND_NORM_DS D	By Age: 25+	68		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	200		Redacted
GEND_NORM_DS D	By Sex: Male	19		Redacted
GEND_NORM_DS D	By Sex: Female	181		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	200		Redacted
GEND_NORM_DS D	By type of activity: Individual	200		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	200		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	33,500	39,532	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	528	1,485	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	439	3,042	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	395	1,897	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	320	3,331	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	305	4,239	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	3,722	3,505	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	6,693	1,670	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	663	381	Redacted

CARE_CURR_DS D	Age/sex: <1 Female	395	1,528	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	469	1,812	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	432	1,844	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	335	3,412	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	424	2,398	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	5,650	4,874	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	7,519	3,827	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	5,211	381	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	33,500	39,626	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,682	9,123	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,383	9,218	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,631	8,045	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,804	10,836	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	33,500	37,222	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	8,662	6,495	Redacted

CARE_NEW_DSD	Age/sex: <1 Male	391	247	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	734	461	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	417	327	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	734	574	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	933	734	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	790	632	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	308	241	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	39	83	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	408	259	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	422	271	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	415	325	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	748	509	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	491	384	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	1,009	796	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	780	612	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	43	40	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	8,662	6,495	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	2,275	1,503	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,070	1,593	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,994	1,280	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2,323	1,724	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	8,662	6,100	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	8,662	6,100	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,620	552	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	2,641	601	Redacted

	during the reporting period			
TB_ART_DSD	Age: 0-4	211		Redacted
TB_ART_DSD	Age: 5-14	50		Redacted
TB_ART_DSD	Age: 15+	2,359		Redacted
TB_ART_DSD	Male	260	315	Redacted
TB_ART_DSD	Female	2,360	237	Redacted
TB_ART_DSD	Sum of Sex disaggregates	2,620	552	Redacted
TB_ART_DSD	Newly tested	998		Redacted
TB_ART_DSD	Known HIV-positive	1,622	257	Redacted
TB_ART_DSD	Sum of Test Status disaggregates	2,620	257	Redacted
TB_ART_DSD	Aggregated Age: <15	1,572	79	Redacted
TB_ART_DSD	Aggregated Age: 15+	1,048	298	Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,620	377	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	883	227	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,033		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	530	149	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	353	78	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	883	227	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	44		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	31,500	25,331	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	979	156	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	143	188	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	273	352	Redacted

TX_CURR_DSD	Age/Sex: 15+ Male	10,131		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	979	164	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	148	195	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	270	353	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	18,577		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,792	25,331	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	979	110	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	979	114	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,395		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,131	1,679	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,397		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	18,577	2,747	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,792		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	28,708	4,426	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	31,500	4,426	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	1,958	504	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,643	5,382	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	442	201	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	830	348	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	472	210	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	830	455	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	598	656	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	506	520	Redacted

TX_NEW_DSD	By Age/Sex: 25-49 Male	197	274	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	25	26	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	462	201	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	478	227	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	470	208	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	846	463	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	315	329	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	646	740	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	500	485	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	26	39	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,643	5,382	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	442	201	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,574		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,326	1,476	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	462	201	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,256		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,487	1,592	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	7,643	3,068	Redacted
TX_NEW_DSD	Pregnancy status	400	125	Redacted
TX_NEW_DSD	Breastfeeding status	150	130	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	24,180	4,188	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	31,000	5,112	Redacted

	those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	347		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	82		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,941		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,941		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	116		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,637		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator:	3,941		Redacted

	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,637		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	440		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	515		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	440		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	515		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or	2		Redacted

	international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	2		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	2		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	11		Redacted
LAB_CAP_DSD	By clinical laboratories	11		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	11		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	11		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	11		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	4	5	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	11	11	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	4		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	4		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of	11		Redacted



	PEPFAR-supported HIV service delivery points			
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	11		Redacted
FPINT_SITE_DSD	Service delivery type: Community	0		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	4		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	4		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	11		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	4		Redacted
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	4		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	33,500	39,532	Redacted

Implementing Mechanism Details

Mechanism ID: 13792	Mechanism Name: Support to the HIV/AIDS Response in Zambia II (SHARE II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount



GHP-State	0
-----------	---

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13792			
Mechanism Name: Support to the HIV/AIDS Response in Zambia II (SHARe II)			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,973	
PP_PREV_TA	Total number of people in the target population	53,812	
PP_PREV_TA	Age/sex: 10-14 Male	0	
PP_PREV_TA	Age/sex: 15-19 Male	110	
PP_PREV_TA	Age/sex: 20-24 Male	478	
PP_PREV_TA	Age/sex: 25-49 Male	4,740	
PP_PREV_TA	Age/sex: 10-14 Female	594	
PP_PREV_TA	Age/sex: 15-19 Female	880	
PP_PREV_TA	Age/sex: 20-24 Female	996	
PP_PREV_TA	Age/sex: 25-49 Female	2,175	
PP_PREV_TA	Sum of Age/Sex disaggregates	9,973	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,550	
HTC_TST_TA	By Test Result: Negative	11,672	
HTC_TST_TA	By Test Result: Positive	878	
HTC_TST_TA	Sum of Test Result disaggregates	12,550	
HTC_TST_TA	Age/sex: <1 Male	0	
HTC_TST_TA	Age/sex: 1-4 Male	0	
HTC_TST_TA	Age/sex: 5-9 Male	0	
HTC_TST_TA	Age/sex: 10-14 Male	134	
HTC_TST_TA	Age/sex: 15-19 Male	912	
HTC_TST_TA	Age/sex: 20-24 Male	1,497	
HTC_TST_TA	Age/sex: 25-49 Male	5,458	

HTC_TST_TA	Age/sex: 50+ Male	0	
HTC_TST_TA	Age/sex: <1 Female	0	
HTC_TST_TA	Age/sex: 1-4 Female	0	
HTC_TST_TA	Age/sex: 5-9 Female	0	
HTC_TST_TA	Age/sex: 10-14 Female	145	
HTC_TST_TA	Age/sex: 15-19 Female	884	
HTC_TST_TA	Age/sex: 20-24 Female	1,048	
HTC_TST_TA	Age/sex: 25-49 Female	2,472	
HTC_TST_TA	Age/sex: 50+ Female	0	
HTC_TST_TA	Sum of Age/Sex disaggregates	12,550	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	134	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,867	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	145	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,404	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	279	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	12,271	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	12,550	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	1,500	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	338	
GEND_NORM_DSD	By Age: 15-19	487	
GEND_NORM_DSD	By Age: 20-24	376	
GEND_NORM_DSD	By Age: 25+	299	
GEND_NORM_DSD	Sum of Age disaggregates	1,500	
GEND_NORM_DSD	By Sex: Male	571	
GEND_NORM_DSD	By Sex: Female	929	
GEND_NORM_DSD	Sum of Sex disaggregates	1,500	



GEND_NORM_DSD	By type of activity: Individual	1,500	
GEND_NORM_TA	Sum of Sex disaggregates	1,500	

Implementing Mechanism Details

Mechanism ID: 14338	Mechanism Name: Sustainability Through Economic strengthening, Prevention, and Support for Orphans, and Vulnerable Children, youth and other vulnerable populations (STEPS OVC) program		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: World Vision International			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14338			
Mechanism Name: Sustainability Through Economic strengthening, Prevention, and Support for Orphans, and Vulnerable Children, youth and other			
Prime Partner Name: vulnerable populations (STEPS OVC) program			
World Vision International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum	0	

	components during the reporting period.		
PP_PREV_DSD	Total number of people in the target population	0	
PP_PREV_DSD	Age/sex: 10-14 Male	0	
PP_PREV_DSD	Age/sex: 15-19 Male	0	
PP_PREV_DSD	Age/sex: 20-24 Male	0	
PP_PREV_DSD	Age/sex: 25-49 Male	0	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	0	
PP_PREV_DSD	Age/sex: 15-19 Female	0	
PP_PREV_DSD	Age/sex: 20-24 Female	0	
PP_PREV_DSD	Age/sex: 25-49 Female	0	
PP_PREV_DSD	Age/sex: 50+ Female	0	
PP_PREV_DSD	Sum of Age/Sex disaggregates	0	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,484	
HTC_TST_DSD	By Test Result: Negative	15,587	
HTC_TST_DSD	By Test Result: Positive	3,897	
HTC_TST_DSD	Sum of Test Result disaggregates	19,484	
HTC_TST_DSD	Age/sex: <1 Male	5	
HTC_TST_DSD	Age/sex: 1-4 Male	559	
HTC_TST_DSD	Age/sex: 5-9 Male	1,724	
HTC_TST_DSD	Age/sex: 10-14 Male	2,602	
HTC_TST_DSD	Age/sex: 15-19 Male	2,372	
HTC_TST_DSD	Age/sex: 20-24 Male	327	
HTC_TST_DSD	Age/sex: 25-49 Male	1,021	
HTC_TST_DSD	Age/sex: 50+ Male	536	
HTC_TST_DSD	Age/sex: <1 Female	5	
HTC_TST_DSD	Age/sex: 1-4 Female	581	
HTC_TST_DSD	Age/sex: 5-9 Female	1,759	
HTC_TST_DSD	Age/sex: 10-14 Female	2,633	

HTC_TST_DSD	Age/sex: 15-19 Female	2,116	
HTC_TST_DSD	Age/sex: 20-24 Female	354	
HTC_TST_DSD	Age/sex: 25-49 Female	1,984	
HTC_TST_DSD	Age/sex: 50+ Female	906	
HTC_TST_DSD	Sum of Age/Sex disaggregates	19,484	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,891	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,255	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,977	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,361	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,868	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,616	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,484	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	345,739	
OVC_SERV_DSD	Sex: Male	161,178	
OVC_SERV_DSD	Sex: Female	184,561	
OVC_SERV_DSD	Sum of Sex disaggregates	345,739	
OVC_SERV_DSD	Age: <1	264	
OVC_SERV_DSD	Age: 1-4	26,734	
OVC_SERV_DSD	Age: 5-9	81,743	
OVC_SERV_DSD	Age: 10-14	122,910	
OVC_SERV_DSD	Age: 15-17	75,521	
OVC_SERV_DSD	Age: 18+	38,567	
OVC_SERV_DSD	Sum of Age disaggregates	345,739	

Implementing Mechanism Details

Mechanism ID: 14339	Mechanism Name: PEPFAR Prevention Small Grants
----------------------------	---



Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 88,755	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	88,755

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14339			
Mechanism Name: PEPFAR Prevention Small Grants			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	88,755	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	810	
PP_PREV_DSD	Total number of people in the target population	22,800	
PP_PREV_DSD	Age/sex: 10-14 Male	71	
PP_PREV_DSD	Age/sex: 15-19 Male	291	
PP_PREV_DSD	Age/sex: 20-24 Male	158	
PP_PREV_DSD	Age/sex: 25-49 Male	30	
PP_PREV_DSD	Age/sex: 50+ Male	54	
PP_PREV_DSD	Age/sex: 10-14 Female	31	
PP_PREV_DSD	Age/sex: 15-19 Female	33	
PP_PREV_DSD	Age/sex: 20-24 Female	50	
PP_PREV_DSD	Age/sex: 25-49 Female	48	
PP_PREV_DSD	Age/sex: 50+ Female	44	
PP_PREV_DSD	Sum of Age/Sex disaggregates	810	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	389	

PP_PREV_TA	Total number of people in the target population	22,800	
PP_PREV_TA	Age/sex: 10-14 Male	21	
PP_PREV_TA	Age/sex: 15-19 Male	87	
PP_PREV_TA	Age/sex: 20-24 Male	40	
PP_PREV_TA	Age/sex: 25-49 Male	7	
PP_PREV_TA	Age/sex: 50+ Male	14	
PP_PREV_TA	Age/sex: 10-14 Female	72	
PP_PREV_TA	Age/sex: 15-19 Female	76	
PP_PREV_TA	Age/sex: 20-24 Female	26	
PP_PREV_TA	Age/sex: 25-49 Female	24	
PP_PREV_TA	Age/sex: 50+ Female	22	
PP_PREV_TA	Sum of Age/Sex disaggregates	389	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	9,170	
HTC_TST_DSD	By Test Result: Negative	200	
HTC_TST_DSD	By Test Result: Positive	8,970	
HTC_TST_DSD	Sum of Test Result disaggregates	9,170	
HTC_TST_DSD	Age/sex: <1 Male	42	
HTC_TST_DSD	Age/sex: 1-4 Male	8	
HTC_TST_DSD	Age/sex: 5-9 Male	423	
HTC_TST_DSD	Age/sex: 10-14 Male	644	
HTC_TST_DSD	Age/sex: 15-19 Male	1,033	
HTC_TST_DSD	Age/sex: 20-24 Male	664	
HTC_TST_DSD	Age/sex: 25-49 Male	296	
HTC_TST_DSD	Age/sex: 50+ Male	400	
HTC_TST_DSD	Age/sex: <1 Female	15	
HTC_TST_DSD	Age/sex: 1-4 Female	35	
HTC_TST_DSD	Age/sex: 5-9 Female	477	
HTC_TST_DSD	Age/sex: 10-14 Female	715	
HTC_TST_DSD	Age/sex: 15-19 Female	1,258	



HTC_TST_DSD	Age/sex: 20-24 Female	485	
HTC_TST_DSD	Age/sex: 25-49 Female	307	
HTC_TST_DSD	Age/sex: 50+ Female	2,368	
HTC_TST_DSD	Sum of Age/Sex disaggregates	9,170	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,389	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,658	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,653	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,470	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,042	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,128	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	9,170	

Implementing Mechanism Details

Mechanism ID: 14420	Mechanism Name: LPHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Lusaka Provincial Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 6,343,344	
Applied Pipeline Amount: 66,950	
Funding Source	Funding Amount
GHP-State	6,343,344

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Water	10
-------	----

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	14420		
Mechanism Name:	LPHO		
Prime Partner Name:	Lusaka Provincial Health Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	896,653	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	898,305	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	495,314	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	272,992	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	165,983	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	198,920	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	508,122	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	397,658	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	244,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	435,393	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,479,246	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	349,958	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,080	1,096	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,244	1,096	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	4,080		Redacted

PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,038		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,042		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	490		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	2,290		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	145		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	7,005		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	4,080		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,000	285	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	20,000	285	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	836	1	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,254	2	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,090	3	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	24,828	20,916	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	29,338	20,916	Redacted
PMTCT_STAT_TA	By: Known positives at entry	591	522	Redacted

PMTCT_STAT_TA	By: Number of new positives identified	885	617	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,476	1,139	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	80	83	Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	80		Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,382	1,073	Redacted
VMMC_CIRC_TA	By Age: <1	541		Redacted
VMMC_CIRC_TA	By Age: 1-9	1,295		Redacted
VMMC_CIRC_TA	By Age: 10-14	1,550	38	Redacted
VMMC_CIRC_TA	By Age: 15-19	1,350	119	Redacted
VMMC_CIRC_TA	By Age: 20-24	1,410	321	Redacted
VMMC_CIRC_TA	By Age: 25-49	1,201		Redacted
VMMC_CIRC_TA	By Age: 50+	35		Redacted
VMMC_CIRC_TA	Sum of Age disaggregations	7,382	478	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	532	32	Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,472	842	Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	2,378	199	Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	7,382	1,073	Redacted
VMMC_CIRC_TA	By circumcision technique:	768		Redacted

	Device-based VMMC			
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,905	862	Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	211	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	25,000	5,790	Redacted
PP_PREV_TA	Total number of people in the target population	35,000	5,790	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	2,500	160	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	3,000	400	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	3,100	918	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	2,900	762	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	2,300	255	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	3,000	635	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	3,700	1,365	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	4,500	1,179	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	25,000	5,790	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	150,000	37,978	Redacted
HTC_TST_TA	By Test Result: Negative	110,000	34,975	Redacted
HTC_TST_TA	By Test Result: Positive	40,000	3,003	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	150,000	37,978	Redacted
HTC_TST_TA	Age/sex: <1 Male	4,000		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	4,000		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	1,000		Redacted



HTC_TST_TA	Age/sex: 10-14 Male	3,000		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	9,000		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	10,000		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	8,799		Redacted
HTC_TST_TA	Age/sex: 50+ Male	3,500		Redacted
HTC_TST_TA	Age/sex: <1 Female	7,000		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	1,900		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	8,000		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	3,800		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	6,780		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	30,000		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	30,221		Redacted
HTC_TST_TA	Age/sex: 50+ Female	19,000		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	150,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	35,000	1,898	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	40,000	13,152	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	30,000	2,788	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,000	20,140	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	65,000	4,686	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	85,000	33,292	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	150,000	37,978	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,891	10,637	Redacted
CARE_CURR_TA	Age/sex: <1 Male	28	116	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	30	130	Redacted

CARE_CURR_TA	Age/sex: 5-9 Male	34	179	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	118	165	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	18	484	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	190	1,559	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	32	1,786	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	46	41	Redacted
CARE_CURR_TA	Age/sex: <1 Female	105	160	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	96	187	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	71	245	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	235	222	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	241	666	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	229	2,153	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	233	2,483	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	185	61	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	1,891	10,637	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	210		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	286		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	507		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	888		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,891		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	30,000	7,477	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	1,000	151	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	1,200	94	Redacted

CARE_NEW_DSD	Age/sex: 5-9 Male	2,000	125	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	2,200	63	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	2,400	325	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	1,400	1,099	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,000	1,258	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	1,400	23	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	1,200	210	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	1,000	129	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	2,800	172	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	3,000	86	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	2,400	443	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	2,000	1,518	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	3,000	1,734	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	2,000	47	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	30,000	7,477	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	5,400		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	4,800		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	10,000		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	9,800		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	30,000		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	30,000		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,500		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	26,496		Redacted
TB_ART_DSD	Age: 0-4	100		Redacted

TB_ART_DSD	Age: 5-14	1,500		Redacted
TB_ART_DSD	Age: 15+	1,900		Redacted
TB_ART_DSD	Male	1,400		Redacted
TB_ART_DSD	Female	2,100		Redacted
TB_ART_DSD	Sum of Sex disaggregates	3,500		Redacted
TB_ART_DSD	Newly tested	1,000		Redacted
TB_ART_DSD	Known HIV-positive	2,500		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	3,500		Redacted
TB_ART_DSD	Aggregated Age: <15	28		Redacted
TB_ART_DSD	Aggregated Age: 15+	3,472		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	3,500		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,674	6	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,244		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,218	6	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,456		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,674	6	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	30		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	13,663	28,343	Redacted
TX_CURR_TA	Age/Sex: <1 Male	52	54	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	128	156	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	552	1,246	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	4,439		Redacted
TX_CURR_TA	Age/Sex: <1 Female	28	64	Redacted

TX_CURR_TA	Age/Sex: 1-4 Female	125	244	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	404	1,870	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	7,935		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	1,289	28,343	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	52		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	28		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	732		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,439		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	557		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	7,935		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,289		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,374		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	13,663		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	80		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	34,650	6,196	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	1,003	122	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	1,007	78	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	1,017	107	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	1,064	56	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,090	265	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,085	905	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,313	1,003	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	1,065	26	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	1,001	168	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	1,009	112	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	1,026	147	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	1,063	78	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	7,203	376	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	7,202	1,260	Redacted

TX_NEW_DSD	By Age/Sex: 25-49 Female	7,302	1,457	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	200	35	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	34,650	6,195	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1,003		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	4,091		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,553		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1,001		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4,099		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	21,907		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	34,650		Redacted
TX_NEW_DSD	Pregnancy status	21,907		Redacted
TX_NEW_DSD	Breastfeeding status	21,907		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,000	4,822	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	30,000	4,822	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,333		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	1,220		Redacted

	initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,022		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,233		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,256		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,343		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,832		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,200		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children	2,553		Redacted

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,022		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,575		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,575		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	3		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	3		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	3		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	3		Redacted

LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	32	22	Redacted
LAB_CAP_DSD	By clinical laboratories	12	22	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	15		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	27		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	3		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	30		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	30		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	25,253		Redacted
TB_SCREEN_DSD	Age: <1	50		Redacted
TB_SCREEN_DSD	Age: 1-4	1,250		Redacted
TB_SCREEN_DSD	Age: 5-9	3,500		Redacted
TB_SCREEN_DSD	Age: 10-14	4,700		Redacted
TB_SCREEN_DSD	Age: 15-19	4,500		Redacted
TB_SCREEN_DSD	Age: 20-24	10,000		Redacted
TB_SCREEN_DSD	Age: 25-49	10,000		Redacted
TB_SCREEN_DSD	Age: 50+	12,000		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	14,000	0	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	9,500		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	36,500		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	46,000		Redacted
TB_SCREEN_DSD	Sex: Male	18,400		Redacted
TB_SCREEN_DSD	Sex: Female	27,600		Redacted



TB_SCREEN_DSD	Sum of Sex disaggregates	46,000		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,891	10,637	Redacted

Implementing Mechanism Details

Mechanism ID: 14421		Mechanism Name: SPMO		
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement		
Prime Partner Name: Southern Provincial Health Office				
Agreement Start Date: Redacted		Agreement End Date: Redacted		
TBD: No		New Mechanism: No		
Global Fund / Multilateral Engagement: N/A				
G2G: Yes		Managing Agency: HHS/CDC		

Total All Funding Sources: 6,029,280	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	6,029,280

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 14421			
Mechanism Name: SPMO			
Prime Partner Name: Southern Provincial Health Office			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	900,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	360,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	275,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	285,049	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	269,921	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	509,310	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	570,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,360,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	600,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	310	176	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	316	176	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	310		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	192	30	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	118	146	Redacted
PMTCT_ARV_DS	Sum of Regimen Type disaggregates	310		Redacted

D				
PMTCT_ARV_DS D	Sum of New and Current disaggregates	310	176	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	631	305	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	639	305	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	631		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	391	45	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	240	260	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	631		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	631	305	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,990	1,867	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	3,990	1,867	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	111	81	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	201	189	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	312	270	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,990	9,928	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	3,990	9,928	Redacted
PMTCT_STAT_TA	By: Known positives at entry	227	45	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	408	225	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	635	270	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	19	115	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	19,686	11,458	Redacted
VMMC_CIRC_DS D	By Age: <1	308	12	Redacted
VMMC_CIRC_DS D	By Age: 1-9	28	0	Redacted
VMMC_CIRC_DS D	By Age: 10-14	4,168	606	Redacted
VMMC_CIRC_DS D	By Age: 15-19	5,947	1,657	Redacted
VMMC_CIRC_DS D	By Age: 20-24	4,412	2,009	Redacted
VMMC_CIRC_DS	By Age: 25-49	4,397		Redacted

D				
VMMC_CIRC_DS D	By Age: 50+	430	575	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	19,690	4,859	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	286	619	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	18,940	10,394	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	460	445	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	19,686	11,458	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	19,665	11,335	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	21	123	Redacted
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	20,127		Redacted
VMMC_CIRC_TA	By Age: 10-14	4,341		Redacted
VMMC_CIRC_TA	By Age: 15-19	6,076		Redacted
VMMC_CIRC_TA	By Age: 20-24	4,723		Redacted
VMMC_CIRC_TA	By Age: 25-49	4,447		Redacted
VMMC_CIRC_TA	By Age: 50+	540		Redacted

VMMC_CIRC_TA	Sum of Age disaggregations	20,127		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	301		Redacted
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	17,639		Redacted
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	161		Redacted
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	20,127		Redacted
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	19,409		Redacted
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	15		Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	224,840	113,162	Redacted
PP_PREV_DSD	Total number of people in the target population	352,980	229,185	Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	7,670	9,021	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	10,540	8,274	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	17,200	11,778	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	27,140	19,185	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	11,750	7,560	Redacted

PP_PREV_DSD	Age/sex: 10-14 Female	44,140	8,407	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	15,650	8,278	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	18,460	12,189	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	60,500	21,405	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	11,790	7,065	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	224,840	113,162	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	502,128	188,506	Redacted
PP_PREV_TA	Total number of people in the target population	1,141,297	246,743	Redacted
PP_PREV_TA	Age/sex: 10-14 Male	24,798	7,603	Redacted
PP_PREV_TA	Age/sex: 15-19 Male	34,071	11,080	Redacted
PP_PREV_TA	Age/sex: 20-24 Male	55,612	20,305	Redacted
PP_PREV_TA	Age/sex: 25-49 Male	87,751	40,182	Redacted
PP_PREV_TA	Age/sex: 50+ Male	37,996	10,922	Redacted
PP_PREV_TA	Age/sex: 10-14 Female	142,714	7,978	Redacted
PP_PREV_TA	Age/sex: 15-19 Female	50,597	12,183	Redacted
PP_PREV_TA	Age/sex: 20-24 Female	59,693	24,031	Redacted
PP_PREV_TA	Age/sex: 25-49 Female	195,609	42,796	Redacted
PP_PREV_TA	Age/sex: 50+ Female	38,120	11,426	Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	726,961	188,506	Redacted
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	115		Redacted
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	49		Redacted

	evidence and/or meet the minimum standards required)			
KP_PREV_TA	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	22		Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	22		Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	22		Redacted
KP_PREV_TA	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,518	22,989	Redacted

HTC_TST_DSD	By Test Result: Negative	44,997	20,812	Redacted
HTC_TST_DSD	By Test Result: Positive	6,521	2,177	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	51,518	22,989	Redacted
HTC_TST_DSD	Age/sex: <1 Male	179		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	381		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	579		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	922		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,321		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	6,224		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	8,897		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,069		Redacted
HTC_TST_DSD	Age/sex: <1 Female	205		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	457		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	707		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	1,357		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	3,223		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	8,541		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	13,323		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	2,133		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	51,518		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,038	1,656	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,487	8,874	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,735	1,761	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	27,258	10,698	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,773	3,417	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	46,745	19,572	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	51,518	22,989	Redacted

HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	104,597	46,741	Redacted
HTC_TST_TA	By Test Result: Negative	91,357	42,314	Redacted
HTC_TST_TA	By Test Result: Positive	13,241	4,427	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	104,598	46,741	Redacted
HTC_TST_TA	Age/sex: <1 Male	363		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	773		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	1,176		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	1,873		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	4,712		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	12,637		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	18,064		Redacted
HTC_TST_TA	Age/sex: 50+ Male	4,201		Redacted
HTC_TST_TA	Age/sex: <1 Female	416		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	929		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,435		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	2,754		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	6,545		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	17,340		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	27,050		Redacted
HTC_TST_TA	Age/sex: 50+ Female	4,330		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	104,598		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,138	918	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	39,565	21,024	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,553	972	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	55,342	23,827	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	9,691	1,890	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	94,907	44,851	Redacted

HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	104,598	46,741	Redacted
GEND_NORM_DS D	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	838		Redacted
GEND_NORM_DS D	By Age: 0-9	0		Redacted
GEND_NORM_DS D	By Age: 10-14	136		Redacted
GEND_NORM_DS D	By Age: 15-19	100		Redacted
GEND_NORM_DS D	By Age: 20-24	102		Redacted
GEND_NORM_DS D	By Age: 25+	500		Redacted
GEND_NORM_DS D	Sum of Age disaggregates	838		Redacted
GEND_NORM_DS D	By Sex: Male	458		Redacted
GEND_NORM_DS D	By Sex: Female	380		Redacted
GEND_NORM_DS D	Sum of Sex disaggregates	838		Redacted
GEND_NORM_DS D	By type of activity: Individual	0		Redacted
GEND_NORM_DS D	By type of activity: Small Group	1		Redacted
GEND_NORM_DS D	By type of activity: Community-level	1		Redacted
GEND_NORM_TA	Sum of Sex disaggregates	838		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	261	87	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant	1,417		Redacted

	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	92	35	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	188	52	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	280	87	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	44		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	65,054	24,301	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	222	51	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	842	344	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	2,215	1,246	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	23,119		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	340	63	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,089	345	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	3,121	1,069	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	34,106		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	7,829	24,301	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	1		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	222		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	340		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,279		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	23,119		Redacted

TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,550		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	34,106		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,829		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	57,225		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	65,054		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	562		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	32,042	23,619	Redacted
TX_CURR_TA	Age/Sex: <1 Male	109	60	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	415	341	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	1,091	798	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	11,387		Redacted
TX_CURR_TA	Age/Sex: <1 Female	167	50	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	537	712	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	1,537	1,069	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	16,799		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	3,856	23,619	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	109		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	167		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,615		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	11,387		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,241		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	16,799		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,856		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	28,186		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	32,042		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	276		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,578	5,163	Redacted

TX_NEW_DSD	By Age/Sex: <1 Male	114	22	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	154	33	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	223	46	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	356	114	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	749	273	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,296	502	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,110	994	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	431	267	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	133	43	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	211	43	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	305	53	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	475	164	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,163	353	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,700	686	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,704	1,215	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	454	355	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,578	5,163	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	114		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	847		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,586		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	133		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,124		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,021		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,578		Redacted
TX_NEW_DSD	Pregnancy status	441	192	Redacted
TX_NEW_DSD	Breastfeeding status	63	158	Redacted
TX_RET_DSD	Number of adults and children who are	2,382	4,018	Redacted

	still alive and on treatment at 12 months after initiating ART			
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,452	4,018	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,227		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,493		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,492		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,827		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,266		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART)	14,265		Redacted

	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,414		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,007		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	460		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	499		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,820		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	12,942		Redacted



	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	10		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	10		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	10		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	10		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	204		Redacted
LAB_CAP_DSD	By clinical laboratories	22		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	81		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	100		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	100		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	100		Redacted

Implementing Mechanism Details

Mechanism ID: 14452	Mechanism Name: Society for Family Health
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 750,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	750,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14452			
Mechanism Name: Society for Family Health			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	5	22
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	2	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	2	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	3	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	3	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical	0	

	device-related AE(s), but no severe medical device-related AE(s)		
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,400	7,500
VMMC_CIRC_DSD	By Age: <1	0	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	1,404	2,150
VMMC_CIRC_DSD	By Age: 15-19	1,242	1,640
VMMC_CIRC_DSD	By Age: 20-24	1,674	2,710
VMMC_CIRC_DSD	By Age: 25-49	1,026	
VMMC_CIRC_DSD	By Age: 50+	54	50
VMMC_CIRC_DSD	Sum of age disaggregates	5,400	6,550
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	150
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	5,400	7,150
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	200
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	5,400	7,500
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	5,130	7,350
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for	270	150

	follow-up care within 14 days of circumcision surgery		
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,000	8,250
PP_PREV_DSD	Total number of people in the target population	14,511	14,000
PP_PREV_DSD	Age/sex: 10-14 Male	1,788	552
PP_PREV_DSD	Age/sex: 15-19 Male	1,626	972
PP_PREV_DSD	Age/sex: 20-24 Male	2,144	1,005
PP_PREV_DSD	Age/sex: 25-49 Male	1,358	1,725
PP_PREV_DSD	Age/sex: 50+ Male	11	115
PP_PREV_DSD	Age/sex: 10-14 Female	1,059	748
PP_PREV_DSD	Age/sex: 15-19 Female	954	878
PP_PREV_DSD	Age/sex: 20-24 Female	1,258	1,000
PP_PREV_DSD	Age/sex: 25-49 Female	797	1,198
PP_PREV_DSD	Age/sex: 50+ Female	5	57
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,000	8,250
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,000	
PP_PREV_TA	Total number of people in the target population	14,511	
PP_PREV_TA	Age/sex: 10-14 Male	1,788	
PP_PREV_TA	Age/sex: 15-19 Male	1,626	
PP_PREV_TA	Age/sex: 20-24 Male	2,144	
PP_PREV_TA	Age/sex: 25-49 Male	1,358	
PP_PREV_TA	Age/sex: 50+ Male	11	
PP_PREV_TA	Age/sex: 10-14 Female	1,059	
PP_PREV_TA	Age/sex: 15-19 Female	954	
PP_PREV_TA	Age/sex: 20-24 Female	1,258	



PP_PREV_TA	Age/sex: 25-49 Female	797	
PP_PREV_TA	Age/sex: 50+ Female	5	
PP_PREV_TA	Sum of Age/Sex disaggregates	11,000	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,400	
HTC_TST_DSD	Age/sex: 10-14 Male	1,404	
HTC_TST_DSD	Age/sex: 15-19 Male	1,242	
HTC_TST_DSD	Age/sex: 20-24 Male	1,674	
HTC_TST_DSD	Age/sex: 25-49 Male	1,026	
HTC_TST_DSD	Age/sex: 50+ Male	54	
HTC_TST_DSD	Sum of Age/Sex disaggregates	5,400	

Implementing Mechanism Details

Mechanism ID: 14507	Mechanism Name: Family Health International
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,784,574	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	3,784,574

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14507			
Mechanism Name: Family Health International			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	30,536	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,702,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	151,796	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	400	100
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	500	100
PMTCT_ARV_TA	Life-long ART (including Option B+)	400	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	100	50
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	300	38
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	12
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of	30	0

	WHO Option A during pregnancy and delivery)		
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	18	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	448	12
PMTCT_ARV_TA	Sum of New and Current disaggregates	400	88
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,490	2,309
PMTCT_STAT_TA	Number of new ANC and L&D clients	7,200	2,309
PMTCT_STAT_TA	By: Known positives at entry	290	150
PMTCT_STAT_TA	By: Number of new positives identified	1,035	100
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,325	250
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	25	0
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	25	
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical	25	

	post-operative AE(s)		
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	0	
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)	0	
VMMC_AE_DSD	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)	0	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	250	0
VMMC_CIRC_DSD	By Age: 10-14	96	0
VMMC_CIRC_DSD	By Age: 15-19	44	0
VMMC_CIRC_DSD	By Age: 20-24	49	0
VMMC_CIRC_DSD	By Age: 25-49	44	
VMMC_CIRC_DSD	By Age: 50+	17	0
VMMC_CIRC_DSD	Sum of age disaggregates	250	0
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	43	0
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	174	0
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	33	0

VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	250	0
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	150	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	100	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,250	
VMMC_CIRC_TA	By Age: <1	0	
VMMC_CIRC_TA	By Age: 1-9	0	
VMMC_CIRC_TA	By Age: 10-14	868	
VMMC_CIRC_TA	By Age: 15-19	420	
VMMC_CIRC_TA	By Age: 20-24	465	
VMMC_CIRC_TA	By Age: 25-49	370	
VMMC_CIRC_TA	By Age: 50+	127	
VMMC_CIRC_TA	Sum of Age disaggregations	2,250	
VMMC_CIRC_TA	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	157	
VMMC_CIRC_TA	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	1,973	
VMMC_CIRC_TA	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	120	
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	2,250	
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	0	
VMMC_CIRC_TA	By follow-up status: Number of surgically	1,830	

	circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery		
VMMC_CIRC_TA	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	400	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,000	3,938
HTC_TST_TA	By Test Result: Negative	25,800	0
HTC_TST_TA	By Test Result: Positive	4,200	0
HTC_TST_TA	Sum of Test Result disaggregates	30,000	0
HTC_TST_TA	Age/sex: <1 Male	60	
HTC_TST_TA	Age/sex: 1-4 Male	150	
HTC_TST_TA	Age/sex: 5-9 Male	210	
HTC_TST_TA	Age/sex: 10-14 Male	1,290	
HTC_TST_TA	Age/sex: 15-19 Male	1,590	
HTC_TST_TA	Age/sex: 20-24 Male	2,880	
HTC_TST_TA	Age/sex: 25-49 Male	5,010	
HTC_TST_TA	Age/sex: 50+ Male	150	
HTC_TST_TA	Age/sex: <1 Female	270	
HTC_TST_TA	Age/sex: 1-4 Female	690	
HTC_TST_TA	Age/sex: 5-9 Female	960	
HTC_TST_TA	Age/sex: 10-14 Female	2,820	
HTC_TST_TA	Age/sex: 15-19 Female	2,640	
HTC_TST_TA	Age/sex: 20-24 Female	3,390	
HTC_TST_TA	Age/sex: 25-49 Female	7,350	
HTC_TST_TA	Age/sex: 50+ Female	540	
HTC_TST_TA	Sum of Age/Sex disaggregates	30,000	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,710	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	9,630	0

	PERMISSION ONLY: 15+ Male		
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,740	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,920	0
HTC_TST_TA	Sum of Aggregated Age/Sex <15	6,450	0
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	23,550	0
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	30,000	0
GEND_GBVDSD	Number of people receiving post-GBV care	500	
GEND_GBVDSD	Age: 0-9	50	
GEND_GBVDSD	Age: 10-14	200	
GEND_GBVDSD	Age: 15-17	100	
GEND_GBVDSD	Age: 18-24	100	
GEND_GBVDSD	Age: 25+	50	
GEND_GBVDSD	Sum of Age disaggregates	500	
GEND_GBVDSD	Sex: Male	5	
GEND_GBVDSD	Sex: Female	495	
GEND_GBVDSD	Sum of Sex disaggregates	500	
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	200	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	300	
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	100	
GEND_GBVT_A	Sum of Age disaggregates	500	
GEND_GBVT_A	Sum of Sex disaggregates	500	
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,000	18,200
CARE_CURR_TA	Age/sex: <1 Male	12	18
CARE_CURR_TA	Age/sex: 1-4 Male	30	310

CARE_CURR_TA	Age/sex: 5-9 Male	42	528
CARE_CURR_TA	Age/sex: 10-14 Male	138	714
CARE_CURR_TA	Age/sex: 15-19 Male	138	1,502
CARE_CURR_TA	Age/sex: 20-24 Male	216	2,758
CARE_CURR_TA	Age/sex: 25-49 Male	402	3,500
CARE_CURR_TA	Age/sex: 50+ Male	30	110
CARE_CURR_TA	Age/sex: <1 Female	54	110
CARE_CURR_TA	Age/sex: 1-4 Female	138	215
CARE_CURR_TA	Age/sex: 5-9 Female	192	740
CARE_CURR_TA	Age/sex: 10-14 Female	684	740
CARE_CURR_TA	Age/sex: 15-19 Female	708	1,790
CARE_CURR_TA	Age/sex: 20-24 Female	1,038	2,985
CARE_CURR_TA	Age/sex: 25-49 Female	2,070	2,060
CARE_CURR_TA	Age/sex: 50+ Female	108	120
CARE_CURR_TA	Sum of Age/Sex disaggregates	6,000	18,200
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	222	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	786	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,068	0
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,924	0
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,000	0
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,000	
CARE_NEW_DSD	Age/sex: <1 Male	12	
CARE_NEW_DSD	Age/sex: 1-4 Male	30	
CARE_NEW_DSD	Age/sex: 5-9 Male	42	

CARE_NEW_DSD	Age/sex: 10-14 Male	138	
CARE_NEW_DSD	Age/sex: 15-19 Male	138	
CARE_NEW_DSD	Age/sex: 20-24 Male	216	
CARE_NEW_DSD	Age/sex: 25-49 Male	402	
CARE_NEW_DSD	Age/sex: 50+ Male	30	
CARE_NEW_DSD	Age/sex: <1 Female	54	
CARE_NEW_DSD	Age/sex: 1-4 Female	138	
CARE_NEW_DSD	Age/sex: 5-9 Female	192	
CARE_NEW_DSD	Age/sex: 10-14 Female	684	
CARE_NEW_DSD	Age/sex: 15-19 Female	708	
CARE_NEW_DSD	Age/sex: 20-24 Female	1,038	
CARE_NEW_DSD	Age/sex: 25-49 Female	2,070	
CARE_NEW_DSD	Age/sex: 50+ Female	108	
CARE_NEW_DSD	Sum of Age/sex disaggregates	6,000	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	222	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	786	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,068	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,924	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,000	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	6,000	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	400	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	550	
TB_ART_DSD	Age: 0-4	6	
TB_ART_DSD	Age: 5-14	81	
TB_ART_DSD	Age: 15+	313	
TB_ART_DSD	Male	120	
TB_ART_DSD	Female	280	

TB_ART_DSD	Sum of Sex disaggregates	400	
TB_ART_DSD	Newly tested	350	
TB_ART_DSD	Known HIV-positive	50	
TB_ART_DSD	Sum of Test Status disaggregates	400	
TB_ART_DSD	Aggregated Age: <15	87	
TB_ART_DSD	Aggregated Age: 15+	313	
TB_ART_DSD	Sum of Aggregated Age disaggregates	400	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	350	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,250	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	150	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	200	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	350	
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	15	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,200	21,893
TX_CURR_DSD	Age/Sex: <1 Male	10	
TX_CURR_DSD	Age/Sex: 1-4 Male	80	
TX_CURR_DSD	Age/Sex: 5-14 Male	150	
TX_CURR_DSD	Age/Sex: 15+ Male	4,695	
TX_CURR_DSD	Age/Sex: <1 Female	10	
TX_CURR_DSD	Age/Sex: 1-4 Female	100	
TX_CURR_DSD	Age/Sex: 5-14 Female	165	
TX_CURR_DSD	Age/Sex: 15+ Female	4,990	
TX_CURR_DSD	Sum of age/sex disaggregates	515	
TX_CURR_DSD	Percent children with advanced HIV infection	5	

	receiving antiretroviral therapy (ART) [CURRENT]		
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	52	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	10	0
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	10	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	240	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,695	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	275	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,990	0
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	515	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,685	0
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,200	0
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	20	0
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	10,200	17,000
TX_CURR_TA	Age/Sex: <1 Male	10	165
TX_CURR_TA	Age/Sex: 1-4 Male	80	920
TX_CURR_TA	Age/Sex: 5-14 Male	150	107
TX_CURR_TA	Age/Sex: 15+ Male	4,695	
TX_CURR_TA	Age/Sex: <1 Female	10	160
TX_CURR_TA	Age/Sex: 1-4 Female	100	600
TX_CURR_TA	Age/Sex: 5-14 Female	165	280
TX_CURR_TA	Age/Sex: 15+ Female	4,990	
TX_CURR_TA	Sum of Age/Sex disaggregations	515	17,000
TX_CURR_TA	Aggregated Age/Sex: <1 Male	10	0
TX_CURR_TA	Aggregated Age/Sex: <1 Female	10	0
TX_CURR_TA	Aggregated Age/Sex: <15 Male	240	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,695	0
TX_CURR_TA	Aggregated Age/Sex: <15 Female	275	

TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,990	0
TX_CURR_TA	Sum of Aggregated Age/Sex <15	515	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	9,685	0
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	10,200	0
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	20	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,000	
TX_NEW_DSD	By Age/Sex: <1 Male	10	
TX_NEW_DSD	By Age/Sex: 1-4 Male	25	
TX_NEW_DSD	By Age/Sex: 5-9 Male	35	
TX_NEW_DSD	By Age/Sex: 10-14 Male	115	
TX_NEW_DSD	By Age/Sex: 15-19 Male	115	
TX_NEW_DSD	By Age/Sex: 20-24 Male	180	
TX_NEW_DSD	By Age/Sex: 25-49 Male	335	
TX_NEW_DSD	By Age/Sex: 50+ Male	25	
TX_NEW_DSD	By Age/Sex: <1 Female	45	
TX_NEW_DSD	By Age/Sex: 1-4 Female	115	
TX_NEW_DSD	By Age/Sex: 5-9 Female	160	
TX_NEW_DSD	By Age/Sex: 10-14 Female	570	
TX_NEW_DSD	By Age/Sex: 15-19 Female	590	
TX_NEW_DSD	By Age/Sex: 20-24 Female	865	
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,725	
TX_NEW_DSD	By Age/Sex: 50+ Female	90	
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,000	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	10	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	185	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	655	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	45	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	890	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	3,270	0

	Female		
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,000	0
TX_NEW_DSD	Pregnancy status	1,100	
TX_NEW_DSD	Breastfeeding status	350	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,800	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,000	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	300	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	800	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,900	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	300	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	700	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the	1,800	

	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,100	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,900	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,000	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,800	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	600	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	700	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	12	

LAB_CAP_DSD	By clinical laboratories	12	
LAB_CAP_DSD	By Point-of-care testing sites	0	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	12	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	12	
LAB_CAP_TA	Sum of Site Support Type disaggregates	12	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	200	
TB_SCREEN_DSD	Age: <1	6	
TB_SCREEN_DSD	Age: 1-4	6	
TB_SCREEN_DSD	Age: 5-9	6	
TB_SCREEN_DSD	Age: 10-14	12	
TB_SCREEN_DSD	Age: 15-19	20	
TB_SCREEN_DSD	Age: 20-24	40	
TB_SCREEN_DSD	Age: 25-49	90	
TB_SCREEN_DSD	Age: 50+	20	
TB_SCREEN_DSD	Sum of Age disaggregates	50	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	30	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	170	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	200	
TB_SCREEN_DSD	Sex: Male	80	
TB_SCREEN_DSD	Sex: Female	120	
TB_SCREEN_DSD	Sum of Sex disaggregates	200	
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,000	18,200



Implementing Mechanism Details

Mechanism ID: 16634	Mechanism Name: Zambia Family Copperbelt-Lusaka Activity
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Expanded Church Response Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,317,938	
Applied Pipeline Amount: 1,650,000	
Funding Source	Funding Amount
GHP-State	4,317,938

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	500,000
Economic Strengthening	1,000,000
Education	500,000
Gender: GBV	500,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	500,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Motor Vehicles: Purchased	221,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16634		
Mechanism Name:	Zambia Family Copperbelt-Lusaka Activity		
Prime Partner Name:	Expanded Church Response Trust		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	42,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,162,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	113,438	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
------------------	-------	------	------



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	80,000	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	80,000	9,658
PP_PREV_DSD	Age/sex: 15-19 Male	10,000	
PP_PREV_DSD	Age/sex: 20-24 Male	20,000	
PP_PREV_DSD	Age/sex: 15-19 Female	10,000	6,368
PP_PREV_DSD	Age/sex: 20-24 Female	20,000	
PP_PREV_DSD	Sum of Age/Sex disaggregates	60,000	9,658
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	90,000	
HTC_TST_DSD	Age/sex: 25-49 Male	45,000	
HTC_TST_DSD	Age/sex: 25-49 Female	45,000	
HTC_TST_DSD	Sum of Age/Sex disaggregates	90,000	
GEND_GBV_DSD	Number of people receiving post-GBV care	30,000	
GEND_GBV_DSD	Age: 15-17	15,000	
GEND_GBV_DSD	Age: 18-24	10,000	
GEND_GBV_DSD	Age: 25+	5,000	
GEND_GBV_DSD	Sum of Age disaggregates	30,000	
GEND_GBV_DSD	Sex: Male	20,000	
GEND_GBV_DSD	Sex: Female	10,000	
GEND_GBV_DSD	Sum of Sex disaggregates	30,000	
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	25,000	
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5,000	
GEND_GBV_TA	Sum of Age disaggregates	30,000	
GEND_GBV_TA	Sum of Sex disaggregates	30,000	
GEND_NORM_DSD	Number of people completing an intervention	30,000	

	pertaining to gender norms, that meets minimum criteria		
GEND_NORM_DSD	By Age: 15-19	20,000	
GEND_NORM_DSD	By Age: 20-24	10,000	
GEND_NORM_DSD	Sum of Age disaggregates	30,000	
GEND_NORM_DSD	By type of activity: Small Group	10,000	
GEND_NORM_DSD	By type of activity: Community-level	20,000	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	100,000	99,897
OVC_SERV_DSD	Sex: Male	40,000	
OVC_SERV_DSD	Sex: Female	60,000	
OVC_SERV_DSD	Sum of Sex disaggregates	100,000	
OVC_SERV_DSD	Age: 1-4	10,000	
OVC_SERV_DSD	Age: 5-9	40,000	
OVC_SERV_DSD	Age: 10-14	15,000	
OVC_SERV_DSD	Age: 15-17	15,000	
OVC_SERV_DSD	Age: 18+	20,000	
OVC_SERV_DSD	Sum of Age disaggregates	100,000	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	80,000	

Implementing Mechanism Details

Mechanism ID: 16656	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 16690	Mechanism Name: SAVVY
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 381,033	
Applied Pipeline Amount: 518,967	
Funding Source	Funding Amount
GHP-State	381,033

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16690		
Mechanism Name:	SAVVY		
Prime Partner Name:	New Partner		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	381,033	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16833	Mechanism Name: Human Resource Information System (HRIS)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 407,212	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	407,212

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	407,212
----------------------------	---------

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	16833		
Mechanism Name:	Human Resource Information System (HRIS)		
Prime Partner Name:	Emory University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	407,212	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16903	Mechanism Name: Evaluation of Integrated Community-Based and Clinical HIV/AIDS Interventions in Sinazongwe, Zambia
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16903		
Mechanism Name:	Evaluation of Integrated Community-Based and Clinical HIV/AIDS Interventions in Sinazongwe, Zambia		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17100	Mechanism Name: Stamping Out and Preventing Gender-Based Violence (STOP GBV) : Prevention & Advocacy
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Zambia Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 1,009,500	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,009,500

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	800,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	433,280
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID:	17100		
Mechanism Name:	Stamping Out and Preventing Gender-Based Violence (STOP GBV) :		
Prime Partner Name:	Prevention & Advocacy Zambia Center for Communication Programs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	132,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	277,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	10,603	5,684
GEND_NORM_DSD	By Age: 0-9	529	
GEND_NORM_DSD	By Age: 10-14	2,120	
GEND_NORM_DSD	By Age: 15-19	2,652	
GEND_NORM_DSD	By Age: 20-24	3,182	
GEND_NORM_DSD	By Age: 25+	2,120	
GEND_NORM_DSD	Sum of Age disaggregates	10,603	
GEND_NORM_DSD	By Sex: Male	3,182	
GEND_NORM_DSD	By Sex: Female	7,421	
GEND_NORM_DSD	Sum of Sex disaggregates	10,603	
GEND_NORM_DSD	By type of activity: Individual	2,602	



GEND_NORM_DSD	By type of activity: Small Group	2,620	
GEND_NORM_DSD	By type of activity: Community-level	5,381	
GEND_NORM_TA	Sum of Sex disaggregates	10,603	

Implementing Mechanism Details

Mechanism ID: 17168	Mechanism Name: Zambian OVC Management Information Systems (ZOMIS) / Data Rising		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Expanded Church Response Trust			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17168



Mechanism Name:	Zambian OVC Management Information Systems (ZOMIS) / Data Rising		
Prime Partner Name:	Expanded Church Response Trust		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,400	
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	0	
HRH_PRE	By Graduates: Midwives	0	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	1,400	
HRH_PRE	Sum of Graduates disaggreagtes	1,400	

Implementing Mechanism Details

Mechanism ID: 17354	Mechanism Name: Livelihoods and Food Security Technical Assistance (LIFT) II
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	
---	--



Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	600,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	100,000
------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17354		
Mechanism Name:	Livelihoods and Food Security Technical Assistance (LIFT) II		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a	21	



	pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	0	
HRH_PRE	By Graduates: Midwives	0	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	21	
HRH_PRE	Sum of Graduates disaggreagtes	21	
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	21	

Implementing Mechanism Details

Mechanism ID: 17355	Mechanism Name: Applying Science to Strengthen & Improve Systems Project (ASSIST)/USAID Healthcare Improvement Project (HCI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: (ASSIST) - Applying Science to Strengthen and Improve Systems Project	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	10,000
Food and Nutrition: Policy, Tools, and Service Delivery	300,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17355		
Mechanism Name:	Applying Science to Strengthen & Improve Systems Project (ASSIST)/USAID Healthcare Improvement Project (HCI)		
Prime Partner Name:	(ASSIST) - Applying Science to Strengthen and Improve Systems Project		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	200,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,300	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	2,039	
FN_THER_DSD	Aggregated Age: <18	700	
FN_THER_DSD	Aggregated Age: 18+	600	
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,300	

Implementing Mechanism Details

Mechanism ID: 17356	Mechanism Name: Food and Nutrition Technical Assistance (FANTA III)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,267,467	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,267,467

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Food and Nutrition: Policy, Tools, and Service Delivery	500,000
Water	100,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17356			
Mechanism Name: Food and Nutrition Technical Assistance (FANTA III)			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	117,467	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	15,792	470

FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	15,792	1,559
FN_THER_DSD	Age: <1	426	46
FN_THER_DSD	Age: 1-4	2,227	40
FN_THER_DSD	Age: 5-14	4,264	112
FN_THER_DSD	Age: 15-17	1,453	55
FN_THER_DSD	Age: 18+	7,422	214
FN_THER_DSD	Sum of Age disaggregates	15,792	467
FN_THER_DSD	Aggregated Age: <18	8,369	
FN_THER_DSD	Aggregated Age: 18+	7,423	
FN_THER_DSD	Sum of Aggregated Age disaggregates	15,792	

Implementing Mechanism Details

Mechanism ID: 17360	Mechanism Name: Time To Learn
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Education Development Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 800,000	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17360			
Mechanism Name: Time To Learn			
Prime Partner Name: Education Development Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	88,000	6,000
OVC_SERV_DSD	Sex: Male	43,407	
OVC_SERV_DSD	Sex: Female	44,593	
OVC_SERV_DSD	Sum of Sex disaggregates	88,000	
OVC_SERV_DSD	Age: 5-9	48,000	
OVC_SERV_DSD	Age: 10-14	32,000	
OVC_SERV_DSD	Age: 15-17	6,530	
OVC_SERV_DSD	Age: 18+	1,470	
OVC_SERV_DSD	Sum of Age disaggregates	88,000	

Implementing Mechanism Details

Mechanism ID: 17395	Mechanism Name: District OVC Systems Strengthening (DOSS) / Community Rising
----------------------------	---



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Luapula Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000	
Applied Pipeline Amount: 612,212	
Funding Source	Funding Amount
GHP-State	1,000,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	100,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17395			
Mechanism Name: District OVC Systems Strengthening (DOSS) / Community Rising			
Prime Partner Name: Luapula Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a	1,250	



	result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre		
HRH_PRE	By Graduates: Doctors	0	
HRH_PRE	By Graduates: Nurses	0	
HRH_PRE	By Graduates: Midwives	0	
HRH_PRE	By Graduates: Social service workers	0	
HRH_PRE	By Graduates: Laboratory professionals	0	
HRH_PRE	By Graduates: Other	1,250	
HRH_PRE	Sum of Graduates disaggreagtes	1,250	
HRH_PRE	By new graduates who are licensed and registered: Doctors	0	
HRH_PRE	By new graduates who are licensed and registered: Nurses	0	
HRH_PRE	By new graduates who are licensed and registered: Midwives	0	
HRH_PRE	By new graduates who are licensed and registered: Social service workers	0	
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	0	
HRH_PRE	By new graduates who are licensed and registered: Other (where applicable)	1,072	

Implementing Mechanism Details

Mechanism ID: 17396	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17399	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17400	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17403	Mechanism Name: Gender Based Violence - Survivor Support Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,800,752	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,800,752

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 17403			
Mechanism Name: Gender Based Violence - Survivor Support Project			
Prime Partner Name: World Vision International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,189,142	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	111,610	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	200,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,382	4,245
HTC_TST_DSD	By Test Result: Negative	3,906	3,646
HTC_TST_DSD	By Test Result: Positive	476	599
HTC_TST_DSD	Sum of Test Result disaggregates	4,382	4,245
HTC_TST_DSD	Age/sex: <1 Male	66	
HTC_TST_DSD	Age/sex: 1-4 Male	68	
HTC_TST_DSD	Age/sex: 5-9 Male	70	
HTC_TST_DSD	Age/sex: 10-14 Male	80	

HTC_TST_DSD	Age/sex: 15-19 Male	80	
HTC_TST_DSD	Age/sex: 20-24 Male	90	
HTC_TST_DSD	Age/sex: 25-49 Male	135	
HTC_TST_DSD	Age/sex: 50+ Male	135	
HTC_TST_DSD	Age/sex: <1 Female	345	
HTC_TST_DSD	Age/sex: 1-4 Female	345	
HTC_TST_DSD	Age/sex: 5-9 Female	345	
HTC_TST_DSD	Age/sex: 10-14 Female	429	
HTC_TST_DSD	Age/sex: 15-19 Female	552	
HTC_TST_DSD	Age/sex: 20-24 Female	562	
HTC_TST_DSD	Age/sex: 25-49 Female	540	
HTC_TST_DSD	Age/sex: 50+ Female	540	
HTC_TST_DSD	Sum of Age/Sex disaggregates	4,382	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	284	66
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	440	530
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,464	758
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,194	2,891
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,748	824
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,634	3,421
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,382	4,245
GEND_GBV_DSD	Number of people receiving post-GBV care	15,751	10,188
GEND_GBV_DSD	Age: 0-9	2,075	
GEND_GBV_DSD	Age: 10-14	2,100	
GEND_GBV_DSD	Age: 15-17	2,226	
GEND_GBV_DSD	Age: 18-24	4,618	
GEND_GBV_DSD	Age: 25+	4,732	
GEND_GBV_DSD	Sum of Age disaggregates	15,751	
GEND_GBV_DSD	Sex: Male	1,575	

GEND_GBVDSD	Sex: Female	14,176	
GEND_GBVDSD	Sum of Sex disaggregates	15,751	
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	14,176	6,050
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	1,575	3,895
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	360	
GEND_GBVTAA	Sum of Age disaggregates	15,751	
GEND_GBVTAA	Sum of Sex disaggregates	15,751	
GEND_NORMDSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	15,720	1,849
GEND_NORMDSD	By Age: 0-9	0	
GEND_NORMDSD	By Age: 10-14	5,560	5,562
GEND_NORMDSD	By Age: 15-19	5,560	5,562
GEND_NORMDSD	By Age: 20-24	2,300	4,602
GEND_NORMDSD	By Age: 25+	2,300	
GEND_NORMDSD	Sum of Age disaggregates	15,720	15,726
GEND_NORMDSD	By Sex: Male	15,720	
GEND_NORMDSD	Sum of Sex disaggregates	15,720	
GEND_NORMDSD	By type of activity: Community-level	15,720	
GEND_NORMTAA	Sum of Sex disaggregates	15,720	

Implementing Mechanism Details

Mechanism ID: 17410	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17413	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17421	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17422	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17425	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17439	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17448	Mechanism Name: Stamping Out and Preventing Gender Based Violence (STOP GBV) : Access to Justice
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Women and Law in Southern Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 457,839	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	457,839

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17448		
Mechanism Name:	Stamping Out and Preventing Gender Based Violence (STOP GBV) :		
Prime Partner Name:	Access to Justice Women and Law in Southern Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	87,839	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	370,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
GEND_GBVDSD	Number of people receiving post-GBV care	4,136	6,840
GEND_GBVDSD	Age: 0-9	1,280	
GEND_GBVDSD	Age: 10-14	640	
GEND_GBVDSD	Age: 15-17	480	
GEND_GBVDSD	Age: 18-24	360	
GEND_GBVDSD	Age: 25+	1,376	
GEND_GBVDSD	Sum of Age disaggregates	4,136	
GEND_GBVDSD	Sex: Male	786	
GEND_GBVDSD	Sex: Female	3,350	
GEND_GBVDSD	Sum of Sex disaggregates	4,136	
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,267	4,735
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	869	3,305
GEND_GBVTAA	Sum of Age disaggregates	4,136	
GEND_GBVTAA	Sum of Sex disaggregates	4,136	

Implementing Mechanism Details

Mechanism ID: 17449	Mechanism Name: Fostering Accountability and Transparency in Zambia (FACT-Zambia)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Counterpart International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 244,327	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	244,327

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17449			
Mechanism Name: Fostering Accountability and Transparency in Zambia (FACT-Zambia)			
Prime Partner Name: Counterpart International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	244,327	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17477	Mechanism Name: ASM
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 650,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	650,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17477		
Mechanism Name:	ASM		
Prime Partner Name:	American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	650,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17478	Mechanism Name: CLSI
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	250,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17478		
Mechanism Name:	CLSI		
Prime Partner Name:	Clinical and Laboratory Standards Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	250,000	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	15		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	15		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	15		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	15		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	15		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	15		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	15		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	15		Redacted

Implementing Mechanism Details

Mechanism ID: 17479	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,258,896	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,258,896

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17479			
Mechanism Name: APHL			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,258,896	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17483	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17497	Mechanism Name: University of Maryland
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,275,371	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	9,275,371

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 17497			
Mechanism Name: University of Maryland			
Prime Partner Name: University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	290,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	775,371	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	410,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	12,900	2,196	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	12,900	2,196	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	12,900		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	3,870	1,561	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	9,030	635	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0	Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	12,900	0	Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	12,900	2,196	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	129,000	61,267	Redacted

PMTCT_STAT_TA	Number of new ANC and L&D clients	135,789	61,394	Redacted
PMTCT_STAT_TA	By: Known positives at entry	5,160	2,346	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	7,740	3,673	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	12,900	6,019	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	10,418	109	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	0		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	0	78	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	10,418	31	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	10,418	109	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	22,800	2,185	Redacted
TX_CURR_TA	Age/Sex: <1 Male	0	21	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	22,800	32	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	0	2	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	0		Redacted
TX_CURR_TA	Age/Sex: <1 Female	0	21	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	0	40	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	0	0	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	0		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	22,800	2,183	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	22,800		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	22,800		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	22,800	2,072	Redacted
TX_NEW_DSD	Number of adults and children newly	9,030	1	Redacted



	enrolled on antiretroviral therapy (ART)			
TX_NEW_DSD	By Age/Sex: <1 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	9,030	0	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	0		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	0	0	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	0	1	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	0		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	0	0	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	9,030	1	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	9,030		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,030	0	Redacted

Implementing Mechanism Details

Mechanism ID: 17499	Mechanism Name: TDRC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tropical Diseases Research Centre	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 520,000	
---	--



Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	520,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17499			
Mechanism Name: TDRC			
Prime Partner Name: Tropical Diseases Research Centre			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	320,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning
-------------------------	--------------	-------------	-------------	-----------------

				Budget Targets
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	77		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	0		Redacted



LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	0		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	77		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	77		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	70		Redacted

Implementing Mechanism Details

Mechanism ID: 17500	Mechanism Name: UNZA M&E, Department of Population Studies
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 74,989	
Applied Pipeline Amount: 223,978	
Funding Source	Funding Amount
GHP-State	74,989

Sub Partner Name(s)



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17500			
Mechanism Name: UNZA M&E, Department of Population Studies			
Prime Partner Name: University of Zambia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	43,643	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	31,346	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17502	Mechanism Name: UNC Eastern
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A

G2G: No Managing Agency:

Total All Funding Sources: 0

Applied Pipeline Amount: 0

Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17502			
Mechanism Name: UNC Eastern			
Prime Partner Name: University of North Carolina			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	437		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	484		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	437		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	175		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	262		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	437		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	437		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	23,778		Redacted

	results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	24,206		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	228		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	294		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	522		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,778		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	24,206		Redacted
PMTCT_STAT_TA	By: Known positives at entry	228		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	294		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	522		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	43,142		Redacted
HTC_TST_TA	By Test Result: Negative	38,998		Redacted
HTC_TST_TA	By Test Result: Positive	4,144		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	43,142		Redacted
HTC_TST_TA	Age/sex: <1 Male	88		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	2		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	134		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	4,780		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	13,852		Redacted
HTC_TST_TA	Age/sex: 50+ Male	0		Redacted
HTC_TST_TA	Age/sex: <1 Female	112		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	0		Redacted

HTC_TST_TA	Age/sex: 5-9 Female	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	16		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	3,196		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	8,428		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	12,534		Redacted
HTC_TST_TA	Age/sex: 50+ Female	0		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	43,142		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	90		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,766		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	128		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,158		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	218		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	42,924		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	43,142		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	387		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	484		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	348		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	39		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	387		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	15		Redacted



Implementing Mechanism Details

Mechanism ID: 17513	Mechanism Name: Ministry of Health
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,013,655	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,013,655

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17513			
Mechanism Name: Ministry of Health			
Prime Partner Name: Ministry of Health, Zambia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	488,655	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	10,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	270,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	245,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17514	Mechanism Name: Jhpiego
----------------------------	--------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,566,894	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	5,566,894

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17514			
Mechanism Name: Jhpiego			
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Governance and Systems	HVSI	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	203,606	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,699,202	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	254,086	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	380,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	810,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	40	404	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV	20,045	40,427	Redacted

	prevention program within the reporting period			
VMMC_CIRC_DS D	By Age: 10-14	7,800	10,765	Redacted
VMMC_CIRC_DS D	By Age: 15-19	6,260	12,321	Redacted
VMMC_CIRC_DS D	By Age: 20-24	2,940	6,762	Redacted
VMMC_CIRC_DS D	By Age: 25-49	2,980		Redacted
VMMC_CIRC_DS D	By Age: 50+	65	75	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	20,045	37,449	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	360	2,766	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	17,680	32,213	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	2,005	5,448	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	20,045	40,427	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	16,036	36,387	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	4,009	4,040	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their	54,256	34,979	Redacted



	test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	1,085	32,213	Redacted
HTC_TST_DSD	By Test Result: Positive	53,171	2,766	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	54,256	34,979	Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,798		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	3,798		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	14,649		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	13,564		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	8,138		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	9,766		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	543		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	54,256		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	22,245	17,330	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,011	17,649	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	22,245	17,330	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	32,011	17,649	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	54,256	34,979	Redacted

Implementing Mechanism Details

Mechanism ID: 17517	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17519	Mechanism Name: CDC Technical Assistance - DRH
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17519		
Mechanism Name:	CDC Technical Assistance - DRH		
Prime Partner Name:	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17523	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17761	Mechanism Name: U.S. Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 263,616	
Applied Pipeline Amount: 58,588	
Funding Source	Funding Amount
GHP-State	263,616

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Education	12,501
Gender: Gender Equality	38,500
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17761		
Mechanism Name:	U.S. Peace Corps		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	193,970	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	39,646	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,254	
PP_PREV_DSD	Total number of people in the target population	30,508	
PP_PREV_DSD	Age/sex: 10-14 Male	1,829	
PP_PREV_DSD	Age/sex: 15-19 Male	2,289	
PP_PREV_DSD	Age/sex: 20-24 Male	1,754	
PP_PREV_DSD	Age/sex: 25-49 Male	1,754	
PP_PREV_DSD	Age/sex: 50+ Male	0	
PP_PREV_DSD	Age/sex: 10-14 Female	1,831	
PP_PREV_DSD	Age/sex: 15-19 Female	2,289	
PP_PREV_DSD	Age/sex: 20-24 Female	1,754	
PP_PREV_DSD	Age/sex: 25-49 Female	1,754	
PP_PREV_DSD	Sum of Age/Sex disaggregates	15,254	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,796	
PP_PREV_TA	Total number of people in the target population	35,592	
PP_PREV_TA	Age/sex: 10-14 Male	2,133	
PP_PREV_TA	Age/sex: 15-19 Male	2,671	
PP_PREV_TA	Age/sex: 20-24 Male	2,046	
PP_PREV_TA	Age/sex: 25-49 Male	2,046	
PP_PREV_TA	Age/sex: 50+ Male	0	
PP_PREV_TA	Age/sex: 10-14 Female	2,137	



PP_PREV_TA	Age/sex: 15-19 Female	2,671	
PP_PREV_TA	Age/sex: 20-24 Female	2,046	
PP_PREV_TA	Age/sex: 25-49 Female	2,046	
PP_PREV_TA	Age/sex: 50+ Female	0	
PP_PREV_TA	Sum of Age/Sex disaggregates	17,796	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	682	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	252	
GEND_NORM_DSD	By Age: 15-19	130	
GEND_NORM_DSD	By Age: 20-24	130	
GEND_NORM_DSD	By Age: 25+	170	
GEND_NORM_DSD	Sum of Age disaggregates	682	
GEND_NORM_DSD	By Sex: Male	341	
GEND_NORM_DSD	By Sex: Female	341	
GEND_NORM_DSD	Sum of Sex disaggregates	682	
GEND_NORM_DSD	By type of activity: Individual	0	
GEND_NORM_DSD	By type of activity: Small Group	682	
GEND_NORM_DSD	By type of activity: Community-level	0	
GEND_NORM_TA	Sum of Sex disaggregates	682	

Implementing Mechanism Details

Mechanism ID: 17781	Mechanism Name: Health Communications Collaborative (HC3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 482,965	
---	--



Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	482,965

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17781		
Mechanism Name:	Health Communications Collaborative (HC3)		
Prime Partner Name:	Johns Hopkins University Center for Communication Programs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	482,965	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17788	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17807	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17833	Mechanism Name: Project SOAR
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,500,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,500,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	50,000
---------------------------	--------

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 17833 Mechanism Name: Project SOAR Prime Partner Name: Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17873	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17891	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17897	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17927	TBD: Yes
REDACTED	



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		43,730		43,730	0
ICASS		1,460,028		1,460,028	439,972
Management Meetings/Professional Development		2,000		2,000	0
Non-ICASS Administrative Costs		196,095		196,095	0
Non-ICASS Motor Vehicles		120,000		120,000	0
Staff Program Travel		0		0	1,005,460
USG Renovation		15,810		15,810	0
USG Staff Salaries and Benefits		3,715,789	0	3,715,789	2,684,373
Total	0	5,553,452	0	5,553,452	4,129,805

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		100,000		100,000	33,600
Indirect Costs		108,843		108,843	12,526



Management Meetings/Professional Development		94,593		94,593	21,000
Non-ICASS Administrative Costs		48,564		48,564	18,400
Staff Program Travel		200,000		200,000	63,000
USG Staff Salaries and Benefits		348,000		348,000	335,500
Total	0	900,000	0	900,000	484,026

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		150,000		150,000	0
Computers/IT Services		460,906		460,906	0
ICASS		2,431,085		2,431,085	0
Indirect Costs		460,000		460,000	0
Institutional Contractors		1,175,000		1,175,000	0
Non-ICASS Administrative Costs		1,160,971		1,160,971	0
Staff Program Travel		1,080,000		1,080,000	0
USG Renovation		0		0	499,995
USG Staff Salaries	2,412,531	2,843,747		5,256,278	0



and Benefits					
Total	2,412,531	9,761,709	0	12,174,240	499,995

U.S. Department of Health and Human Services/Office of the Secretary

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
USG Staff Salaries and Benefits		350,000		350,000	0
Total	0	350,000	0	350,000	0

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		4,999		4,999	0
ICASS		350,000		350,000	0
Indirect Costs		444,763		444,763	0
Management Meetings/Professional Development		35,000		35,000	0
Non-ICASS Administrative Costs		85,000		85,000	0
Staff Program Travel		15,000		15,000	0
USG Staff Salaries and Benefits		46,270		46,270	433,940
Total	0	981,032	0	981,032	433,940



U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Institutional Contractors				0	0
Non-ICASS Administrative Costs		651,593		651,593	47,283
Peace Corps Volunteer Costs		2,227,797		2,227,797	40,098
Staff Program Travel		151,944		151,944	10,657
USG Staff Salaries and Benefits		1,053,106		1,053,106	1,074
Total	0	4,084,440	0	4,084,440	99,112